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The overarching theme is to improve understanding of oral glucocorticoid (GC) use, 
including the benefits and harms of GC treatment in inflammatory rheumatic diseases, 
with an emphasis on rheumatoid arthritis (RA). The introduction summarises 
inflammation as a normal physiological process, and its contribution to chronic 
inflammatory diseases, commonly treated with GCs. It further describes GCs in detail, 
identifying three key areas where the literature is lacking and/or conflicting that are 
addressed as the thesis aims. 
 
The first section of the thesis explores how GCs are used in RA and the influence of 
patient and prescriber factors in two large databases in the United Kingdom (UK) and 
Australia. In Chapter 2, primary care data from clinical practice research datalink (CPRD) 
demonstrated that half of patients with incident RA received GCs in primary care, with 
an average GC use of 7.5 mg (prednisolone equivalent daily dose, PEQ) for 25% of the 
time. GCs were prescribed more commonly in certain high-risk populations. In Chapter 
3, data from Australian Rheumatology Association Database (ARAD), found the 
probability of GC use has decreased over time. In contrast to CPRD, GC use in ARAD RA 
patients was less likely with increasing age, with older patients being less likely to 
commence GCs, but also less likely to cease GCs. 
 
The second section of the thesis explores the patient perspective of the benefits and 
harms of GC use, and the need for a patient reported outcome measure (PRO). A cross-
sectional survey administered to GC users with rheumatic diseases in Australia and 
United States (US) demonstrated that most patients with rheumatic diseases feel that 
GCs are effective treatments and that the benefits of GC use, outweigh the harms.  
Many adverse effects important to patients, cannot be easily measured, such as skin 
thinning/easy bruising, sleep disturbance, mood disturbance, and change in facial 
shape. This chapter also discusses the role of Outcome Measures in Rheumatology 
(OMERACT) in developing a PRO for GC use, describing additional work by the author 
contributing to both this thesis and the OMERACT GC working group. 
 
The final section of the thesis focuses on cataract and glaucoma, as two important 
potential harms of GC use. Chapter 5 presents a published manuscript reporting the 
results of a systematic literature review and meta-analysis, concluding that although the 
current literature suggests a possible association between GC use and the development 




In addition, there was insufficient evidence to determine the risk of GC use and the 
development of glaucoma.  
 
To address this gap in the literature, analyses of different models of GC exposure in 
CPRD were performed to quantify the risk of developing cataracts and glaucoma in RA 
patients.  The results demonstrated that current GC exposure is associated with a two-
fold increased risk of developing cataracts and 60% increased risk of developing 
glaucoma in patients with RA. For cataracts, cumulative doses greater than 1000mg PEQ 
are associated with increased risk, more so at doses above 4000mg PEQ, whereas for 
glaucoma, the risk is seen only with higher cumulative doses greater than 4000mg. The 
results of these three sections of work expand current knowledge about GC use, with 
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Inflammation is an essential protective response to infection and tissue damage (1). 
There are five classical signs of inflammation, including redness (rubor), heat (calor), 
pain (dolor), swelling (tumor) and loss of function (2). These occur as a result of the 
cellular and vascular changes that make up the inflammatory process. Inflammation is 
initiated by immune cells already resident within the affected tissue, such as 
macrophages, dendritic cells and mast cells. These cells possess pattern recognition 
receptors (PRRs), which bind two subclasses of molecules: pathogen-associated 
molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) (3). 
When PAMPs or DAMPs bind to PRRs in response to infection or tissue damage, 
inflammation is initiated and signalling pathways lead to the release of inflammatory 
mediators, including cytokines and chemokines (3). These, in turn, trigger the vascular 
components of inflammation, including arteriolar dilatation leading to increased blood 
flow to the affected region, presenting as heat and redness, and increased capillary 
permeability leading to protein leakage and oedema, which presents as swelling. The 
final stage of acute inflammation is control and resolution of the process and repair of 
damaged tissue. If this stage fails to occur, acute inflammation can become chronic, 
leading to chronic inflammatory diseases including Rheumatoid Arthritis (RA) (4). 
1.2 Glucocorticoids 
 
Glucocorticoids (GCs) are a class of medications commonly used in the treatment of 
chronic inflammatory disorders, targeting multiple stages of the inflammatory process. 
GCs, along with mineralocorticoids, are the two main subtypes of corticosteroid 
hormones produced in the adrenal cortex. Naturally occurring GCs include cortisol 
(hydrocortisone), corticosterone and cortisone, while aldosterone is a naturally 
occurring mineralocorticoid. Like many physiological processes, synthetic versions of 
these hormones have been developed for their therapeutic effects. Synthetic GCs were 
first shown to be effective anti-inflammatory medications in 1948, when Hench and 
Kendall reported the almost ‘miraculous’ effects of synthetic cortisone (known as 
Compound E) administered to a patient with RA (5). In 1950, along with Reichstein, they 
were awarded the only Nobel Prize for Rheumatology for this work (6). There was rapid 
progression in this area, and by 1958 there were six synthetic glucocorticoid agents 
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available for the treatment of inflammatory conditions. However, as these agents were 




Physiological GC (cortisol) secretion, which is regulated by adrenocorticotrophic 
hormone (ACTH), is produced in the anterior pituitary and released in bursts. ACTH 
production is in turn driven by corticotrophin releasing hormone (CRH) from the 
hypothalamus. Pulses of ACTH occur every 30-120 minutes. The varying amplitude of 
ACTH pulses leads to the normal diurnal rhythm of cortisol production. Plasma cortisol 
is highest in the early morning, low in the afternoon and evening, and lowest one to two 
hours after sleep begins. Cortisol has a negative feedback on ACTH and CRH production, 
therefore when GC production is impaired, as in Addison disease, ACTH is elevated. 
Similarly, excess GC (either endogenous or exogenous) suppresses ACTH (7). The effects 
of GCs are often broadly divided into metabolic and immune. However, GC receptors 
can be found in almost all cell types and the effects of GCs are widespread, affecting all 
major body systems (8). 
 
The metabolic effects of GCs include: 1. The stimulation of hepatic gluconeogenesis, with 
conversion of protein to carbohydrate and the storage of carbohydrate as glycogen (9), 
2. Mobilisation of amino acids from extrahepatic tissues, making them available as 
substrates for gluconeogenesis (10), 3. Inhibition of glucose uptake in peripheral tissues 
such as muscle and adipose tissue in order to conserve glucose for glycogen production 
in the liver (9), and 4. Contradictory adipogenic and lipolytic effects on lipid metabolism, 
which occur through a number of different mechanisms (11). GCs increase the hydrolysis 
of circulating triglycerides by lipoprotein lipase activity, increasing the amount of fatty 
acids in the circulation, which are then available for ectopic fat distribution (liver, muscle, 
and central adipocytes) (12). They also increase lipid production in hepatocytes through 
increased expression of fatty acid synthase (13). The dual action of GCs on adipocytes 
appears to be dependent on the cell type, with adipogenic effects of GCs promoting pre-
adipocyte conversion to mature adipocytes resulting in hyperplasia of the adipose tissue, 
and lipolytic effects primarily affecting mature adipocytes (14). The immune effects of 
GCs include anti-inflammatory and immunosuppressive effects, which occur via a 
number of complex mechanisms as described below. GCs help to protect cells from 
damage caused by the inflammatory response. 
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Mechanisms of action 
When GC molecules enter a cell, they bind to inactive, protein-bound glucocorticoid 
receptors (GRs) in the cytoplasm. After GC binding, the GR detaches from its proteins 
and the GC/GR complex can then enter the nucleus where it binds to glucocorticoid 
response elements (GREs) on target genes. The binding of the GC/GR complex to the 
GRE leads to gene transcription, the production of messenger RNA and the synthesis of 
proteins (Figure 1.1).  
 




Three types of GREs have been described: 1. Simple GREs occur in the promoter regions 
of target genes and typically bind homo-dimeric GC/GR complex, 2. Composite GREs 
also occur in the promoter region but bind other transcription factors together with the 
GC/GR complex, and 3. Tethering GREs are sites on DNA that bind other transcription 
factors (NF-кβ, Stat3) which in turn bind the GC/GR complex (15, 16). GC mechanisms 
of action can be divided into genomic and non-genomic effects (17) as summarised in 
Figure 1.2. 
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The GC/GR interaction with the GRE complex can lead to transcriptional activation 
(trans-activation) of genes encoding anti-inflammatory proteins such as annexin 1, 
mitogen-activated kinase phosphatase-1 (MKP-1), glucocorticoid induced lucine zipper 
(GILZ) and secretory leukocyte peptidase inhibitor (SLPI). The GC/GR complex can also 
regulate gene transcription via negative GREs (nGREs) which occur on genes encoding 
interleukin-1β (IL-1β), as well as those relevant to GC AEs such as osteocalcin (bone 
metabolism), corticotropin releasing hormone (hypothalamic-pituitary axis) and 
keratins (skin structure) (18). The GC/GR complex also causes transcription repression 
(trans-repression) of genes encoding pro-inflammatory cytokines such as IL-1β, IL-2, IL-
6, IL-8, tumour necrosis factor (TNF) and granulocyte macrophage colony stimulating 
factor (GM-CSF) as well as other inflammatory mediators such as cyclooxygenase-2 
(COX-2) (19). This occurs when the GC/GR complex binds to and blocks other pro-
inflammatory transcription factors such as nuclear factor kappa-beta (NF-κβ) and 
activator protein-1 (AP-1, comprised of c-Jun and c-Fos).  
 
Post-transcriptional mechanisms 
In non-inflammatory states, after transcription has occurred, the mRNA encoding pro-
inflammatory genes (such as IL-1β, IL-6, IL-8 and TNF) is unstable and rapidly degraded 
by RNases (20, 21). However, in states of active inflammation, inflammatory cytokines 
activate the p38 MAP kinase pathway, which stabilises mRNA and promotes the 
translation of more inflammatory cytokines (22). GC activation of MKP-1 leads to 
reduced p38 MAP-kinase activity (23), reducing mRNA stability and inflammatory 
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cytokine production (24). GCs can also reduce mRNA stability by increasing the 
expression of proteins such as tristetraprolin (20, 25). 
 
Non-genomic mechanisms 
Four non-genomic mechanisms by which GCs might affect inflammation, have been 
described. These include: 1. Signalling pathway via a membrane-bound GR (mGR), 2. 
Direct membrane effects, 3. Interaction of the GR with other proteins in the cytoplasm 
and 4. GR translocation on mitochondria (16). mGR was first described in 1999, when 
GC binding to the cell membrane was observed in mouse and human lymphoid cell lines 
(26). The amount of mGR in monocytes is correlated with clinical status in systemic 
lupus erythematosus (SLE) (27), RA (28) and ankylosing spondylitis (AS) (29), suggesting 
a role in inflammatory diseases, however further work is needed to define this apparent 
functionality (16). Direct membrane effects of GCs have been described, including: 
increased membrane lipid mobility in lymphocytes and some cancer cells (30).This 
suggests GCs are able to directly modulate of the physiochemical properties of the cell 
membrane in order to regulate cell functions such as Na and Ca ion channels, cell fluid 
shift response and tight junction formation. The binding of GCs to GRs in the cytoplasm 
leads to rapid (within minutes) intracellular signalling events separate from 
transcriptional interactions with the GREs (31). Translocation of the GC/GR complex to 
mitochondria influences sensitivity to GC-induced apoptosis (32). 
 
Therapeutic Use of GCs 
Due to their widespread anti-inflammatory actions, synthetic GCs are frequently used 
to treat many chronic inflammatory disorders, including those affecting the 
musculoskeletal, respiratory, gastrointestinal, neurological and renal systems, as well as 
the skin. In addition, they are also used to treat hormone deficient endocrine conditions 
and malignancies and to prevent rejection in transplant medicine. Approximately 0.5-
1% of the adult population are long-term GC-users (33-35). Asthma is the most common 
indication for GC use, followed by polymyalgia rheumatic (PMR) and giant cell arteritis 
(GCA), chronic obstructive pulmonary disease (COPD) and RA (34). Indications for GC 
therapy are listed in Table 1.1. 
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Table 1.1. Indications for Glucocorticoid Therapy by Specialty 
Respiratory  Asthma Gastroenterology Ulcerative colitis 
 COPD  Crohn's disease 
 Hypersensitivity pneumonitis  Autoimmune hepatitis 
 Sarcoidosis Haematology Lymphoma 
 Eosinophilic pneumonia  Leukaemia 
 Non-specific interstitial   Haemolytic anaemia 
 pneumonia  ITP 
Rheumatology Rheumatoid arthritis  Multiple myeloma 
 Psoriatic arthritis Ophthalmology Uveitis 
 Systemic lupus erythematosus  Keratoconjunctivitis 
 Sjögren’s syndrome Neurology Multiple sclerosis 
 Polymyalgia rheumatica  Myasthenia gravis 
 Giant cell arteritis  Cerebral oedema 
 Inflammatory myositis Renal Glomerulonephritis 
 Polyarteritis nodosa  Nephrotic syndrome 
 ANCA associated vasculitis  Acute interstitial nephritis 
 Behçet’s Disease Other Neoplasms 
 IgG4 related disease  Transplantation 
Allergy Urticaria Endocrinology  Addison's disease 
 Allergic rhinitis (usually at Adrenal insufficiency 
 Angioedema physiologic Congenital adrenal  
 Anaphylaxis doses) Hyperplasia 
 Food allergies   
 Drug allergies   
 Nasal polyps   
Dermatology Atopic dermatitis/eczema   
 Cutaneous vasculitis   
 Cutaneous lupus   
 Contact dermatitis   
 Psoriasis   
 Pemphigus vulgaris   
ITP=Idiopathic thrombocytopenic purpura 
 
There are many different routes by which GCs can be administered, including systemic 
(oral, intramuscular, intravenous), rectal, intra/peri-articular injections, epidural 
injections, inhaled preparations, intranasal preparations, intradermal injections, topical 
dermatologic preparations (creams or ointments), topical ocular preparations applied 
to the eyes or eyelids (eye drops or eye ointments), preparations for periocular delivery 
(subconjunctival, subtenon’s or retrobulbar injections) and intravitreal preparations 
Chapter 1. Introduction 
19 
 
(injections or implants). The evidence for the use of GCs administered via various routes 
to treat different inflammatory conditions is vast and beyond the scope of this thesis.  
 
Glucocorticoid Adverse Effects 
Soon after GCs were introduced into clinical practice for their anti-inflammatory effects, 
their many AEs were also recognised and described. AEs associated with GC use are 
listed below, in Table 1.2 (36). 
 
Table 1.2. Glucocorticoid Adverse Effects 
Dermatological Musculoskeletal Endocrine and metabolic 
Thin/fragile skin Osteoporosis Weight gain 
Easy bruising Fragility fractures Moon-like facies 
Acne Avascular necrosis Truncal obesity 
Striae Proximal myopathy Buffalo hump 
Hirsutism Tendon rupture Diabetes 
Alopecia Psychological Insulin resistance 
Impaired wound healing Sleep disturbance Hyperglycaemia 
Gastrointestinal Agitation Anovulation, irregular periods 
Gastro-oesophageal reflux Anxiety Infectious 
Peptic ulcer Depression Viral infections 
Bloating Irritability Bacterial infections 
Nausea/vomiting Euphoria Increased frequency 
Colitis Poor concentration Increased severity 
Pancreatitis Hyperactivity Atypical infections 
Increased appetite 
 
Reduced libido Skin infections 
Cardiovascular  Psychosis Thrush- oral, vaginal 
Hypertension Ophthalmological Other 
Dyslipidaemia Cataract Altered taste 
Atherosclerosis Glaucoma Voice hoarseness 
Cardiovascular disease Neurological  
Palpitations Tremor  
Fluid retention Headache  
Peripheral oedema Vertigo  
 Dizziness  
 Tinnitus  
Modified from Hoes et al, Ann Rheum Dis 2009 
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In the general population, GCs account for 2.5% of all adverse drug reactions leading to 
hospital admission (37). GCs use is also known to be associated with increased mortality 
(38-40). In rheumatology, clinical guidelines advocate for short-term use of low dose 
GCs (41-43), an acknowledgment that longer duration of therapy and higher dosages 
are associated with increased risk of developing certain AEs such as infection (44). 
Indeed, the concept of a ‘steroid-sparing agent’ reflects a recognised need to limit 
exposure to GC adverse effects.  
 
The first recommendation from the European League against Rheumatism (EULAR) 
guidelines for the use of systemic GCs in rheumatic diseases is that the potential harms 
of GCs be discussed with patients prior to therapy (45). However, while GC AEs are well 
described in the literature, the evidence quantifying these harms is often lacking. The 
impact of dose, duration of therapy and how recently GCs were used is largely unknown 
for many GC AEs. Recent work looking at infection and diabetes has used novel 
statistical methods to better define GC exposure and address some of these 
unanswered questions (44, 46). 
 
Balancing the benefits and harms of glucocorticoid treatment 
The balance between the benefits and harms of treatment, underpins all medical 
management. Four key aspects of any benefit and harm have been described, including: 
1. Its nature, described by its quality, intensity, and time course (onset, duration, and 
reversibility), 2. The probability that it will occur, 3. Its importance to the person 
experiencing it, and 4. How the benefit can be maximised, or the harm prevented or 
minimised (47). To ensure shared decision making, clinicians must be able to 
communicate to patients the potential benefits and harms of a given treatment so that 
informed therapeutic decisions can be made. This is dependent not only on the four 
elements of the risks and benefits of a given therapy being known, but also on the 
clinician’s ability to understand and communicate risk and the patient’s ability to 
understand this information (48).  
 
Like all medications, the decision to treat with GCs is based on an assessment of the 
benefits of treatment, weighed against the potential harms of GC AEs (47). In some 
circumstances, this decision is clear-cut because the condition being treated is either 
life or organ-threatening and GCs are the only viable treatment option. An example is 
GCA, a form of vasculitis that primarily affects the elderly. Patients with this condition 
are at risk of blindness if not treated with high doses of GCs, making the decision to treat 
with GCs relatively straightforward. In other conditions, such as RA, the use of GCs is 
more controversial.  
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1.3 Glucocorticoid Use in Rheumatoid Arthritis 
 
Rheumatoid Arthritis 
RA is a chronic inflammatory arthritis that affects approximately 0.5-1% of the 
population worldwide (49, 50). It classically presents as a symmetrical polyarthritis 
which often begins in the small joints of the hands and feet, however it can affect all 
peripheral joints as well as the cervical spine. In Australia, the prevalence of RA is 2% 
(1.7% in females, 1.4% in males), based on self-reported data from the Australian 
Bureau of Statistics 2014-2015 National Health Survey (51). Inflammation of the joint 
synovium leads to the acute symptoms of joint pain, swelling and stiffness, while the 
long-term consequences of untreated persistent inflammation include joint damage 
and deformity. RA was the first condition in which GCs were shown to be effective as 
anti-inflammatory agents over 60 years ago and are still commonly used as therapeutic 
options today. However, the treatment of RA has evolved dramatically since Hench and 
Kendall first discovered the effectiveness of GCs. The recognition of the need for early 
diagnosis and treatment within a ‘window of opportunity’ has altered the course of the 
disease significantly, and disease deformity is now  less common. Treatment options for 
RA have grown exponentially, and include conventional synthetic disease modifying 
anti-rheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs) and new targeted 
synthetic DMARDs (tsDMARDs)(52). With the recent development of biosimilar 
bDMARDs, these can now be divided into bio-original (boDMARDs) and biosimilar 
(bsDMARDs). The different DMARD categories, medications and mechanisms of action 
are shown below in Table 1.3. 
  
Chapter 1. Introduction 
22 
 
Table 1.3: Disease Modifying Anti-Rheumatic Drugs, Categories and Mechanisms 
DMARD Category Medications Mechanism of Action 
csDMARDs Still commonly used in RA  
 Methotrexate Purine metabolism 
inhibitor 
 Sulfasalazine Suppression of IL-1 & TNF-
alpha, induces apoptosis of 
inflammatory cells and 
increases chemotactic 
factors 
 Hydroxychloroquine Suppression of TNF-alpha, 
induces apoptosis of 
inflammatory cells and 
decreases chemotaxis 
 Leflunomide Pyrimidine synthesis 
inhibitor 
 No longer commonly used 
in RA 
 
 IM Gold injections Unknown, inhibits antigen 
processing by 
macrophages 
 Penicillamine Reduces numbers of T-
lymphocytes 
 Chloroquine Suppression of IL-1, 
induces apoptosis of 
inflammatory cells and 
decreases chemotaxis 
 Cyclosporine A Calcineurin inhibitor 
 Azathioprine Purine synthesis inhibitor 
bDMARDs Abatacept T-cell costimulatory signal 
inhibitor 
 Anakinra IL-1 receptor antagonist 
 Adalimumab TNF inhibitor 
 Etanercept TNF inhibitor 
 Golimumab TNF inhibitor 
 Infliximab TNF inhibitor 
 Rituximab Anti-CD20 (B-cell) 
monoclonal antibody 
 Tocilizumab IL-6 receptor antagonist 
tsDMARDs Tofacitinib Janis kinase (JAK) inhibitor 
 Baracitinib JAK inhibitor 
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Inflammation in Rheumatoid Arthritis (RA) 
RA is thought to develop as a result of an underlying genetic predisposition, such as the 
HLA-DRB1 shared epitope, combined with a number of environmental triggers which 
may include smoking, periodontitis and alterations to the gut microbiome(53). RA is an 
autoimmune disorder in which joint inflammation(synovitis) is often (but not always) 
triggered by autoantibodies including rheumatoid factor (RF) and antibodies to 
citrullinated peptides (ACPA) (53). These autoantibodies have been shown to precede 
clinical RA by an average of 3-5 years (54). Synovitis occurs when leukocytes accumulate 
in the synovial compartment due to cell migration. The cellular composition of synovitis 
in RA includes both innate immune cells (monocytes, dendritic cells, mast cells and 
innate lymphoid cells) and adaptive immune cells (T-helper-1 and T-helper-17 cells, B 
cells, plasmablasts and plasma cells) (55). This mix of inflammatory cells in the synovial 
compartment is regulated by a complex network of cytokines and chemokines, including 
pro-inflammatory mediators, like tumour necrosis factor alpha (TNFα) and interleukin 6 
(IL-6) (56). Activated fibroblasts, together with the accumulated immune cells, trigger 
osteoclast generation via the interaction between receptor activator of nuclear factor 
κB ligand (RANKL) and its receptor RANK (57). This results in bony erosions, which form 
at the junction between cartilage, periosteal synovial membrane insertion and bone. 
 
GC anti-inflammatory effects in RA  
GC treatment has multiple cell-specific anti-inflammatory effects in RA (58). T-cells play 
a central role in the pathogenesis of RA, as evidenced by the high levels of T cells in 
inflamed synovium(59). GCs are thought to reduce T-cell induced inflammation via a 
number of mechanisms, including inhibition of T-cell cytokine production and a 
reduction in the number of activated T-helper cells (TH1 and TH17) (58). B-cells have an 
important role in the pathogenesis of RA, producing autoantibodies against citrullinated 
proteins, forming aggregates at sites of inflammation in bone, synovium and cartilage 
and they are also the predominant antigen presenting cell in the late stages of the 
disease (60). The actions of GCs on B-cells are not well understood, with conflicting 
studies on their ability to suppress B-cell production of immunoglobulin-G (IgG). In the 
early phase of RA, antigens are presented by dendritic cells. Glucocorticoids induce 
apoptosis of immature dendritic cells and also inhibit dendritic cell migration, 
differentiation, maturation and antigen presentation (58). Macrophages also play an 
important role in the aetiology of RA, with the number of macrophages markedly 
increased in patients with RA compared to healthy individuals (53). In RA, GC therapy is 
associated with a substantial decrease in the number of macrophages in synovial 
tissues. GCs also induce an anti- inflammatory macrophage phenotype, characterised 
by increased phagocytosis, decreased adhesiveness and reduced expression of classical 
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pro-inflammatory cytokines such as TNF, IL-1β and IL-6 (58). GCs also increase osteoclast 
maturation, but inhibit osteoblast proliferation and can induce apoptosis or autophagy 
of these cells (58). 
 
GC use in RA 
GCs are used in approximately 60% of patients with RA worldwide (61). They have been 
shown to have disease modifying properties (62, 63), however there was significant 
heterogeneity in the dosage protocols used in these efficacy studies, with starting doses 
as high as 60mg used in some studies, compared to low doses of 5mg daily used in other 
studies (64), Table 1.4. Furthermore, there are concerns about the long-term use of GCs 
in RA, due to their significant AE profile (65, 66), and the availability of many effective, 
alternative therapies. For this reason, international guidelines recommend that the 
lowest possible dose and duration of GC therapy be used, usually in the setting of newly 
diagnosed active disease or disease flares (67, 68). However, many still advocate for the 
long-term use of low dose oral GCs in RA, arguing that the disease modifying benefits 
outweigh the potential harms, which can often be medically managed (63). With 
manuscript titles such as ‘Resolved: low dose prednisolone is indicated as a standard 
treatment in patients with rheumatoid arthritis’ (69) and ‘Resolved: low-dose 
glucocorticoids are neither safe nor effective for the long-term treatment of rheumatoid 
arthritis’ (70) appearing alongside each other in the same issue of the same journal, it is 
clear that the question surrounding the role of GC use in RA is not resolved. 
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Table 1.4 GC Protocols in RCTs of GC Efficacy in RA 
Modified from Hoes et al. Nature Reviews Rheumatology, 2010 (64) 
Study name and details Protocol in GC-treatment group 
ARC  
Kirwan et al. (1995)( 71) 
2 year study, n= 128  
(glucocorticoid, 61; control, 67) 
7.5 mg predniso(lo)ne, with any DMARD 
COBRA 
Boers et al. (1997) (72) 
80 week study, n = 155  
(glucocorticoid, 76; control, 79) 
60 mg predniso(lo)ne tapered to 0 mg over 28 
weeks, with methotrexate, sulfasalazine 
BeSt 
Goekoop-Ruiterman et al. (2007) (73) 
2 year study, n= 508  
(glucocorticoid, 133; control, 375) 
60 mg predniso(lo)ne tapered to 0 mg over 28 
weeks, with methotrexate, sulfasalazine 
Hansen et al. (1999) (74) 
1 year study, n= 102  
(glucocorticoid, 51; control, 51) 
Median 6 mg predniso(lo)ne, with any DMARD 
FIN-RaCo  
Mottonen et al. (1999) (75) 
2 year study, n= 195  
(glucocorticoid, 97; control, 98) 
Median 5 mg predniso(lo)ne for ≥9 months, 
with sulfasalazine, methotrexate, 
hydroxychloroquine 
van Everdingen et al. (2002) (76) 
2 year study, n= 81  
(glucocorticoid, 41 control, 40) 
10 mg predniso(lo)ne, no DMARD 
(sulfasalazine rescue after 6 months) 
TICORA  
Grigor et al. (2004) (77) 
1.5 year study, n = 110  
(glucocorticoid, 55; control, 55) 
Intra-articular GCs were administered to each 
swollen joint as therapy with each new 
DMARD begun, oral GCs as part of step-up 
protocol, with sulfasalazine, methotrexate, 
hydroxychloroquine, cyclosporine 
WOSERACT 
Capell et al. (2004) (78) 
2 year study, n= 128  
(glucocorticoid, 61; control, 67) 
7 mg predniso(lo)ne, with sulfasalazine 
LDPT 
Wassenberg et al. (2005) (79) 
2 year study, n= 76  
(glucocorticoid, 34; control, 42) 
5 mg predniso(lo)ne, with intramuscular gold 
or methotrexate 
BARFOT 
Svensson et al. (2005) (80) 
2 year study, n= 258  
(glucocorticoid, 119; control, 139) 
7.5 mg predniso(lo)ne, with any DMARD 
CARDERA 
Choy et al. (2008) (81) 
2 year study, n= 376  
(glucocorticoid, 131; control, 236) 
60 mg predniso(lo)ne tapered to 0 mg over 34 
weeks, with methotrexate or methotrexate 
and ciclosporin 
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Given the multitude of treatment options and poorly defined role of GCs in the 
management of RA, the question arises as to how GCs are actually used to treat RA in 
‘real-life’ clinical practice and what factors influence this? Concern about GC AEs is well-
described in the literature, and it is likely that certain patient characteristics such as age, 
comorbidities and concurrent therapies might affect GC prescribing and use to differing 
extents. The divided opinions about GC use in RA, also highlighted in the literature, 
suggest that different prescribers may have vastly different values surrounding GC use 
and therefore the patient characteristics that influence one prescriber might differ from 
those that influence another. To expand these questions further, it also worth 
considering factors that influence whether GCs are commenced or ceased. 
 
Rheumatologists are generally divided as to whether GCs should be used regularly as 
disease modifying agents, or more sparingly to treat disease flares (82). These differing 
clinician attitudes are well documented in the rheumatology literature and are in part 
driven by evidence gaps, particularly the quantification of risks associated with GC use 
and how these risks vary with differing levels of exposure, including dose, duration and 
timing of GC treatment (82). Patients and clinicians also place their own value 
judgements on GCs (82). For clinicians, their value judgements may be based on past 
experience with GCs, and for patients this may be influenced by the opinions of their 
doctors, family, friends and the media (83). As well as having different value judgements 
to their doctors, patients are likely to vary in how they weight the benefits and harms 
of treatment depending on their attitudes to risk, with some patients more benefit 
driven and others more risk-averse (84). Patient preferences are therefore an important 
consideration in the assessment of the benefits and harms of glucocorticoid treatment. 
How patients’ preferences can be usefully captured in research and clinical settings 
remains challenging, particularly as eliciting preferences for GC safety is time 
consuming, taking over two hours per subject in a research study (85). 
 
1.4 Glucocorticoids and Patient Reported Outcomes 
 
In addition to discussing benefits and potential harms prior to commencing treatment, 
it is also important to assess and measure these benefits and harms in both clinical care 
and research settings. In particular, it is important to capture these outcomes from the 
patient perspective. Patient reported outcomes are now recognised as important 
indicators of quality research and clinical care, and as a consequence, the need for well-
designed and validated PROs has arisen (86, 87). Numerous organisations now exist, 
with the purpose of bringing appropriate patient, clinician, research and industry 
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representatives together to develop PROs. In the field of rheumatology, OMERACT 
fulfils this role, with the aim to improve and standardise outcome measures in 
rheumatology. A key principle of OMERACT is patient involvement and there is 
integration of patient stakeholders in every stage of the OMERACT process (88). A 
current project within OMERACT is the development of a PRO for GCs, which will allow 
the benefits and harms of treatment to be measured from the patient perspective. 
 
OMERACT- Outcome Measures in Rheumatology 
OMERACT is an international organisation made up of an executive committee, steering 
committee and individual working groups which include a chair, co-chair, fellow, 
patients, clinicians, researchers, industry representatives and policy makers. The work 
of OMERACT is facilitated by the working group participants who provide input on the 
development of the OMERACT research agendas. The research agendas focus initially 
on developing a core domain set, and later on selecting measurement instruments. 
OMERACT have developed a number of tools to ensure these processes are consistent 
and evidence based. These tools include the ‘OMERACT onion’ for domain selection, 
‘the OMERACT way’ for instrument selection and the OMERACT Filter 2.0 (89). 
 
OMERACT emphasises the measurement issues to consider when selecting an 
instrument include truth, discrimination and feasibility. Truth refers to whether the 
measurement instrument actually measures what it intends to, covering issues of face, 
content, construct and criterion validity. Discrimination refers to whether the 
instrument can distinguish between situations of interest, capturing the instrument’s 
reliability and sensitivity to change. Feasibility is about whether the measurement 
instrument can be applied easily, given constraints of time, money, and interpretability. 
This criterion addresses the pragmatic reality of using the measurement instrument 
(90). 
 
OMERACT have run biennial consensus conferences since 1992. At each meeting there 
are educational sessions, special interest groups (SIGs) and workshops, as well as 
specialised programs for patients, fellows and returning-fellows. SIGs allow the 
international members of a working group to come together and discuss the research 
that has been carried out to date as well as the ongoing research agenda. Workshops 
bring the whole OMERACT community together to vote on the different stages of 
defining core outcomes and developing measurement instruments, with the aim of 
achieving consensus.  
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The spirit of OMERACT is described by the 8 C’s (90): 
1. Consensus-commitment 
2. Communication- respectful across 5Ps stakeholders, especially patients  
3. Collaboration- truly participatory across all disciplines/sectors, international 
representation 
4. Critical- evidence driven 
5. Careful/conscientious- apply critical thinking, systematic 
6. Concrete outcomes- e.g. OMERACT Filter; Core Sets 
7. Continuous Learning- updated methods and core sets 
8. Continuity- Planned succession through Fellowship Program 
 
Need for a patient reported outcome measure for GC use 
A EULAR taskforce on GC therapy has published two systematic reviews concluding that 
there is a need to systematically capture GC-AEs in a standardised manner (45, 91). In 
addition, EULAR recommendations for GC monitoring suggest new tools are required 
(92), supporting the need for the development of instruments to measure the outcomes 
of GC therapy across a wide range of indications. 
 
This has led to the recent development of the glucocorticoid toxicity index (GTI), which 
measures the physiological AEs of systemic glucocorticoid use, and includes items such 
as BMI, glucose tolerance, blood pressure, lipids and bone density, among others (93). 
However, discordance between rheumatologists and patients regarding GC AEs 
suggests that the physiological AEs important to clinicians may not be of highest 
importance to patients (85, 94). Therefore, development of a PRO that specifically 
measures the impact of GC use on patients’ quality of life and experience, would be 
complementary to the GTI (95). 
 
At OMERACT 2014, members of the PMR working group noted that many of the issues 
that were important to patients with PMR, were in fact related to their treatment with 
GCs. It was also recognised that many of these treatment outcomes cannot currently be 
measured. This led to the formation of the GC working group, which met for the first 
time at OMERACT 2016 and again at OMERACT 2018. The group has undertaken a body 
of qualitative and quantitative work to better understand the benefits and harms of GC 
therapy from the patient perspective, that will ultimately lead to the development of a 
GC PRO. Some of the first unanswered questions to address in this process were: how 
frequently do patients report having experienced different GC AEs, which of these AEs 
do patients experience as the worst AEs, do patients feel GCs help their disease and do 
they feel that the benefits of treatment outweigh the harms? 
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1.5 Glucocorticoid Related Eye Disease 
 
Another aspect of GC use that is important to patients, that has had relatively little 
attention is eye disease. Cataracts and glaucoma are frequently listed as GC related AEs 
and while the literature surrounding their development in the setting of ophthalmic GC 
use is fairly comprehensive, they appear far less frequently in the oral GC literature, 
particularly in comparison to other GC AEs such as infection, diabetes, osteoporosis and 
fractures. Cataracts and glaucoma are the leading cause of blindness worldwide (96) 
and account for significant disability and healthcare related costs (97, 98). The incidence 
of cataracts and glaucoma increases with age (99-101) but the impact of GC use on the 
background incidence has not been well described, making it difficult to properly inform 
patients of the potential eye-related harms of GC therapy. For patients to be properly 
informed, a more detailed understanding of how GC use impacts the development of 
cataracts and glaucoma is required, including the influence of dose, duration of 




A cataract is an opacity of the lens of the eye, which prevents light from passing through 
the lens and reaching the retina. Cataracts are the leading cause of blindness worldwide 
(51%) (102) and the second most common cause of vision impairment in Australia (97). 
They are associated with significant disability and cost to the healthcare system, with 
estimates approximating Aus$1 billion per year (97). The Australian-based Blue 
Mountains Eye Study (BMES) found the 10-year cumulative incidence of cataracts to be 
54%, compared to 38% in the Beaver Dam Eye Study (BDES) based in Wisconsin, USA. 
However, age and gender-matched cumulative incidence rates were very similar with a 
10-year cumulative incidence of 77% (BMES) and 75% (BDES) in those aged 65-74 years 
and 87% (BMES) and 88% (BDES) in those aged over 74 years. In both studies there was 
a statistically significant increase in cumulative incidence with increasing age (P<0.0001) 
(99, 100).  
 
Globally, cataracts are the leading cause of blindness in those aged 50 years and older. 
Cataracts accounted for 35% of blindness and 25% of vision impairment in adults aged 
50 years and older in 2015. However, there are large differences in the causes of 
blindness by region in this age group. In 2015, the proportion of blindness in those aged 
50 years and older attributable to cataract ranged from <22% in high- income 
subregions to more than 44% in southeast Asia and Oceania (96). 
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Classification of cataracts 
Cataracts can be defined according to their age of onset, with congenital cataracts 
present from birth, infantile cataracts developing in childhood and age-related/senile 
cataracts developing in adulthood, usually after the age of 40. There are three main 
subtypes of age-related cataract, including nuclear cataracts, cortical cataracts and 
posterior subcapsular cataracts (PSCs). 
 
Nuclear sclerosis involves the diffuse yellowing and hardening of the entire central 
nucleus of the lens and tends to worsen gradually over time. Cortical cataracts involve 
the fibres at the periphery of the lens, with the opacification occurring in a spoke-like 
manner. They tend to be relatively asymptomatic until advanced, when the 
opacification spokes extend to the nucleus and interfere with light passing through the 
centre of the lens. Posterior subcapsular cataracts are caused by a granular layer of cells 
between the lens and its capsule. They are often the most debilitating form of cataract 
due to unbearable glare and often occur at a younger age compared to nuclear and 
cortical cataracts. Other causes of cataract include traumatic cataracts (due to blunt or 
penetrating eye injuries, electrocution, chemical burns or radiation exposure) and 
metabolic cataracts (occur secondary to diabetes, galactosaemia, Wilson disease or 
myotonic dystrophy). 
 
Cataract Symptoms and Risk Factors 
The symptoms of cataracts are described below in Table 1.5. 
 
Table 1.5. Cataract Symptoms 
Symptoms Details 
Blurred vision Blurred or cloudy vision 
Glare Halos or streaks around lights 
Difficulty seeing in the presence of bright lights 
Difficulty seeing in low light Including poor night vision 
Loss of ability to discern colours Fading or yellowing of colours 
Increasing myopia Including a “second sight” phenomenon where vision 
improves in those with pre-existing hyperopia 
Monocular diplopia Uncommon, can occur with nuclear sclerotic 
cataracts 
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Risk Factors for developing cataracts include (103, 104): 
• Increasing age 
• Diabetes or hyperglycaemia 
• Glucocorticoid use 
• Ultraviolet exposure  
• Smoking 
• Excessive alcohol intake 
• Obesity 
• Ocular diseases: Retinitis Pigmentosa, Uveitis 
• Ocular Trauma 
• Prior ocular surgery  
• Genetic predisposition 
 
Treatment of cataracts- cataract surgery 
The progression of age-related cataracts is variable and unpredictable. Untreated, most 
people with a cataract will develop severe visual impairment (105). There is no set level 
of visual acuity for which surgery is indicated, instead referral for cataract surgery is 
considered when there is visual impairment caused by the cataract, and the person's 
lifestyle is affected (eg. driving, reading), and the person wants to undergo surgery 
(105). Poor eyesight affects the ability of people to live independently and places them 
at risk of falls and preventable injuries (106). Benefits of surgery include improved visual 
acuity, improved clarity of vision and improved colour vision. Cataract surgery is the 
most common elective surgical procedure in Australia (107). It involves replacing the 
lens with a clear, permanent, artificial lens. In Australia, 90% of cataract operations are 
performed in people aged 60 years and over, with only 1% performed in those under 40 
years of age (108). In 2014–15, the Australian cataract surgical rate was 2,138 
hospitalisations per 100,000 people aged 40 years and over (108). The prevalence of 
PSCs is reported to be 5-15% of all cataracts (100, 109, 110), however the PSC subtype 
accounts for up to 40% of cataracts requiring surgery (111).  
 
GC induced cataracts 
Glucocorticoid- induced cataracts were first described by Black et al in 1960, and were 
recognised specifically as PSCs (112). In this study, 17 out of 47 patients treated with 
systemic GCs for RA developed bilateral PSCs, with PSCs appearing after approximately 
one year of GC treatment. No PSCs were found in the 19 patients who did not receive 
GCs.  There appeared to be a dose-related response, with PSCs found in 29% of those 
on moderate doses of GCs (12.5-25mg/day prednisolone) compared to 75% of those 
receiving high doses (>25mg/day prednisolone). However, this was the first of a number 
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of early cross-sectional studies limited by their design in their inability to capture the 
effect of dose and duration of treatment over time. Systemic GCs (112), inhaled GCs 
(113-115) and GCs administered to the eye topically (116, 117) or via injection (118-121) 
have been shown to be associated with the development of PSCs. However, the results 
of these studies are often conflicting, for example in the Blue Mountain Eye Study 
(BMES) there was an association between current GC use and PSCs (OR 4.11, 95%CI 
1.67–10.08) and nuclear cataracts (OR 3.45, 95% CI 1.26–9.43) but not cortical cataracts 
(OR 1.08, 95%CI 0.44–2.64)(122). In comparison, the Beaver Dam Eye Study (BDES) 
found GC use was associated with an increased incidence of cortical cataracts (OR 2.59, 
95%CI 1.45–4.62) but not PSCs (OR 1.27, 95%CI 0.42–3.86) or nuclear cataracts (OR 1.41, 
95%CI 0.77–2.56) (123). Very few studies have looked at the effect of dose, duration 
and/or the timing of GC use on the development of cataracts (124-127), and there has 
been no systematic review or meta-analysis to summarise and quantify these effects. It 
is well recognised that observational research is an ideal platform to explore long-term 
safety outcomes. A well-designed observational study that captures ‘real-life’ GC use 
over time, would be the ideal setting in which to address these unanswered questions 
relating to the development of cataracts. In addition, careful selection of analyses and 
modelling of time-varying GC exposure including dose, duration and timing of therapy 
is needed in order to capture some of the complexities of GC use. 
 
Potential mechanisms of GC induced cataracts 
A number of potential mechanistic pathways involved in the development of GC- 
induced PSCs have been investigated, including: 1. The role of the GC receptor in lens 
cells, 2. Lens epithelial cell migration, 3. Growth factors, 4. GC modifications to signal 
transduction and 5. Oxidation and lens hydration. The lens contains GC receptors (128, 
129) that are functional and able to induce or repress gene transcription(128, 130). DNA 
microarray studies in cultured lens epithelial cells exposed to GCs have indicated that a 
broad range of transcripts are up- or down-regulated compared to unexposed cells, 
however only two transcripts were altered at all time points looked at in these studies 
(4h, 16h, 24h and 48h) (129, 130). These transcripts were for GILZ and plasminogen 
activator inhibitor-1 (PAI-1). These proteins have been shown to have diverse roles in 
different cell types, however their role in GC treated lens epithelial cells is not yet 
known.  
 
Lens epithelial cells can be found underlying the lens capsule anterior to but not 
posterior to the lens equator. This narrow band of epithelial cells at the lens equator, 
proliferate and differentiate into fibre cells, enabling the lens to grow slowly throughout 
life as these new lens fibres are added to the cortex. This process is ordered and 
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carefully regulated (131). In PSC, the proliferation and differentiation of lens epithelial 
cells appears to be disrupted, with histologic studies of GC-induced PSC describing the 
migration of these cells at the posterior lens pole (132). It is not yet known if GCs have 
a direct effect on lens epithelial cells or whether this is an indirect effect due to changes 
in intra-ocular growth factors (133). 
 
Jobling and Augusteyn (134) were the first to propose that changes in intraocular 
growth factor may play a role in the development of GC-induced PSCs. A number of 
growth factors are known to play a role in  the regulation of epithelial cell differentiation 
into lens fibre cells, including fibroblast growth factor-2 (FGF-2), insulin-like growth 
facto -1 (IGF-1), epidermal growth factor (EGF), transforming growth factor-beta (TGF-
β), lens epithelium derived growth factor (LEDGF), platelet derived growth factor (PDGF) 
and bone morphogenetic proteins (BMPs).The effects of GCs on ocular levels of growth 
factors is unknown but it has been hypothesised that because GCs can modify the 
production of growth factors in other cell types, they may also disrupt the balance of 
growth factors within the ocular compartments. 
 
Glucocorticoid modifications to signal transduction in lens epithelial cells has also been 
proposed as a potential mechanism, based on studies that show GCs modify signal 
transduction in other cell types (135-137) and limited DNA array data with lens epithelial 
cells (128). Growth factor activity is primarily mediated through cell surface receptors 
that signal via mitogen-activated protein kinase (MAP kinase) and phosphoinositide-3 
kinase (PI-3 kinase) signal transduction pathways. Growth factors activated by these 
pathways include serum glucocorticoid kinase (SGK), which is upregulated in lens 
epithelial cells by GC treatment (128). SGK can also promote cell survival by protecting 
cells against apoptosis (138). Cells obtained from human PSCs, exhibit a reduced 
propensity to undergo apoptosis when stimulated by staurosporine (139). These 
observations suggest that GC treatment may cause an anti-apoptotic response in lens 
epithelial cells, suppressing the differentiation of lens epithelial cells at the equator and 
promoting their proliferation (133). 
 
Finally, two general mechanisms thought to play a role in the formation of cataracts are 
oxidation of lens proteins and disruption of the level of lens hydration (133). Some 
studies have suggested that GC molecules form covalent adducts with lysine residues of 
lens particles leading to oxidation of lens proteins and opacities (140, 141). However, 
other studies do not support this hypothesis (142, 143). Altered lens hydration may 
contribute to age-related and diabetic cataracts (144), and some have hypothesised that 
steroids inhibit the sodium-potassium pump (Na/K pump) in the lens epithelium, 
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leading to the accumulation of water within the lens fibres and agglutination of lens 
proteins (145). In support of this, systemic GC treatment has been shown to directly 
affect the expression of NA/K-ATPase pumps and intracellular fluid balance in other cell 
types (146, 147), and levels of NA/K-ATPase transcript were increased at 48 hours in GC 




Along with cataracts, glaucoma is also recognised as a GC-associated eye disease. 
Glaucoma is a form of optic neuropathy, which occurs when the trabecular meshwork 
becomes blocked and aqueous humour is unable to drain. The subsequent increase in 
intra-ocular pressure (IOP) leads to pressure on the optic nerve and small nerve fibres 
of the retina causing visual impairment and visual field defects. Glaucoma accounts for 
8% of blindness worldwide and is the second leading cause, after cataract (102). The 
prevalence of glaucoma cited in two Australian population-based studies is 3% (148, 
149). Glaucoma accounts for 1.49% and 0.55% of vision impairment in non-Indigenous 
and Indigenous Australians, respectively (150).  
 
Classification of glaucoma 
Glaucoma can be classified into two broad categories, angle-closure glaucoma and open 
angle glaucoma (OAG), both of which can be primary or due to secondary causes (151). 
Primary angle closure glaucoma may be acute, chronic or intermittent (151). Primary 
open angle glaucoma (POAG) may be either high pressure or normal pressure (151). The 
term ‘glaucoma suspect’ describes an individual with an ocular finding that puts them 
at risk of developing POAG. It can be defined as an adult who has one of the following 
findings in at least one eye (152): 
 
1. An optic nerve or nerve fibre layer defect suggestive of glaucoma (enlarged cup–
disc ratio, asymmetric cup–disc ratio, notching or narrowing of the neuro-retinal 
rim, a disc haemorrhage, or suspicious alteration in the nerve fibre layer) 
2. A visual field abnormality consistent with glaucoma 
3. An elevated IOP greater than 21 mmHg  
 
If two or more of these findings are present, the diagnosis of POAG is supported. 
Diagnosis of a ‘glaucoma suspect’ is also dependent on a normal open angle on 
gonioscopy (152). This involves the use of a gonio-lens in conjunction with a slit lamp to 
view the irido-corneal angle, the anatomical angle formed between the eye's cornea 
and iris (153). Ocular hypertension is defined by the following features (151): 
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•  IOP > 21 mm Hg without treatment 
• Visual field: normal 
• Optic disc and retinal nerve fibre layer: normal 
• Gonioscopy: open anterior chamber angle  
 
Causes of secondary OAG include ocular diseases such as uveitis and neovascular 
(secondary to diabetic retinopathy), ocular trauma, and iatrogenic causes such as GCs, 
surgery and laser therapy (151). 
 
Risk factors for open angle glaucoma 
There are three large longitudinal studies which have investigated risk factors for OAG: 
the Barbados Incidence study of Eye Diseases (BISED) (154), the Melbourne Visual 
Impairment Project (VIP) and the Rotterdam Eye Study (RES) (155). The BISED studied 
the 9-year incidence of OAG in a sample of the African descent population in Barbados. 
The VIP studied the 5-year incidence (of ‘probable OAG’) in a sample of white patients 
in Melbourne, Australia and the RES studied the 6.5-year incidence in a sample of white 
patients in Rotterdam, Netherlands. The most important risk factors for OAG, seen 
consistently across all 3 studies were older age and baseline IOP ≥1mmHg higher than 
the average population(156), with the relative risk increasing by 4%-6% for each one 
year increase in baseline age and a 10-14% increased risk associated with higher 
baseline IOP. Family history of OAG was investigated in the BISED and VIP studies, 
however the results were conflicting, with a 2.6 fold increased risk seen in the BISED 
study but no significant increase in risk seen in the VIP study. In regards to comorbidities, 
systolic blood pressure was only reported in the BISED study and found to be associated 
with a 10% reduced risk of OAG per 10mmHg. Self-reported diabetes was included in all 
three studies and was not significant in any. Interestingly, GC use was not included in 
any of these 3 main studies. 
 
GC-induced ocular hypertension and glaucoma 
Steroid-induced ocular hypertension was first reported in 1950 when McLean (157) 
described  an increase in IOP associated with the systemic administration of ACTH. Four 
years later, Francois was the first to report increased IOP caused by the local 
administration of cortisone to the eye (158). Increased IOP can occur as a consequence 
of oral, intravenous, inhaled, topical, periocular, or intravitreal GC therapy (121, 159-
168). The mode of GC administration effects how rapidly IOP can rise, with the rise 
usually occurring  over a period of weeks if GCs are used topically (169-171), compared 
to years, if used systemically (172). If the ocular hypertension is of significant magnitude, 
and not recognised and treated, subsequent GC-induced glaucoma can develop, a form 
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of secondary OAG. It is reported that IOP remains chronically elevated, converting to 
glaucoma in only a small subset of patients. In one series, 2.8% of eyes with GC induced 
ocular hypertension converted to glaucoma, and all affected patients had a family 
history of glaucoma (173). 
 
Most studies describing GC induced ocular hypertension have quantified the increase in 
intraocular pressure associated with GC use, rather than addressing the question of risk, 
which is important when considering the benefits and harms of GC use. In the few 
studies that do address this question, the results have been conflicting. In a cross-
sectional study of RA patients from 1969, only one case of glaucoma was seen among 
148 oral GC users, with one case also seen among 159 non-users (174). Similarly, in a 
retrospective medical record review, one of 112 RA patients who received low dose GCs 
for >1 year developed glaucoma as did one of 112 matched RA patients not treated with 
GCs (175). In a German cohort of RA patients, no significant association was seen 
between prednisolone equivalent (PEQ) daily dose (categorised as PEQ  <5mg, 5-7.5mg 
and >7.5mg) and the development of glaucoma (176).  A case-control study using data 
from the Quebec universal health insurance program for the elderly, looked at the risk 
of developing ocular hypertension or OAG associated with oral GC use in patients aged 
65 years or older (160). It found that GC current use (in the past 14 days) was associated 
with an increased risk of developing glaucoma (OR 1.41, 95%CI 1.22-1.63), but former 
use in the past 15-45 days (OR 1.18, 95% CI 0·87–1·62) or 46-365 days (OR 0·92, 95%CI 
0·78–1·08) was not. It also showed that the risk increased with average daily dose (PEQ 
daily dose 0.4- <10mg OR 1.26, 10- <20mg OR 1.40, ≥20mg 1.88) and duration of 
continuous GC therapy of 3 months or more (3-5 months OR 1.63, 6-11 months OR 1.87, 
≥12 months OR 1.52).  
 
Risk factors for GC-induced ocular hypertension and glaucoma 
Most of the studies looking at risk factors for GC-induced hypertension and glaucoma, 
focus on topical administration of GCs. This may in part be explained by the rapid 
increase in IOP with topical GCs compared to systemic treatment. Topical 
administration also allows for the other eye to act as the control. The concept of steroid 
responsiveness arose in the early studies of Becker (168) and Armaly (177-179), which 
looked at the IOP response to topical GC administration and classified responders as 
low, intermediate or high responders according to either their final IOP or change in 
IOP. Since then risk factors for steroid responsiveness have been investigated and 
extrapolated as risk factors for GC-induced glaucoma, but have not been confirmed in 
longitudinal studies. These risk factors are summarised below: 
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• Pre-existing POAG  
90% developed increased IOP >6mmHg after a 4-week course of topical 
dexamethasone 0.1% (180) and highly significant increases in IOP and decreased 
outflow facility were seen during a 2-4 week treatment course with topical 
betamethasone  0.1% (169) 
• Glaucoma Suspect  
1/3 developed increased IOP >6mmHg after a 4-week course of topical 
dexamethasone 0.1% (180) and highly significant increases in IOP and decreased 
outflow facility were seen during a 2-4 week treatment course with topical 
betamethasone  0.1% (169) 
• A first-degree relative with POAG  
Siblings (181) and offspring (182, 183) of those with POAG are more likely to be 
steroid responders compared to the general population 
• Increasing age in adulthood (170) 
• Exposure during childhood (particularly under age 6)(184) 
• Autoimmune connective tissue diseases (M>F)  
34 patients with connective tissue diseases used dexamethasone drops 0.1% in 
one eye for six weeks. There was a higher incidence of positive steroid response 
than would be expected in a normal population. Most of the male patients were 
responders (185) 
• Type 1 Diabetes Mellitus (186) 
• High Myopia (187) 
• Endogenous hypercorticolism (188) 
 
Clinical features of GC-induced glaucoma 
The clinical presentation of GC-induced glaucoma is indistinguishable from POAG, with 
the majority diagnosed when asymptomatic. The diagnosis is usually made during a 
routine eye test or as an incidental finding when presenting with another ophthalmic 
condition (e.g. diabetic retinopathy). Typically, patients only become symptomatic in 
late disease, when they may develop constricted visual fields or blurred vision. 
Occasionally, awareness of earlier visual field defects occurs when performing 
monocular tasks (such as using the viewfinder of a camera).  
 
Potential mechanisms of GC-induced ocular hypertension and glaucoma 
In this form of glaucoma, IOP is elevated primarily due to outflow resistance (189). 
Several theories have been proposed to explain how GCs impair aqueous outflow 
including: 
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1. GCs alter trabecular meshwork cell morphology by increasing nuclear transport 
of glucocorticoid receptors (GRs) (190). 
2. GCs increase expression of extracellular matrix protein fibronectin, polymerised 
glycosaminoglycans, and elastin, leading to their accumulation in the trabecular 
meshwork, obstructing the outflow pathway (191-193). 
3. The endothelial cells of the trabecular meshwork are phagocytic and can thus 
remove and destroy debris entering the meshwork from the anterior chamber. 
GCs are known to suppress this phagocytic activity, which may allow debris in 
the aqueous humor to accumulate and act as a barrier to outflow (194, 195). 
4. GCs cause physical obstruction of the trabecular meshwork with pigmented, 
crystalline steroid particles (196). 
 
Treatment of GC-induced ocular hypertension and glaucoma  
Management options for GC induced hypertension and glaucoma include (197, 198): 
 
• Cessation of GC treatment or dose reduction. In the majority of cases, an acute rise 
in IOP will normalise within days of discontinuing GC therapy, while more chronic 
forms take 1-4 weeks.  
• Consideration of steroid sparing agents may be needed. 
• In rare cases, IOP remains elevated after GCs are ceased and antiglaucoma medical 
therapy or surgery may become necessary. The duration of GC therapy may also 
influence the reversibility of the IOP elevation (199).  
• Medical therapy may include topical beta blockers, prostaglandin analogues 
(latanoprost), alpha agonists (brimonidine) and carbonic anhydrase inhibitors (oral 
or topical). 
• Surgery such as trabeculotomy or trabeculectomy are reserved for medically 
uncontrolled, intractable glaucoma. 
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1.6 Summary of the evidence gaps 
 
In reviewing the literature, three main areas where the evidence for GC use was lacking 
or conflicting were identified: 
 
1. The literature regarding oral GC use in RA is conflicting, with polarising views 
regarding dosing and long-term use. International guidelines advocate for the 
lowest possible dose to be given for the shortest duration of time, with other experts 
suggesting long-term use of low dose GCs, while many of the RCTs demonstrating 
that GCs have disease modifying effects in RA use protocols that include high dose 
GCs. With such variation in the literature, it is unclear how GCs are used in real-life 
clinical practice, how use is influenced by patient characteristics and whether this 
varies according to prescriber.  
 
2. Another aspect of GC use that has received relatively little attention in the literature 
is the patient perception of the benefits and harms of GC use. The benefits and 
harms of GC therapy that are most important to patients often differ from those 
most important to doctors. In addition, the value judgements patients and doctors 
place on these benefits and harms can also vary. Patient reported outcomes are 
important quality indicators in research and clinical practice and play an important 
role in any assessment of the benefits and harms of treatment. It is therefore 
important to develop a PRO that will provide a standardised and validated means of 
measuring the benefits and harms of GC use, from the patient perspective. In order 
to develop such a PRO, it is necessary to first gather data on how patients treated 
with GCs perceive the benefits and harms of their treatment. 
 
3. GC related eye disease, including cataracts and glaucoma, is another area under-
represented in the GC literature. Cataracts and glaucoma were recognised as AEs of 
GC use soon after GCs were introduced as therapeutic agents over 60 years ago, 
however the risks have not been well quantified with conflicting results seen in the 
existing literature. In addition, the impact of dose, timing of dose and cumulative 
dose has not been clearly defined. GCs are commonly used in the treatment of RA, 
but there are a multitude of other treatment options available, making this an ideal 
condition in which to explore these unresolved questions.  
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1.7 Research Aims 
 
The aims of this PhD were therefore as follows: 
 
1. To describe the use of oral glucocorticoids and explore patient and prescriber 
factors that influence their use in rheumatoid arthritis in the UK (Chapter 3) and 
Australia (Chapter 4) 
2. To better understand the benefits and harms of glucocorticoid use from the 
patient perspective (Chapter 5) 
3. To determine whether the risk of cataract and glaucoma associated with 
glucocorticoid use in patients with rheumatoid arthritis can be quantified in a 
systematic review of the current literature (Chapter 6) 
4. To quantify the risk of GC exposure and the development of cataract and 
glaucoma in RA and to explore the risk associated with different patterns of GC 
exposure, including dose, timing of dose and cumulative dose (Chapter 6)
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2 Dataset Description and Methodological Challenges 
 
The two datasets used to address research Aims 1 and 4 are described in detail below. 
Clinical Practice Research Datalink (CPRD) is a UK research database derived from 
anonymised primary care electronic medical records. CPRD was used for the work 
presented in Chapters 3 and 6. Australian Rheumatology Association Database (ARAD) 
is an Australian biologics registry. ARAD data was used for the work presented in 
Chapter 4. 
2.1 CPRD- Clinical Practice Research Datalink 
 
CPRD is an e-health research service that provides anonymised UK Primary Care health 
records for public health research. It was initially developed in London by a general 
practitioner, to facilitate the day-to-day management of his own general practice, in 
collaboration with IT staff at a shoe factory near to his practice. In 1987 Value Added 
Information Medical Products (VAMP) was established as a company to recruit other 
practices and form an information database. This initially small database grew and was 
donated to the Department of Health in 1993, at which time it became General Practice 
Research Database (GPRD). In 2012 it was expanded to allow for data linkage and re-
launched as CPRD. Established linkages include Hospital Episode Statistics 
(hospitalisation data), Office for National Statistics6 (mortality data including causes of 
death), Index of Multiple Deprivation and Townsend scores (deprivation data) and 
disease registries including the National Cancer Intelligence Network, and the 
Myocardial Ischaemia National Audit Project (200).  
 
The database benefits from the unique nature of the National Health Service (NHS) as 
essentially the single provider of health care in the UK. Over 98% of the UK population 
are registered with a primary care general practitioner (GP) and under the NHS, GP visits 
are free of charge (200). Each patient in the NHS has a unique patient identifier (NHS 
number), which can be used by a trusted third party for data linkage. This number is 
never released to researchers to ensure patient anonymity is always maintained. The 
NHS utilises a primary care gatekeeper approach to care, where patients require a 
referral from their general practitioner in order to access specialist care, hospital care 
and diagnostic tests (201, 202). As of March 2017, CPRD held data on >24 million 
patients from >800 GP practices. Studies have shown CPRD data to be representative of 
the UK population in terms of age and gender structure (203, 204), and validation 
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studies have demonstrated good completeness and accuracy of the data particularly for 
chronic diseases (205, 206).  
 
Until recently CPRD collected data only from practices using Vision practice 
management software, one of the most popular clinical systems used within primary 
care in the UK. This CPRD database is known as CPRD GOLD. In October 2017, CPRD 
launched a second database which collects data from practices using EMIS Web, the 
most common software in UK primary care, used in 56% of English practices (207). This 
second dataset is known as CPRD Aurum, and as of September 2018, included 7 million 
patients who were alive and registered at contributing practices, representing around 
13% of the population of England (208). A comparison of CPRD GOLD and CPRD Aurum 
is shown in Table 2.1. 
 
Table 2.1. Comparison of CPRD GOLD and CPRD Aurum 
 CPRD GOLD CPRD Aurum 
UK Countries participating Consenting practices in 
England, Wales, Scotland 
and Northern Ireland 
Consenting practices in 
England and Northern 
Ireland 
Who is included? >24 million patients from 
>800 GP practices using 
Vision software 
19 million patients from 738 
GP practices using EMIS 
Web software 









factors, tests and results 
Period of data collection From 1987 to present From 1995 to present 
 
Data Quality 
CPRD has developed data quality markers over many years to account for variability 
between GPs and over time. They are designed to ensure logical consistency of patient 
registration data, complete longitudinal records and complete, continuous, plausible 
practice level data. There are two data quality markers used in CPRD: 1. The 
‘acceptability flag’, which is an indicator of data quality at the individual patient level 
and 2. The ‘up-to-standard’ (UTS) date, which is an indicator of data quality at the 
practice level (209). Patient data are checked for a series of indicators that raise 
suspicion of poor data recording or identify non-continuous follow up. A patient is 
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flagged as unacceptable if any of these indicators are found. Criteria for acceptable 
patients are shown in Table 2.2. 
 
Table 2.2: CPRD Criteria for Acceptable Patients 
Criteria Details 
Gender Must be valid (1=male, 2=female, 3=indeterminate) 
Birth year Must be present, no events prior to birth year 
Age  Must be ≤ 115 at last collection date/transferred out date 
First registration date  Must be on or after birth 
Current registration date  Must be valid, on or after birth, on or after first registration 
date, permanent registration (not temporary) 
Transferred out date Must exist if there is a transferred out reason, must have a 
transferred out reason recorded, must be on or after the first 
registration date and the current registration date  
Event dates Must be 1 or more valid event dates (unacceptable if all 
event dates are invalid or missing) 
 
The practice UTS date is the date from which practice data is deemed to be of research 
quality. It is based on two core criteria including: 1. Practice mortality rates must be 
within an expected range and 2. There is continuity in data recording within a practice. 
The first ensures that data is provided for patients who have died (patients haven’t been 
deleted from the system), that deaths are being recorded and is a marker of 
irregularities in practice. 
 
ISAC (Independent Scientific Advisory Committee) for MHRA (Medicines & 
Healthcare products Regulatory Agency)Database Research 
ISAC is a non-statutory expert advisory body established in 2006 to provide scientific 
advice on research related requests to access data provided by CPRD. Members were 
appointed by the Department of Health Appointments Commission until 2015, and the 
MHRA now appoints members directly. The role of the committee is to review the 
scientific merit of proposals for research using CPRD data and safeguard patient 
confidentiality. ISAC approval was obtained for both CPRD projects included in this 
thesis, as detailed in the manuscripts. 
 
Coding in CPRD GOLD 
VISION and CPRD use Read codes (version 2), a hierarchical clinical classification system 
containing over 96, 000 codes. During a consultation, a GP, nurse, practice manager or 
administrator may enter a number of Read codes to describe a patient’s symptoms, 
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diagnoses, lifestyle factors (such as smoking status), tests performed and therapy 
recommended.  Prescriptions issued by the GP are automatically recorded with a 
product name, product code and British National Formulary (BNF) code, alongside the 
dosage instructions and quantity. Medical and Product Browsers available to generate 
Read and product code lists.  The Medical Browser can search on Medical code, Read 
code or Read term. The Product Browser can search on Product code, Gemscript code, 
product name, drug substance name, BNF code and BNF header. 
 
Database Structure and Files Provided 
CPRD data is provided as a number of different files under the headings: clinical, 
additional clinical details, therapy, referral, test and immunisation. In addition, there are 
consultation, patient, staff and practice files containing demographic and visit details. 
Figure 2.1 depicts how the files fit within the database structure as described by Forbes 
et al (200). Due to the size of some of these files, some are provided in numbered sub-
files that can then be merged. Relevant aspects of the main files can also be merged 
based on a single common variable. For example, the patient identification variable 
‘patid’ can be used to merge the patient file with the clinical file and the Product code 
variable ‘prodcode’ can be used to merge the therapy file with the product file. 
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2.2 ARAD- Australian Rheumatology Association Database 
 
The Australian Rheumatology Association Database (ARAD) is an Australian biologic 
registry established in 2001. It collects patient-reported long-term safety, and other 
outcome data from patients with inflammatory arthritis, including RA, psoriatic arthritis 
(PsA), ankylosing spondylitis (AS) and juvenile idiopathic arthritis (JIA) (210). It includes 
participants commenced on bDMARDS as well as controls on conventional treatments 
(enrolment of controls since Feb 2007), with recruitment occurring at any time after 
diagnosis. Participation is voluntary and rheumatologists refer patients to the registry 
with minimum baseline information required including diagnosis, RF and ACPA-status 
(ACPA collected since Nov 2010). In order to reflect real-life clinical practice, the 
diagnosis of participants included in the registry is based on expert clinical opinion 
(rheumatologist) rather than classification criteria. All participants, including controls, 
may commence, switch or cease bDMARDs at any point during their follow-up, as per 
their routine care.  
 
Following written informed consent, participants complete a baseline ARAD 
questionnaire, with a follow-up questionnaire completed every 6 months for 2 years, 
then at 12-monthly intervals. The initial questionnaire is defined as the ‘baseline’ 
questionnaire and there are no exclusions for disease duration, prior therapies or 
associated comorbidities. The questionnaire was initially available only in paper-form, 
but an electronic version has been available since August 2009. Patients have the option 
to opt out of ARAD at any time or alternatively they may also convert to ‘tracking only’ 
status where they no longer complete questionnaires but agree to ongoing data linkage. 
The initial and follow up questionnaires collect an array of patient-reported data 
including: 
 
• Demographic Data- level of education, employment status, marital status 
• Smoking and alcohol consumption 
• Medical Illnesses- checklist 
• Cancer History-checklist and diagnosis dates 
• Medical History- symptoms checklist 
• Infection History- checklist, including mild, moderate or severe status 
• Hospitalisations 
• Weight 
Chapter 2. Dataset Description and Methodological Challenges 
46 
 
• Medications and other treatments for arthritis- bDMARDS, csDMARDS, oral 
prednisone/prednisolone, NSAIDS, analgesics, herbal or complementary 
medicines, joint surgery, cortisone injections (IV, IM, IA or tendon) 
• Quality of life measures- HAQ, SF-36, AQOL, EURQOL 
• Global evaluation of disease activity visual analogue scale (VAS) measures- 
amount of pain in the past week, overall arthritis activity in the past week 
 
Oral GC data is collected on a checklist, along with other csDMARDs. Participants are 
asked to indicate if they have ‘never taken’, are ‘currently taking’, ‘stopped taking’ or 
‘don’t know’ prednisone/prednisolone. They are also asked to fill in the year the 
medication was commenced, any side effects (from a list of codes) and reason for 
stopping (also from a list of codes). ARAD does not collect information on dose and 
duration of therapy can only be inferred by looking at whether the patient is on 
prednisone/prednisolone from one questionnaire to the next. ARAD was initially 
established to track safety outcomes, in particular, infections and malignancies, but also 
other safety outcomes including death. These outcomes are captured in the 
questionnaire and can also be validated with data linkage to other registries including 
the PBS, cancer registry and death registry. 
 
Access to bDMARDs in Australia 
In Australia, there is universal access to medications via funding though the 
Pharmaceutical Benefits Scheme (PBS). bDMARDs have been available on the PBS since 
August 2004, and prior to this, were accessed through clinical trials. PBS prescribing of 
bDMARDs for RA, PsA, AS and JIA is restricted to rheumatologists. There are set criteria 
for each diagnosis, that must be met in order for a bDMARD prescription to qualify for 
PBS subsidisation. For RA, the criteria are as follows: 1. The patient has severe, active 
RA, 2. They have failed a 6-month intensive csDMARD trial with a minimum of two 
agents (including methotrexate) for a minimum of three months each, 3. The patient 
can demonstrate failure to achieve an adequate response to six months of intensive 
prior treatment by an elevated ESR >25mm/hr and/or an elevated CRP > 15mg/L and 
the patient has an active joint count of at least 20 active (swollen and tender) joints or 
at least 4 major active joints (elbow, wrist, knee, ankle, shoulder and/or hip). Similar 
prescribing criteria exist for PsA, AS and JIA. 
2.3 Methodological Challenges 
 
The specific methods for each study in this thesis, including a description of the 
population, exposures and outcomes are described in the manuscripts presented in 
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Chapters 3-6. This section of the thesis, describes in more detail some of the 
methodological challenges associated with the use of prescription data derived from 
electronic medical records (EMRs) such as CPRD. 
 
Glucocorticoid Prescription Data in CPRD 
In Chapters 3 and 6, GC exposure was defined using prescription data from CPRD. 
Prescription information in CPRD is currently available in the ‘therapy’ and ‘product’ 
files, with a third ‘textID’ file previously available.  Prescription data from the ‘therapy’ 
file includes the prescription date, numeric daily dose (ndd, number of tablets/units to 
be taken per day), the quantity (qty, total number of tablets prescribed) and the 
duration of therapy. Prescription data from the ‘product file’ includes the product code 
identifying the product used, the medication strength, formulation and route of 
administration. The ‘text ID’ file contained anonymised free text instructions e.g. “take 
two three times a day for 5 days”.  All prescriptions of GCs (prednisolone, cortisone, 
hydrocortisone, triamcinolone, methylprednisolone, dexamethasone, 
bethamethasone, budesonide and deflazacort) were identified using the product code 
identifying the medication prescribed. Those administered orally were then selected.  
 
Challenges of working with an EMR derived dataset and prescription data 
Datasets derived from EMRs, such as CPRD, are an invaluable resource for exploring 
long-term medication safety outcomes as they provide real-life data from large 
populations over long periods of time. However, the primary purpose of an EMR is 
clinical care, and this is the focus at the point of data entry, rather than research-quality 
data. In addition, typographical errors are not uncommon in this setting, and there are 
often missing, implausible and conflicting data to deal with. Recent work in the field of 
pharmacoepidemiology has shown that decisions made when preparing prescription 
data can effect outcomes to varying but sometimes significant extents (211). The 
authors of this work highlight that prescription data preparation is usually unreported, 
and they have developed a statistical algorithm and framework for capturing these 
important steps that can affect study reproducibility as shown below in Figure 2.2. This 
work highlights the importance of a systematic data cleaning process when working 
with prescription data derived from EMRs.  
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Figure 2.2 Statistical algorithm and framework for capturing the steps in prescription 
data preparation 
 
Reproduced from Pye et al, Pharmacoepidemiol Drug Saf, 2018 (211) 
License:  https://creativecommons.org/licenses/by/4.0/ No changes were made. 
 
 
Glucocorticoid Prescription Data Preparation 
GC prescription data is particularly challenging to work with because of the many 
different GC types, formulations, routes of administration, strengths and non-
standardised dosing regimens.  To prepare the GC prescription data in CPRD for analysis, 
a data preparation script that includes a series of decisions was adapted and modified 
using Stata statistical software. These decisions were informed by an in-depth review of 
their downstream impact in a small subset of patients. Clinical experience was essential 
in making these decisions, in order to ensure the final dataset was clinically plausible. 
Although this script was prepared prior to the creation of the prescription data 
preparation framework described above, it can be broadly divided into the same three 
sections including: A. Data cleaning, B. Define Prescription Length and C. Handle 
concurrent and sequential prescriptions. However, to avoid unwanted downstream 
effects, data cleaning was required before (A1) and after (A2) defining the prescription 
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length. The decisions made, and their order, in the data cleaning script are detailed 
below: 
 
A1. Data Cleaning: Initial data cleaning dealt with contradictory and implausible 
data. 
 
Corrections for when numeric entries conflict with free text 
• When free text was available and numeric entries did not match free text, the 
numeric entries were updated to match with the free text (numeric daily dose 
and duration of therapy variables were affected) 
 
Dealing with implausible values 
• If duration of therapy, numeric daily dose and quantity of tablets was entered as 
‘0’, this was deemed implausible and changed to missing 
• If duration of therapy for a single script was greater than 365 days, this was 
deemed implausible and changed to missing 
 
B. Define Prescription Length (duration of therapy) 
 
• There were three possible ways to define duration of therapy which was 
available from the therapy file, text ID file or could be derived from the therapy 
file by dividing the total quantity of tablets by the numeric daily dose (qty/ndd). 
• For each prescription there were three duration variables, with 0-3 durations 
recorded depending on the extent of missing data. 
• Three different stop date variables were created using the start date and the 
three duration variables. These were missing if the corresponding duration of 
therapy variable was missing 
• If only one stop date was available for a given script, this was assumed to be 
correct and taken as the ‘real stop date’ 
• If two stop dates were available and the same, this stop date was assumed to be 
correct and taken as the real stop date 
• If two stop dates were available but different, then the stop date calculated from 
a duration directly entered was used in preference to one derived from the 
calculation qty/ndd. This rule was decided on as it led to the generation of the 
least number if implausible daily doses (>100mg/d) 
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• If three stop dates were available but different, the real stop date was taken to 
be that based on the duration from the therapy file (again, because this 
produced the least number of implausible doses >100mg/d) 
• The ‘real duration’ was taken to be that which corresponded to the ‘real stop 
date’ 
• At this stage of the data cleaning, real duration and real stop were still missing 
for those with missing data for all three duration variables 
 
A.2 Data cleaning: further data cleaning to deal with missing values and any 
implausible doses once converted to a prednisolone equivalent daily dose 
 
Dealing with missing numeric daily dose: 
• If the numeric daily dose was a missing variable, it was calculated by dividing the 
quantity of tablets by the real duration (qty/realduration) 
• If numeric daily dose was still missing, because either quantity or real duration 
were missing, then it was replaced by the median numeric daily dose for that 
prednisolone-equivalent strength across all prescriptions 
 
Dealing with missing quantity: 
• If quantity was a missing variable, it was replaced by the median quantity for 
that prednisolone-equivalent strength across all prescriptions 
 
Dealing with missing real duration and real stop: 
• If real duration was missing at this point, it was calculated by dividing quantity 
by the numeric daily dose, qty/ndd (this was now possible for scripts where ndd 
or qty had been replaced by the median) 
• Missing real stop dates were then calculated based on start date plus real 
duration 
 
Generating a prednisolone-equivalent dose per day: 
• The prednisolone equivalent strength was calculated using a standard GC 
conversion calculator 
• The prednisolone equivalent dose per day was then calculated by multiplying 
the prednisolone equivalent strength by the numeric daily dose (number tabs 
per day) 
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Dealing with implausible daily doses >100mg/d 
• Where possible, this was corrected by calculating a new numeric daily dose 
based on an alternate duration of therapy (21 scripts remained uncorrected 
because scripts were for methylprednisolone 100mg which converts to 
prednisolone 125mg) 
 
C. Handling concurrent and sequential prescriptions 
 
Dealing with duplicate scripts 
• Scripts were considered to be true duplicates if they were for the same patient, 
with the same start date, stop date, product code and strength 
• These duplicates were removed so that only a single copy remained 
 
Dealing with overlapping scripts 
• For scripts written for the same patient with the same start date and stop date 
but different strengths- the prednisolone equivalent dose was added up and 
excess events were deleted 
• Scripts written for the same patient, on the same day but for different durations 
were also combined with doses for overlapping periods added together 
 
The data preparation script described above was used to define the GC prescription data 
for the work presented in Chapter 3. However, due to some minor changes to CPRD file 
and variable names over time, this script was updated for the work presented in Chapter 
6. While the statistical code had to be carefully reviewed and updated, the assumptions 
essentially remained unchanged. CPRD requires considerable coding to produce an 
analysis-ready data set, and familiarisation with the dataset and variables, learning how 
to use a powerful statistical software package to create the statistical code for data 
preparation scripts, were major components of the work in this thesis. 
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3 GC Use in RA in the UK (CPRD) 
 
This chapter addresses the first aim of the thesis: 
 
To describe the use of oral glucocorticoids and explore patient and prescriber factors 
that influence their use in rheumatoid arthritis in the UK (Chapter 3) and Australia 
(Chapter 4) 
3.1  Introduction 
The literature clearly describes polarised views regarding GC use in RA, with some 
concluding that GCs should be used at ‘the lowest possible dose for the shortest time 
possible’ and others promoting the long-term use of low-dose oral GCs as disease-
modifying agents (82). This chapter includes a published manuscript describing the 
epidemiology of oral GC use among incident RA patients in the UK and looks at patient 
and prescriber characteristics that influence GC use.  These analyses were carried out 
using CPRD, which provides an ideal setting in which to explore patterns and factors 
influencing GC use among RA patients seen in UK primary care. As this database contains 
prescription data, it was possible to explore ever-never exposure as well as dose and 
duration of therapy. This paper also looks at patient factors, including age, gender, 
comorbidities and the use of other medications, and their association with GC use. In 
addition, prescribers were categorised as either ‘high’ or ‘low ’GC prescribers, based on 
their tendency to prescribe GCs across all indications. Analyses were carried out to 
explore whether factors that influenced GC use differed according to prescriber 
tendency. 
 
A major component of the methodology of this work involved preparing the GC 
prescription data, which has been described in detail in Chapter 2. Familiarisation with 
the variables in such a large and complex dataset was time consuming but important. 
Learning the required coding skills and developing the statistical code to manipulate and 
tidy the data was also an important part of this work, and necessary for building the GC 
data cleaning script used to prepare the prescription data. 
 
The findings identified that GC use is greater among patients with characteristics which 
may put them at greater risk of GC AEs, including older age and cardiovascular 
comorbidities. These findings have the potential for clinical translation as they identify 
certain sub-populations where a more careful assessment of the benefits and harms of 
GC treatment may be indicated.  In order for this work to be carried out, customised 
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skills in statistical coding and data cleaning are indispensable. These skills will be 
invaluable for future research in the current climate of ‘big data’.  
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Half of UK patients with rheumatoid
arthritis are prescribed oral glucocorticoid
therapy in primary care: a retrospective
drug utilisation study
Rachel J. Black1,2,5*, Rebecca M. Joseph1,3, Benjamin Brown4, Mohammad Movahedi1, Mark Lunt1
and William G. Dixon1,3,4,6
Abstract
Background: Patients with rheumatoid arthritis (RA) have shared care between rheumatologists and general
practitioners (GPs). Rheumatologists guide immunosuppressive therapy, whilst GPs rely on analgesia and
glucocorticoid (GC) therapy to manage active disease. The objective of this study was to describe patterns of
GC prescribing for patients with RA in primary care and to determine the influence of patient characteristics
and prescriber.
Methods: Incident RA patients were identified within the Clinical Practice Research Datalink, a United Kingdom
(UK) primary care research database. Descriptive statistics identified patterns of oral GC prescribing. Prescribers
were categorised by their tendency to prescribe GCs (high/low). Logistic regression was used to identify
baseline characteristics associated with GC prescriptions during follow-up and to examine whether baseline
characteristics influenced prescribing differently in high versus low prescribers.
Results: A total of 7777 patients (47 %) received ≥1 GC prescription during follow-up. The average daily dose
was 7.5 mg (IQR 5–15.3 mg). Of those who received GCs, >50 % were prescribed >10 mg/day and 20 % >30 mg/day.
The median proportion of time spent on GCs was 26.3 % (IQR 3.8–70.0 %). Age and cardiovascular disease (CVD) were
associated with increased likelihood of receiving GCs. High prescribers more commonly prescribed GC therapy in older
patients and patients with hypertension.
Conclusions: Half of patients with incident RA received GCs in primary care. Average GC use was 7.5 mg for 25 % of the
time, perhaps higher usage than rheumatologists and GPs might expect. GCs were prescribed more commonly in certain
high-risk populations, including older patients and those with CVD.
Keywords: Glucocorticoids, Rheumatoid arthritis, Drug utilisation, Primary care
Background
Glucocorticoid (GC) therapy was first introduced as a
treatment for rheumatoid arthritis (RA) over 60 years
ago [1]. GCs have potent anti-inflammatory properties
that rapidly relieve joint pain, swelling and stiffness and
also prevent structural damage [2]. However, they are as-
sociated with significant and predictable side effects
(SEs) of concern to both patients and physicians [3, 4].
In the general population, GCs account for 2.5 % of all
adverse drug reactions leading to hospital admission [5].
Guidelines for rheumatologists advocate short-term use
of GCs [6], an acknowledgment that longer duration of
therapy is associated with increased risk of developing
certain SEs such as infection [7].
The management of RA, a condition where disease ex-
acerbations are part of the natural history, involves
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shared care between the treating rheumatologist and the
patient’s general practitioner (GP). Shared care for pa-
tients with RA is recommended in many international
guidelines and standards of care [8–11] and is common
practice in the UK. In early RA, GPs will often com-
mence initial therapy, which may include simple anal-
gesia, non-steroidal anti-inflammatory drugs (NSAIDs)
and GCs. The treating rheumatologist then guides on-
going management with advice about disease-modifying
anti-rheumatic drugs (DMARDs) and GC use. When
faced with active disease, rheumatologists can initiate
changes to DMARD therapy, however GPs rarely alter
DMARDs and their options for treating disease flares
that occur between rheumatology appointments are usu-
ally limited to GCs and analgesia. In some instances,
GPs will initiate or continue GCs based on the recom-
mendation of the treating rheumatologist, and on other
occasions they may initiate therapy based on their own
clinical judgement. The extent and pattern of GC pre-
scribing for RA in primary care has not been well quan-
tified or described. Therefore, it is not known if doses
and duration of treatment are in keeping with current
guidelines. It is important to understand if certain pa-
tient groups are more likely to receive GCs in primary
care, in particular those at increased risk of developing
GC SEs such as older patients or those with pre-existing
comorbidities. Doctors are known to have differing be-
liefs about GC use and its risks [12–14], therefore it is
also important to understand if certain doctors prescribe
more GCs.
The purpose of this study is to examine how oral GCs
are prescribed for patients with RA in UK primary care.
The primary objective is to describe overall drug utilisa-
tion and patterns of dose and duration. Secondary objec-
tives are to explore the association between patient
characteristics and GC use, and to examine variability in
prescribing practices between prescribers.
Method
Data source
This study utilised the Clinical Practice Research Data-
link (CPRD) [15], an automated database that contains
pseudonymised, prospectively collected electronic med-
ical records from registered UK general practices. In the
UK, healthcare is centralised through GPs and electronic
medical records are maintained and updated within gen-
eral practices. The electronic medical records contain all
primary care details plus information about referrals.
Anonymised prescriber and practice codes are also avail-
able as part of the CPRD dataset.
Studies have found the data held by the CPRD to be
representative of the UK population in terms of age and
gender structure [16, 17]. Validation studies have dem-
onstrated good completeness and accuracy of the data,
particularly for chronic diseases [18, 19]. The CPRD has
its own internal quality measures at the patient and
practice level, including acceptability flags based on con-
tiguity and quality of patient data, and an ‘up to stand-
ard’ date for practices based on continuity of data
recording [20]. UK primary care electronic medical re-
cords use a unique coding system with Read codes
assigned to medical diagnoses and Product codes
assigned to medications [21].
Population and follow-up period
Figure 1 outlines how the cohort of incident RA was
derived. All patients with an RA code recorded in
CPRD between 1 January 1992 and 31 December
2009 were identified. A validated algorithm, shown to
have a sensitivity of 84 % and a specificity of 86 %
when compared to the American College of Rheuma-
tology 1987 revised RA classification criteria [22], was
then used to identify patients with true RA. The RA
diagnosis date was defined as the date of the first RA
code in patients with validated RA. Patients with inci-
dent RA were identified as those with an RA diagno-
sis date on or after the 1 January 1992 and at least
12 months of data recorded prior to diagnosis. Those
with a GC prescription greater than a pre-defined
maximum prednisolone equivalent dose of 100 mg
per day and those aged less than 16 years were
excluded. Follow-up began on the date of RA diagno-
sis and ended when the patient left the practice, died,
the study period finished (31 December 2009) or on
the date data was last collected from the practice,
whichever occurred first.
Outcome measure: glucocorticoid prescriptions
All prescriptions of oral GCs (prednisolone, cortisone,
hydrocortisone, triamcinolone, methylprednisolone,
dexamethasone, bethamethasone, budesonide and defla-
zacort) were identified. Dosages were converted to a
prednisolone-equivalent daily dose. Patients were classi-
fied as having ever or never been prescribed oral GCs
according to receipt of at least one prescription during
their follow-up period.
Predictors: patient characteristics and prescriber tendency
Baseline patient characteristics postulated to poten-
tially influence prescribing were divided into demo-
graphics, other inflammatory indications for GCs,
GC-associated comorbidities (e.g. osteoporosis, dia-
betes) and DMARD use as a surrogate for disease
severity (Table 1). Characteristics and DMARDs were
defined as being present at baseline if the diagnosis
date or first prescription date occurred on or before
RA diagnosis date.
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The primary (i.e. most frequent) prescriber of all medi-
cations was determined for each patient. For each pri-
mary prescriber, the mean proportion of time their
patients spent on GCs during follow-up was calculated
by dividing the length of time spent on GCs by the
length of follow-up time for each patient and then deter-
mining the mean of this value amongst all patients seen
by a given primary prescriber. Prescriber tendency was
then assigned as ‘high’ or ‘low’ prescribers based on
whether the mean proportion of time their patients
spent on GCs was above or below the median value.
Statistical analysis
Descriptive analysis
Descriptive statistics were used to identify patterns of
GC prescribing including: ever use (yes/no), dose,
Table 1 Patient characteristics thought to be potentially relevant to GC prescribing practices
Patient demographics Age
Gender
GC-associated comorbidities Musculoskeletal Osteoporosis, avascular necrosis, myopathy
Endocrine/metabolic Diabetes
Cardiovascular Hypertension, hyperlipidaemia, cardiovascular diseases (myocardial infarction, angina, stroke)
Gastrointestinal Peptic ulcer disease, pancreatitis
Psychological/behavioural Depression, psychosis, insomnia
Inflammatory comorbidities Respiratory Chronic obstructive pulmonary disease, asthma, lower respiratory tract infections
Skin diseases Atopic eczema, cutaneous vasculitis, cutaneous lupus





Other DMARDs Cyclosporine, azathioprine, penicillamine, chloroquine, gold
GC glucocorticoid, DMARDs disease-modifying anti-rheumatic drugs
Fig. 1 Steps taken to obtain the final cohort
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duration and then dose and duration combined. Ever
use was determined as a binary yes/no variable for the
observation period and separately for the 12 months
prior to diagnosis. For patients who received at least one
GC prescription during the observation period, the
average, lowest and highest prednisolone equivalent
daily doses were determined for the time they were
exposed. The median of these values across all treated
patients was then calculated as a population summary
statistic. The proportion of patients to ever receive
greater than 5 mg, 10 mg, 20 mg and 30 mg per day
was also determined.
The total number of patient years contributing to the
follow-up period was determined, as was the number of
patient years spent on and off GCs. For each patient that
ever received GCs, the duration of follow-up, duration
on GCs and proportion of their total follow-up time
spent on GCs was determined. The median of these
values was calculated as a population summary statistic.
A GC course was defined as consecutive GC prescrip-
tions where the end date of the first prescription was
not more than one calendar day different from the start
date of the next prescription. The median number of
courses per year and the number of patients with a sin-
gle course longer than 3 months and 1 year was deter-
mined. Finally, dose and duration were combined and
the proportion of patients taking more than 5 mg/day
and 10 mg/day for greater than 3 months and 1 year
was calculated.
The number of patients receiving a GC injection and
the median number of injections per patient was also
determined.
Patient characteristics
Univariate logistic regression, adjusted for age and gen-
der, was initially carried out and then stepwise logistic
regression was used to identify baseline patient charac-
teristics associated with GC prescriptions (ever versus
never) including demographics, other possible inflamma-
tory indications, GC-associated comorbidities and
DMARDs.
Prescriber tendency
Univariate logistic regression with an interaction term
was used to determine the effect of prescriber tendency
on the likelihood of receiving a GC prescription (ever
versus never) during follow-up and to test the inter-
action between prescriber tendency and baseline
patient characteristics, including patient demographics
and GC-associated comorbidities.
All analyses were carried out using Stata version 12.1
(StataCorp LP, College Station, TX, USA). The study was
approved by the CPRD Independent Scientific Advisory
Committee (protocol 11_113RA2).
Results
From 1 January 1992 to 31 December 2009, 60,186
patients had at least one code for RA. Once the vali-
dated algorithm was applied to this cohort, 38,884 RA
patients from 636 general practices across the UK were
identified. Of these, 4856 were excluded because their
RA diagnosis date occurred after their end of follow-up
date, 12 were excluded due to a prednisolone-equivalent
daily dose greater than a pre-defined maximum of 100
mg per day and 139 were excluded because they were
aged less than 16 years. A total of 16,536 remained in
the final cohort after the definition for incident RA was
applied as shown in Fig. 1. The majority of the patients
were female (69.3 %) and the median age was 59.8 years
[interquartile range (IQR) 49.0–70.3].
Patterns of GC use
Ever use (yes/no)
There were 7777 (47 %) patients who received at least
one oral GC prescription during the study period and
these patients were classified as ever receiving a GC pre-
scription. There were 3412 patients (20.6 %) who re-
ceived a GC prescription in the 12 months preceding
their diagnosis. Of these, 2940 (86.2 %) were prescribed
further GCs during the follow-up period.
Dose
For those that ever received GCs, the population distri-
bution was a median of 7.5 mg per day (IQR 5–15.3 mg)
for the average dose, 5 mg per day (IQR 2.5–7.5 mg) for
the lowest dose and 15 mg per day (IQR 7.5–30 mg) for
the highest dose. Of those prescribed GCs during
follow-up, 83 % ever received a prednisolone equivalent
daily dose of more than 5 mg/day, 58 % more than
10 mg/day, 39 % more than 20 mg/day and 18 %
more than 30 mg/day.
Duration of GC therapy
Total follow-up time was 92,641 patient years (mean 5.6
years/patient), with 14,382 (15.5 %) patient years spent
on GCs and 78,259 (84.5 %) patient years spent off GCs.
Of the 7777 patients who received GCs during follow-
up, the median duration of follow-up time spent on GCs
was 0.80 years (IQR 0.15–2.56) and the proportion of
time spent on GCs was 26.3 % (IQR 3.8–70.0 %).
Of those who received GCs in the 12 months prior to
diagnosis, the median proportion of time spent on GCs
during that year was 22.7 % (IQR 5.4–67.2 %). Table 2
summarises GC doses and duration of use.
Of those that received GCs, the median number of GC
courses throughout follow-up was 5 (IQR 2–12) and the
median number of courses per year was 1.4 (IQR 0.4–3.0).
The number of patients that received more than two GC
courses per year was 3060 (39.3 % of those that received
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GCs). The median duration of each GC course was 50
days (IQR 21–111). Of those that received GCs, 57.1 % re-
ceived a course longer than 3 months and 13.1 % were
prescribed a GC course lasting longer than 1 year.
Dose and duration of treatment
Of those prescribed GCs, 26.6 % received continuous treat-
ment with more than 5 mg/day for longer than 3 months
and 2.4 % received continuous treatment with greater than
5 mg/day for longer than 1 year. 4.7 % received more than
10 mg/d for more than 3 consecutive months.
GC injections
There were 8373 prescriptions for GC injections (intra-
muscular, intra-articular and periarticular) during the
study period in 2911 patients (37 % total cohort). The
majority were for methylprednisolone (72 %), followed
by triamcinalone (21 %), prednisolone (4 %) and hydro-
cortisone (3 %). The median number of injections per
patient was 2 (IQR 1–3).
Patient factors associated with GC prescribing
Each 10-year increase in age was associated with a 17 %
greater likelihood of being prescribed GCs [odds ratio
(OR), 1.17 95 % confidence interval (CI) 1.14–1.20].
Higher GC prescribing was seen in patients with in-
flammatory comorbidities of the lung: asthma (OR
1.58, 95 % CI 1.42–1.76), chronic obstructive pulmonary
disease (OR 1.63, 95 % CI 1.33–1.99) and lower respiratory
tract infections (OR 1.22, 95 % CI 1.11–1.34). However,
there was no association with inflammatory conditions of
the skin or gastrointestinal tract (GI) tract (Table 3).
The association with pre-existing comorbidities known to
be associated with GC therapy was less consistent. GC pre-
scribing was higher in patients with pre-existing cardiovas-
cular disease (CVD) (OR 1.25, 95 % CI 1.03–1.51) and in
current smokers (OR 1.22, 95 % CI 1.13–1.32) but lower in
patients with diabetes mellitus (DM) (OR 0.71, 95 %
CI 0.62–0.82) and high cholesterol (OR 0.86, 95 % CI
0.76–0.97). There was an association with osteopor-
osis, depression and insomnia seen in the univariate
model, but these factors were not included in the
final multivariate model. There was no significant as-
sociation with other GC-associated comorbidities at
baseline including avascular necrosis, myopathy,
hypertension (HTN), peptic ulcer disease (PUD) or
pancreatitis.
A previous GC prescription prior to RA diagnosis was
the strongest predictor of ever receiving a prescription
post-diagnosis (OR 9.50, 95 % CI 8.51–10.60). GC pre-
scribing was lower with baseline methotrexate and sulfa-
salazine use, but higher with leflunomide and ‘other’
DMARD use.
Prescriber tendency and GC prescribing
In total 3270 GPs were assigned as primary prescribers.
The mean proportion of time their patients spent on GCs
ranged from 0 to 100 % (median 11.3 %, IQR 0.11–25.9 %).
GPs were thus categorised as ‘high’ prescribers if their pa-
tients spent a mean of ≥11.3 % of follow-up on GCs. A total
of 6427 (38.9 %) patients were assigned a ‘low’ GC pre-
scriber and 10,109 (61.1 %) were assigned a ‘high’ GC
prescriber.
By definition, the likelihood of a patient receiving a GC
prescription during follow-up was greater if they were
seen by a ‘high’ GC prescriber compared to a ‘low’ GC
prescriber (OR 3.10, 95 % CI 2.90–3.31). The probability
of receiving a GC prescription increased with each decade
of patient age for both ‘low’ (OR 1.15, 95 % CI 1.11–1.20)
and ‘high’ (OR 1.26, 95 % CI 1.23–1.29) prescriber groups
(Table 4). This effect differed significantly between the
two prescriber groups (p <0.001), suggesting that although
all older patients were more likely to receive GCs, the ef-
fect of age was greater in those seen by a ‘high’ prescriber.
In other words, high prescribers were even more likely to
prescribe GCs in elderly patients.
Table 2 Summary statistics of GC doses and duration of use per patient during follow-up and in the 12 months prior to study entry
for those patients ever prescribed GCs (n = 7777)
Follow-up period 12 months prior to study entry
Measure* Median IQR Median IQR
Duration of follow-up (years) 5.29 2.62–8.58 - -
Cumulative duration of GC use (years) 0.80 0.15–2.56 0.23 0.05–0.67
Proportion of follow-up time on GCs (%) 26.3 3.8–70.0 22.7 5.4–67.2
Average dose** (mg) 7.5 5–15.3 10 5–20
Lowest dose** (mg) 5 2.5–7.5 5 3–15
Highest dose** (mg) 15 7.5–30 15 6–30
GC glucocorticoid, IQR interquartile range
*Summary statistics were obtained by calculating the value for each patient and then determining median values across the whole population
**All doses are prednisolone-equivalent daily doses
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It was hypothesised that those with a greater ten-
dency to prescribe GCs may be prescribing inappro-
priately to those with baseline GC-associated
comorbidities. This was only seen for prescribers
whose patients had a baseline diagnosis of HTN, who
were more likely to receive a GC prescription in the
’high’ prescriber group (OR 1.29 95 % CI 1.17–1.42),
but not in the ‘low’ prescriber group (OR 1.08 95 %
CI 0.95–1.24), with the effect differing significantly
between groups (p = 0.039).
Discussion
This study set out to describe the utilisation of GC ther-
apy for RA in primary care, patterns of GC prescribing
and to examine the influence of patient factors and pre-
scriber tendency on GC prescribing amongst GPs for pa-
tients with RA. Nearly half the cohort received a GC
prescription in primary care during follow-up, consistent
with the findings of the QUEST-RA study [23]. The
population distribution of the mean prednisolone-
equivalent daily dose was 7.5 mg, taken for around 25 %
Table 3 Baseline patient characteristics associated with GC prescriptions





(odds ratio, 95 % CI)
Multivariate stepwise analysis
(odds ratio, 95 % CI)
Baseline demographics
Age (decades) 1.02, 1.02–1.02** 1.17, 1.14–1.20
Gender (female) 5313, 68.32 % 6153, 70.25 % 0.94, 0.88–1.00
Current smoking (versus never) 2147, 27.61 % 2385, 27.23 % 1.04, 1.00–1.08** 1.22, 1.13–1.32
Baseline GC-associated comorbidities
Osteoporosis 427, 5.49 % 279, 3.19 % 1.42, 1.21–1.66**
Avascular necrosis 7, 0.09 % 4, 0.05 % 1.68, 0.49–5.78
Myopathy 14, 0.18 % 10, 0.11 % 1.35, 0.60–3.08
Diabetes mellitus 603, 7.75 % 699, 7.98 % 0.85, 0.76–0.95** 0.71, 0.62–0.82
Cardiovascular disease 364, 4.68 % 264, 3.01 % 1.22, 1.04–1.44** 1.25, 1.03–1.51
Hypertension 1842, 23.69 % 1754, 20.03 % 0.98, 0.90–1.06
Hyperlipidaemia 798, 10.26 % 830, 9.48 % 0.93, 0.84–1.04 0.86, 0.76–0.97
Peptic ulcer disease 382, 4.91 % 334, 3.81 % 1.13, 0.97–1.32
Pancreatitis 46, 0.59 % 43, 0.49 % 1.11, 0.73–1.70
Depression 1684, 21.65 % 1847, 21.09 % 1.11, 1.03–1.19 **
Insomnia 985, 12.67 % 865, 9.88 % 1.21, 1.10–1.34**
Psychosis 56, 0.72 % 52, 0.59 % 1.24, 0.84–1.81
Baseline inflammatory comorbidities
Chronic obstructive pulmonary disease 540, 6.94 % 189, 2.16 % 2.74, 2.31–3.25** 1.63, 1.33–1.99
Asthma 1492, 19.18 % 925, 10.56 % 2.07, 1.89–2.27** 1.58, 1.42–1.76
Lower respiratory tract infection 1717, 22.08 % 1342, 15.44 % 1.47, 1.35–1.59** 1.22, 1.11–1.34
Inflammatory bowel disease 78, 1.11 % 63, 0.72 % 1.35, 0.96–1.89
Cutaneous lupus 13, 0.17 % 11, 0.13 % 1.30, 0.58–2.93
Cutaneous vasculitis 6, 0.08 % 0, 0.00 % 1
Atopic eczema 1084, 13.94 % 1127, 12.87 % 1.10, 1.00–1.20**
Baseline DMARD use
Methotrexate 465, 5.98 % 501, 5.72 % 1.07, 0.93–1.22 0.80, 0.66–0.97
Sulfasalazine 468, 6.02 % 581, 6.63 % 0.91, 0.80–1.03 0.69, 0.58–0.83
Hydroxychloroquine 259, 3.33 % 256, 2.92 % 1.20, 1.00–1.43**
Leflunomide 105, 1.35 % 71, 0.81 % 1.83, 1.35–2.49** 1.75, 1.18–2.59
Other DMARDs*** 277, 3.56 % 151, 1.72 % 2.06, 1.68–2.52** 1.68, 1.28–2.19
GC glucocorticoid, DMARDs disease-modifying anti-rheumatic drugs, CI confidence interval
*Adjusted for age and gender
**Significant in univariate analysis
***Other DMARDs include gold, penicillamine, cyclosporine, chloroquine and azathioprine
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of follow-up time in GC users. This average dose of 7.5
mg is within the European League Against Rheumatism
(EULAR) definition of low-dose therapy of ≤7.5 mg per
day [24], and in keeping with studies reporting efficacy
[25–28] and reduced adverse effects with low-dose
therapy[4]. However, more than 50 % were prescribed
doses >10 mg per day at some point and nearly 20 %
were prescribed doses greater than 30 mg per day. The
indication for prescriptions is not available in CPRD,
therefore it is difficult to know whether high-dose ste-
roids were prescribed for the patient’s RA or for other
indications. The median cumulative duration of time
spent taking GCs was 0.8 years/10 months with the
interquartile range spanning from 0.15 years/2 months
to 2.56 years. This highlights that some patients are
taking GCs for longer than recommended [29], placing
them at increased risk of developing SEs [30, 31].
As expected, the presence of certain inflammatory co-
morbidities at diagnosis, in particular inflammatory lung
conditions, influenced GC prescribing. Of concern, GC
therapy was prescribed more commonly in certain
higher risk populations, including older patients and
those with CVD. These findings are in keeping with a
recent prospective RA study that found rheumatologists
were more likely to prescribe GCs and less likely to
commence DMARDs in patients who develop RA at an
older age, who were also more likely to have comorbidi-
ties including CVD, HTN and DM [32]. The authors
postulated that this might be due to clinician concerns
about the potential side effects of DMARDs in older pa-
tients, particularly those with more comorbidities. How-
ever, they also point out that DMARDs are well
tolerated in older patients [33] compared to the poten-
tial difficulties of GC SEs in older patients. It has been
shown that RA patients taking ≥7.5 mg prednisolone per
day are at increased risk of CVD [34, 35]. Pre-existing
CVD, HTN and smoking, an important risk factor for
CVD, may worsen cardiovascular outcomes further. Al-
though patients with baseline DM and hyperlipidaemia
received fewer GC prescriptions, it was also concerning
that other baseline conditions such as PUD had no influ-
ence on GC prescribing.
Baseline use of methotrexate and sulfasalazine was as-
sociated with less GC prescribing and is in keeping with
the knowledge that early treatment of RA within the
‘window of opportunity’ leads to lower disease activity
[36], and potentially reduced GC requirement. Several
studies have suggested that GC prescribing is also influ-
enced by biological DMARDs (bDMARDs), which have
been shown to have a GC-sparing effect [37–40]. In the
UK, bDMARDS can only be prescribed by rheumatolo-
gists and this data is therefore not captured by CPRD.
Table 4 Effect of baseline characteristics on GC prescriptions according to prescriber tendency
Variable Low prescriber group (OR, 95 % CI) High prescriber group (OR, 95 % CI) p value**
Demographics
Age (decades) 1.15, 1.11–1.20* 1.26, 1.23–1.29* <0.001
Gender (female) 0.98, 0.87–1.10 0.89, 0.82–0.97* 0.211
Current smoker (versus never) 1.09, 1.02–1.17* 1.07, 1.02–1.13* 0.744
GC-associated comorbidities
Osteoporosis 1.49, 1.14–1.95* 1.84, 1.50–2.25* 0.225
Avascular necrosis 2.28, 0.32–16.22 1.84, 0.36–9.51 0.870
Myopathy 2.29, 0.57–9.15 1.23, 0.45–3.38 0.479
Diabetes mellitus 0.88, 0.72–1.08 1.02, 0.88–1.18 0.257
Cardiovascular disease 1.38, 1.04–1.84* 1.62, 1.31–2.00* 0.373
Hypertension 1.08, 0.95–1.24 1.29, 1.17–1.41* 0.039
Hyperlipidaemia 1.10, 0.92–1.31 1.07, 0.94–1.22 0.829
Peptic ulcer disease 1.36, 1.06–1.74* 1.33, 1.09–1.63* 0.910
Pancreatitis 1.00, 0.49–2.05 1.44, 0.81–2.54 0.442
Depression 1.09, 0.96–1.23 1.09, 0.99–1.20 0.994
Insomnia 1.27, 1.08–1.50* 1.36, 1.20–1.54* 0.548
Psychosis 1.14, 0.60–2.17 1.29, 0.78–2.14 0.767
Prior use
GC prescription prior to follow up 6.52, 5.51–7.71* 11.76, 10.24–13.51* <0.001
GC glucocorticoid, OR odds ratio, CI confidence interval
*Significant predictors of GC prescriptions (unadjusted)
**p value indicates significance of any differing effect between high and low prescriber groups
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Therefore this study was unable to assess the influence
of these agents on GC prescribing.
The strengths of this study include the large cohort
size and the real-life setting in which CPRD data is cap-
tured. All oral GC prescriptions were recorded within
the database, meaning there was no missing prescription
data. The main limitation of this study design was the
lack of access to measures of disease activity, which
would be expected to be important in understanding
which patients receive GC prescriptions. The informa-
tion needed for standard measures of disease activity
such as EULAR response and disease activity score
(28-joint count) (DAS28) are not routinely collected
by GPs and were therefore not available on the CPRD
database. A second limitation of this study is that it
was unable to assess the influence of rheumatologist
prescribing practices or advice on GC prescribing in
primary care as rheumatologist prescribing data is not
captured in CPRD. However, it is likely that some GC
prescriptions will be initiated by a rheumatologist and
continued in primary care. On other occasions, GPs
may initiate GCs knowing that this is the practice/rec-
ommendation of the treating rheumatologist when
faced with active disease. This interaction between
prescribers is of interest and warrants further investi-
gation in the future.
Conclusions
In conclusion, this study has found that 50 % of patients
with incident RA were prescribed GCs in UK primary
care for 25 % of the time they were observed. Of those
who received GCs, more than 50 % were prescribed
doses >10 mg per day and nearly 20 % were prescribed
doses greater than 30 mg per day. Many GPs and rheu-
matologists may be surprised by the proportion of pa-
tients, the dosages prescribed and the duration of use of
GCs in primary care, highlighting the need to be aware
of GC use in this setting in order to avoid excess ex-
posure and associated side effects. Certain baseline co-
morbidities influenced GC prescribing, including some
high-risk patient groups that were more likely to re-
ceive GC prescriptions. This information is useful for
both rheumatologists and GPs involved in the care of
patients with RA because it highlights the extent of GC
prescribing in primary care and identifies at risk groups
more likely to receive GCs. Given the variety of treat-
ment options available for RA, it is important to con-
sider the individual patient’s specific comorbidities and
risk of developing GC SEs and introduce alternative
therapies where appropriate.
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4 GC Use in RA in Australia (ARAD) 
 
This chapter also addresses the first aim of the thesis, in a second cohort in Australia: 
 
To describe the use of oral glucocorticoids and explore patient and prescriber factors 




This chapter includes a published manuscript describing the epidemiology of oral GC use 
among Australian patients with RA enrolled in ARAD. It explores patient factors that 
influence GC use in a second population as well as expanding this question to look at 
patient factors associated with the commencement and the cessation of GC use. ARAD 
does not collect information on GC dose, however the registry format has the benefit 
of collecting the same data at consistent time intervals longitudinally. This study looked 
at how GC use has changed over time as well as at factors influencing GC current use, 
commencement and cessation. Potential influencing patient factors explored in this 
work included demographics, concurrent medications, Health Assessment 
Questionnaire (HAQ) and visual analogue scale (VAS) measures of pain and arthritis 
activity in the past week. Previous studies have shown bDMARDS to have a steroid-
sparing effect in RA in terms of dose reduction (212-216), however the question of 
whether bDMARD use leads to GC cessation or prevents GC commencement has not 
previously been addressed in the literature. This study used transition state analysis in 
order to specifically assess this, and found that while bDMARD use was associated with 
reduced commencement of GCs, it did not influence the cessation of GCs. Unlike the 
CPRD cohort, the findings of this study were that GC use was less likely with increasing 
age. The transition state analysis added to this finding, showing that while older patients 
were less likely to commence GCs, they were less likely to cease GC treatment, once 
started. 
 
The selection of appropriate statistical analyses was an important aspect of the 
methodology of this paper. In order to ensure the analyses were answering the research 
questions posed, whilst maximising the use of the data available, we moved away from 
traditional regression models and instead used panel regression and transition state 
analyses. These types of statistical models are well described in the statistical literature 
but less commonly seen in the medical literature. As described by Douglas Altman in 
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1994, there is a recognised delay in the translation of new bio-statistical methods to 
medical research (217). In the dataset used for this work, the GC outcome variable, 
along with many of the predictor variables, was time-varying. Most traditional models 
are unable to deal with the time-varying nature of these variables and require a cross-
sectional snapshot, ignoring large amounts of the data available. Cox regression analysis 
is traditionally used when time- varying variables are present, however a time-to-event 
analysis would not have addressed the research questions in this scenario, given the 
repeated episodic nature of patterns of GC use. 
 
In summary, this section of work expanded on the work carried out in CPRD in 
understanding how GCs are used in RA. In particular, it provided an Australian 
perspective of how GC use has changed over time and looked at factors influencing GC 
commencement and cessation as well as current use.  
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Factors associated with oral glucocorticoid
use in patients with rheumatoid arthritis: a
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Abstract
Background: Glucocorticoids (GCs) are used in ~ 60% of patients with rheumatoid arthritis (RA). Although disease-
modifying, they also have significant adverse effects. Understanding factors associated with GC use may help minimise
exposure. The aims of the present study were to describe oral GC use in RA; determine any change in use over time;
and determine factors associated with oral GC use, commencement or cessation.
Methods: Adult patients with RA were identified in the Australian Rheumatology Association Database (ARAD), a national
Australian registry that collects long-term outcome data from patients with inflammatory arthritis. Patients were
categorised by their ARAD date of entry (DOE), with population-averaged logistic regression and transition state
analysis used to determine any change in GC use over time. Fixed-effects panel regression was used to examine
whether GC current use was associated with pain/arthritis activity/Health Assessment Questionnaire (HAQ) scores
or medication use. Transition state analysis was used to assess whether these factors influenced the commencement or
cessation of GCs.
Results: A total of 3699 patients with RA completed a baseline ARAD questionnaire (73% female, mean age 57 years).
The probability of GC use decreased over time according to ARAD DOE: September 2001 to March 2005, 55% (95% CI
52–58%); March 2005 to September 2008, 47% (45–49%); September 2008 to March 2012, 42% (39–45%); and March
2012 to October 2015, 39% (34–43%) (p < 0.001). Conventional synthetic disease-modifying anti-rheumatic drugs (OR
10.13; 95% CI 8.22–12.47), non-steroidal anti-inflammatory drugs (1.18; 1.02–1.37) and opioids (2.14; 1.84–2.48) were
associated with GC current use, as were lower pain scores (0.94; 0.90–0.98), higher arthritis activity scores (1.09; 1.05–1.
14) and poorer HAQ scores (1.52; 1.30–1.79). Use of biologic disease-modifying anti-rheumatic drugs (bDMARDs) was
not associated with GC current use (0.98; 0.83–1.15) or GC cessation (HR 0.87; 95% CI 0.75–1.01), but it was associated
with GC commencement (0.54; 0.47–0.62).
Conclusions: The probability of oral GC use decreased over time, with reduced commencement and increased cessation
of GCs. The modest effect of bDMARDs on GC cessation was not statistically significant.
Keywords: Glucocorticoids, Rheumatoid arthritis, Epidemiology, Drug use
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Background
Glucocorticoids (GCs) are used in ~ 60% of patients with
rheumatoid arthritis (RA) globally [1]. Although they
have been shown to have disease-modifying properties
[2], they are also associated with significant adverse effects
[3, 4]. For this reason, many international guidelines
recommend that the lowest possible dose and duration of
GC therapy be used, if prescribed [5, 6]. Understanding
the factors that are associated with GC use may help to
minimise GC use. The use of GCs in RA may have chan-
ged over time with the introduction of biologic disease-
modifying anti-rheumatic drugs (bDMARDs). Patients
with severe disease resistant to conventional synthetic
disease-modifying anti-rheumatic drugs (csDMARDs)
prior to the introduction of bDMARDs may have been
more likely to receive GCs than those with resistant
disease and early access to bDMARDs. Previous stud-
ies have shown that bDMARDs can have a GC-sparing
effect in RA, with a significant GC dose reduction seen
in those commenced on bDMARDs compared with
those who are not [7–11]. However, no prior studies
have looked at the association between bDMARD use
and GC cessation. Arguably, GC cessation rather than
reduction should be the goal of therapy.
The following were the aims of the present study:
1. To describe the use of GCs among patients with RA
enrolled in the Australian Rheumatology Association
Database (ARAD) and any change in use over time
2. To determine factors associated with GC current
use, including demographics, patient-reported pain
score, arthritis activity score, Health Assessment
Questionnaire (HAQ) score and concurrent
medication use
3. To determine factors associated with the
commencement and cessation of GCs in order to




ARAD is a voluntary Australian biologic registry estab-
lished in 2001 to collect patient-reported long-term safety
and other outcome data from patients with inflammatory
arthritis, including RA, psoriatic arthritis, ankylosing
spondylitis and juvenile idiopathic arthritis [12]. It includes
participants commenced on bDMARDs as well as control
subjects on conventional treatments (enrolment of control
subjects since February 2007). Rheumatologists refer
patients to the registry with minimal baseline information,
including diagnosis, as well as rheumatoid factor and anti-
citrullinated protein antibody (ACPA) status (ACPA
collected since November 2010). All participants may com-
mence, switch or cease bDMARDs at any point during
their follow-up. Following written informed consent,
participants complete a baseline ARAD questionnaire, with
a follow-up questionnaire completed every 6 months for
2 years and then at 12-monthly intervals. The initial ques-
tionnaire is defined as the ‘baseline’ questionnaire, and
there are no exclusions for disease duration, prior therapies
or associated co-morbidities. The questionnaire was ini-
tially available in paper form only, but an electronic version
has been available since August 2009. Adult participants
with a diagnosis of RA were selected for this analysis, with
data censored at October 2015. In order to reflect real-life
clinical practice, participants are included in the registry
with a diagnosis of RA based on expert clinical opinion
(rheumatologist) rather than classification criteria. In
Australia, bDMARDs can be prescribed for RA only by
rheumatologists, and prescribing is restricted on the basis
of the following criteria: (1) The patient has severe, active
RA; (2) the patient has failed a 6-month intensive
csDMARD trial with a minimum of two agents for a mini-
mum of 3 months each; (3) the patient can demonstrate
failure to achieve an adequate response to 6 months of
intensive prior treatment by an elevated erythrocyte sedi-
mentation rate > 25 mm/h and/or an elevated C-reactive
protein level > 15 mg/L, and the patient has an active joint
count of ≥ 20 active (swollen and tender) joints or ≥ 4
major active joints (elbow, wrist, knee, ankle, shoulder
and/or hip). In Australia, there is universal access to medi-
cations via the Pharmaceutical Benefits Scheme (PBS).
bDMARDs have been available on the PBS since August
2004. Prior to this, patients accessed bDMARDs through
clinical trials.
Ethics approval for ARAD has been obtained from 18
committees and organisations across Australia (Additional
file 1). This study was approved by The University of
Adelaide Office of Research Ethics, Compliance and Integ-
rity (approval number H-2015-258).
Outcome measure
For oral GC current use, each questionnaire contains a
section ‘medications for arthritis’ where patients indicate
their use of oral GCs (prednisolone/prednisone) since
their previous questionnaire as ‘never taken’, ‘currently
taking’, ‘stopped taking’ or ‘don’t know’. Data regarding
dosage are not collected. For this analysis, a time-varying
‘current use’ variable was created for which ‘currently
taking’ was coded as ‘yes’ and ‘never taken’, ‘stopped taking’
and ‘don’t know’ responses were coded as ‘no’. The current
use variable includes only oral GC use, with injectable GC
use described but not included in the analyses.
Predictors
Patient demographics, including age and sex, at base-
line/initial questionnaire and a time-varying current age
variable were considered as predictors in the analyses.
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Current use of bDMARDs and csDMARDs were coded
as yes/no time-varying variables using the same method
described for current oral GC use. Current use of
bDMARDs included use of etanercept, adalimumab,
anakinra, infliximab, rituximab, abatacept, tocilizumab,
golimumab or certolizumab. Current csDMARD use
included use of methotrexate, leflunomide, sulphasalazine,
hydroxychloroquine, azathioprine, cyclosporin, intramus-
cular gold or penicillamine. Current use of non-steroidal
anti-inflammatory drugs (NSAIDs) included use of cele-
coxib, diclofenac, ibuprofen, indomethacin, ketoprofen,
meloxicam, naproxen, piroxicam or any other NSAID.
Current use of opioids included use of aspirin and codeine,
paracetamol and codeine, dextropropoxyphene, oxycodone,
OxyContin, morphine or tramadol.
The ARAD questionnaire also contains a global evalu-
ation of disease activity section in which patients are
asked to indicate their level of pain and overall arthritis
activity in the past week on a 0–100 visual analogue
scale (0 indicates no pain/arthritis activity, and 100 indi-
cates pain as bad as it could be/extreme arthritis activ-
ity). In addition to other measures of health-related
quality of life, the questionnaire contains the HAQ [13].
HAQ scores range from 0 to 3, with higher scores
reflecting greater disability [14]. These variables were
also time-varying.
Statistical analysis
Descriptive statistics were used to determine the patterns
of oral GC use at baseline and throughout follow-up. It
was hypothesised that GC use might vary according to the
date of the baseline questionnaire. Prior to the availability
of bDMARDs, there were limited treatment options for
patients with RA with ongoing disease activity despite
maximal csDMARD therapy. GC use may have been dif-
ferent in these patients who would have joined ARAD in
the years closest to its inception, compared with those
who joined in more recent years, when bDMARDs were
more readily available. Population-averaged logistic
regression (generalised estimating equation model) and
transition state analysis were used to assess change in GC
use over time, according to the date of baseline question-
naire. Date of entry (DOE) categories were created accord-
ing to the date of the baseline questionnaire: 12 September
2001–15 March 2005, 15 March 2005–15 September 2008,
15 September 2008–15 March 2012, or 15 March 2012–6
October 2015.
A multivariable fixed-effects panel regression model
was used to examine whether oral GC current use was
associated with current age; disease duration; self-
reported pain score; self-reported arthritis activity score;
HAQ score; and current medication use, including
bDMARDs, csDMARDs, NSAIDs and opioids. Age, self-
reported pain score and self-reported arthritis activity
score were transformed (divided by 10) for ease of inter-
preting the results. A fixed-effects model was chosen
over a random effects model on the basis of the Haus-
man test. The fixed-effects model allows within-patient
comparisons so that each patient is effectively acting as
his or her own control.
Univariate transition state analysis was used to assess
how these same factors influenced the HR of either
commencing or ceasing oral GCs, with HRs relative to
the first time point. In this analysis, two transition states
were of interest: the transition from GC non-use at one
visit to GC use at the next visit, and the transition from
GC use at one visit to GC non-use at the next visit.
The fixed-effects panel regression model and transi-
tion state analyses included all patients with at least one
follow-up visit after baseline. The panel regression
model excluded those who were either on oral GCs at all
visits or off oral GCs at all visits. Regression models were
carried out using Stata version 12.1 software (StataCorp,
College Station, TX, USA). The transition state analysis was
carried out using R version 3.2.3 software (library msm
version 1.6.4) [15, 16].
Results
A total of 3699 ARAD participants with a diagnosis of
RA completed a baseline questionnaire upon entry to
ARAD, 73% of whom were female, with a mean age of
57 years (SD 13). Baseline characteristics of the cohort
are shown in Table 1. At baseline 44% were taking an
oral GC, 54% were taking a bDMARD, 74% were taking
a traditional csDMARD, 43% were taking an NSAID and
32% were taking an opioid. There were 41% on com-
bined bDMARD and csDMARD therapy, 13% on a
bDMARD without csDMARDs, and 33% on csDMARDs
without a bDMARD. Throughout follow-up (median
4 years, IQR 1.5–7 years), the prevalence of oral GC
ever-use was 61%.
Change in GC use over time, according to ARAD date of
entry
To test the hypothesis that GC use may vary over time,
the probability of GC use throughout follow-up was
examined according to DOE categories. The probability
of oral GC use throughout follow-up deceased over
time: September 2001 to March 2005, 55%; March 2005
to September 2008, 47%; September 2008 to March
2012, 42%; and March 2012 to October 2015, 39%, (p <
0.001) (Fig. 1a). In addition, the transition state analysis
showed that the HR of commencing oral GCs compared
with the first DOE category decreased with date of base-
line questionnaire (March 2005 to September 2008 HR
0.42; September 2008 to March 2012 HR 0.30, March
2012 to October 2015 HR 0.20), and the HR of ceasing
oral GCs increased (March 2005 to September 2008 HR
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1.60, September 2008 to March 2012 HR 2.38, March
2012 to October 2015 HR 3.56) (Fig. 1b). Data from the
transition state analysis can also be expressed as ‘sojourn
times’, which is the average amount of time (in months)
patients have spent in each state (Table 2).
Patient factors associated with oral GC current use
In the fixed-effects panel regression model (Table 3),
longitudinal within-patient comparisons revealed that
increasing age was associated with decreased GC current
use (OR 0.24; 95% CI 0.07–0.81), but there was no
association with disease duration (OR 1.05; 95% CI
0.93–1.19). Current use of bDMARDs was not associ-
ated with GC current use (OR 0.98; 95% CI 0.83–1.15);
however, use of csDMARDs (10.13; 8.22–12.47), opioids
(2.14; 1.84–2.48) and NSAIDs (1.18; 1.02–1.37) were all
associated with increased GC current use. Higher
current pain score (OR 0.94; 0.90–0.98) was associated
with decreased GC current use, and higher arthritis
activity scores (1.09; 1.05–1.14) and poorer HAQ scores
(1.52; 1.30–1.79) were associated with increased GC
current use.
Patient factors associated with oral GC commencement
and cessation
In the transition state analysis (Fig. 2), within-patient
comparisons revealed that increasing age was associated
with decreased commencement and decreased cessation
of oral GCs. Female sex was also associated with increased
oral GC cessation. The moderate association between
bDMARD use and oral GC cessation did not reach
Table 1 Baseline characteristics of adult patients with rheumatoid
arthritis enrolled in Australian Rheumatology Association Database
Baseline characteristics (n = 3699) No. (%)a
Age, years, mean (SD) 57.1 (13.0)
Female sex 2761 (73.4%)
RF-positiveb 2554/3083 (82.8%)
ACPA-positiveb 162/239 (67.8%)
Disease duration, years, median (IQR) 10 (1–34)
Duration of ARAD follow-up, years, median (IQR) 4 (1.5–7)
Oral GC use 1641 (44.4%)
GC injection use 740 (20.0%)
bDMARD use 1983 (53.6%)
csDMARD use 2727 (73.7%)
bDMARD and csDMARD combined use 1517 (41.0%)
bDMARD use only (without csDMARD) 466 (12.6%)
csDMARD use only (without bDMARD) 1210 (32.7%)
Neither bDMARD nor csDMARD use 506 (12.7%)
NSAID use 1576 (42.6%)
Opioid use 1174 (31.7%)
Abbreviations: ARAD Australian Rheumatology Association Database, RA
Rheumatoid arthritis, RF Rheumatoid factor, ACPA Anti-citrullinated protein
antibody, GC Glucocorticoid, bDMARD Biologic disease-modifying anti-rheumatic
drug, csDMARD Conventional synthetic disease-modifying anti-rheumatic drug,
NSAID Non-steroidal anti-inflammatory drug
aUnless otherwise stated
bIn those with known RF/ACPA status
Fig. 1 The association between glucocorticoid (GC) use and date of Australian Rheumatology Association Database baseline questionnaire.
a Average probability of oral GC use throughout follow-up, according to date of baseline questionnaire. b The HR of commencing and
ceasing an oral GC according to date of baseline questionnaire (HRs are relative to the first time point)
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statistical significance. However, bDMARD, csDMARD or
NSAID use was associated with a reduced HR of com-
mencing oral GC therapy. Opioid use was associated with
a reduced HR of both commencing and ceasing oral GCs.
Higher HAQ score (greater disability) was associated with
a greater HR of commencing oral GCs and a reduced HR
of ceasing GCs. Higher pain scores were associated with
an increased HR of commencing GCs, but there was no
association between pain score and GC cessation. Higher
arthritis activity score was not associated with either
commencement or cessation of oral GCs.
Discussion
In this study, we sought to describe the use of GCs
amongst patients with RA over time and to determine
factors associated with GC current use as well as GC
commencement and cessation. In addition, we aimed to
determine whether bDMARD use is associated with the
cessation of GCs. This was carried out using data from
patients with RA enrolled in ARAD, a longitudinal
biologic registry.
In this RA cohort, the probability of GC use decreased
over time and in recent years, the probability of com-
mencing GCs had reduced, whereas the probability of
ceasing GCs had increased. This potentially reflects an
increasing awareness of GC-related adverse events (AEs)
as well as increased availability of effective disease-
modifying agents.
The influence of sex and increasing age on GC use
was also of interest. In the panel regression model,
increasing age was associated with a reduced HR of
current GC use. In keeping with this, in the transition
state analysis, we found that increasing age was associ-
ated with a reduced HR of commencing GCs, suggesting
that clinicians are more cautious about commencing GC
treatment in older patients. However, increasing age was
also associated with a reduced HR of ceasing GCs,
suggesting that, once started, it is more difficult to
discontinue GC treatment in older patients. In the
transition state analysis, females were more likely to
cease GCs, which is in keeping with previous findings
that females are more concerned than males about GC
use [17].
In the panel regression model, patients had lower pain
scores at times when they were on GCs than at times
when they were not. Adding to this, the transition state
analysis showed that individuals were more likely to
commence GCs at times when their pain scores were
higher, but that current pain scores had no influence on
GC cessation. Given that GCs are effective anti-
inflammatory agents in RA, it is not surprising that their
use was associated with lower pain scores and that they
were more likely to be commenced at times when pain
scores were higher. The lack of association between
lower pain scores and GC cessation may represent an
opportunity for clinicians to reduce GC use; however,
this would need to be assessed in the context of
traditional disease activity scores.
The panel regression model also showed that patients
had greater disability (as indicated by higher HAQ
scores) at times when they were on GCs than at times
when they were not. This raises the question whether
GC use contributes to disability in RA, as has been
shown in other rheumatic conditions such as systemic
lupus erythematosus and ANCA-associated vasculitis
[18–20]. The transition state analysis adds to our under-
standing of this, showing that patients with greater
disability were more likely to commence GC therapy
and less likely to cease therapy. Traditional measures of
disease activity are not collected in ARAD; however,
patients had slightly higher patient-reported arthritis ac-
tivity scores when they were on GCs than when they
were not. When considering the panel regression and
Table 2 Sojourn times: mean amount of time (in months) spent
on and off glucocorticoids, by Australian Rheumatology Association
Database date of entry category
ARAD DOE category State 1 (off GCs) State 2 (on GCs)
Mean 95% CI Mean 95% CI
12 Sep 2001 to 15 Mar 2005 57 52–63 151 130–175
15 Mar 2005 to 15 Sep 2008 137 123–152 94 86–104
15 Sep 2008 to 15 Mar 2012 193 159–234 63 56–72
15 Mar 2012 to 6 Oct 2015 292 172–493 42 33–54
GC Glucocorticoid
Table 3 Multivariable fixed-effects panel regression model to
determine factors associated with oral glucocorticoid current
use at any time point
Factors associated with GC current use OR 95% CI
Age, decades 0.24 0.07–0.81a
Disease duration, years 1.05 0.93–1.19
Current bDMARD use 0.98 0.83–1.15
Current csDMARD use 10.13 8.22–12.47a
Current NSAID use 1.18 1.02–1.37a
Current opioid use 2.14 1.84–2.48a
Self-reported pain score (10) 0.94 0.90–0.98a
Self-reported arthritis activity score (10) 1.09 1.05–1.14a
HAQ score (3) 1.52 1.30–1.79a
Abbreviations: GC Glucocorticoid, bDMARD Biologic disease-modifying anti-
rheumatic drug, csDMARD Conventional synthetic disease-modifying anti-
rheumatic drug, NSAID Non-steroidal anti-inflammatory drug, HAQ Health
Assessment Questionnaire
The analysis included patients with rheumatoid arthritis with at least one follow-up
visit after baseline and excluded those who were on oral GCs at all visits or off oral
GCs at all visits (n = 1161). The fixed-effects model uses all available time
points and allows for within-patient comparisons where each patient acts
as his or her own control
aIndicates p < 0.05
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transition state analysis together, it appears that the
HAQ was a more important driver of oral GC use than
pain or self-reported arthritis activity scores.
Patients were more likely to be taking GCs at times
when they were also taking csDMARDs, NSAIDs or
opioids than at times when they were not using these
concurrent medications. However, concurrent bDMARD
use was not associated with either increased or de-
creased current GC use. If it were assumed that current
GC use reflects ongoing disease activity, then these find-
ings would suggest that when patients were on
csDMARDs, NSAIDs or opioids, their disease was more
active than when they were not on these agents.
Although this may seem to contradict our knowledge
that csDMARDs reduce disease activity, in the setting of
bDMARD use ongoing csDMARD use may indeed re-
flect patients with ongoing disease activity not controlled
by bDMARD treatment alone. In the transition state
analysis, the moderate association between bDMARD use
and GC cessation did not reach statistical significance,
suggesting that bDMARDs do not have a significant
steroid-sparing effect in regards to GC cessation.
GC use is associated with many AEs, and the likeli-
hood of these developing is influenced by total GC
exposure (dose and duration of therapy) [21, 22]. GC
cessation is therefore a clinically meaningful outcome
when assessing the steroid-sparing effects of bDMARDs
and other disease-modifying agents. Use of bDMARDs
and csDMARDs was associated with a reduced HR of
commencing GCs, which may be due to a reduced need
for GCs because these agents are effective at controlling
disease activity. NSAID or opioid use was also associated
with a reduced HR of commencing GCs, and this may
be because use of these agents reflects joint damage
rather than active disease. Opioids were associated with
a reduced HR of ceasing GCs. Patients on both opioids
and GCs may represent a subgroup of patients with
ongoing disease activity requiring GCs and joint dam-
age leading to pain treated with opioids. It is plausible
that it is more difficult to cease GCs in this subgroup
of patients.
The main limitations of this study are that all data in
ARAD are patient-reported, and neither GC dosage nor
conventional measures of disease activity are collected.
Fig. 2 Transition state analysis of factors associated with the commencement and cessation of an oral glucocorticoid (GC). a Two transition states
of interest are shown: (1) off oral GC at one time point, then on oral GC at the next time point (green triangle = oral GC is commenced), and (2)
on oral GC at one time point, then off oral GC at the next time point (red circle = oral GC is ceased). The probability of commencing or ceasing an
oral GC in any 12-month period is shown. b The association between age (decades) and sex (female) and the HR of commencing or ceasing an
oral GC. c The association between Health Assessment Questionnaire (HAQ) score and pain score and the HR of commencing or ceasing an oral
GC. d The association between concurrent medication use (biologic disease-modifying anti-rheumatic drug [bDMARD], conventional synthetic
disease-modifying anti-rheumatic drug [csDMARD], non-steroidal anti-inflammatory drug [NSAID] and opioid) and the HR of commencing or ceasing
an oral GC
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In addition, questionnaires are completed by patients at
6- to 12-monthly intervals and may therefore be associ-
ated with a recall bias. Enrolment in ARAD is done on
an opt-in basis; therefore, there may be fundamental
differences between those who do and do not choose to
participate in the database. The ARAD questionnaire
asks about GC use in the section ‘medications for arth-
ritis’, and it is therefore assumed that the GC use
reported has been prescribed for RA. However, many
patients will have co-morbidities that are also indications
for GCs, and it is possible that some of the reported GC
use is driven by these co-morbidities. This could poten-
tially bias the results towards the null hypothesis that
there is no association between bDMARD use and GC
cessation. The mortality in this sample was low, with 8%
of the RA cohort recorded as deceased. Only limited
data were available regarding cause of death; however,
given the analyses made within-patient comparisons, it
is unlikely that mortality would have significantly influ-
enced the results.
Strengths of this study include the systematic and
consistent way in which data are captured longitudinally
in a real-life setting. In the treatment of RA in clinical
practice, oral GCs may be given as short- or medium-
term courses or used as a long-term therapy. Therefore,
treatment may be started and stopped on numerous
occasions throughout follow-up. Traditional methods for
classifying GC use tend to be cross-sectional and do not
capture the dynamic patterns of use that occur in clin-
ical practice. For example, current use is often defined
as use at a particular time point, such as at baseline or
at the time of a predefined event (i.e., clinical remission
or the development of an adverse effect). ARAD is a
longitudinal dataset, allowing ‘current use’ to be
defined as a time-varying indicator of whether a patient
was taking oral GCs at each questionnaire time point.
Most other relevant variables in the dataset were time-
varying as well. The primary analyses (fixed-effects
panel regression and transition state analysis) were spe-
cifically chosen in order to use the longitudinal nature
of the data to determine within-patient concomitant
predictors of both oral GC use and a change in use
(commencement and cessation). This avoids the
confounding due to unobserved/unmeasured variables
that may occur in cross-sectional analyses.
Conclusions
Oral GC use among Australian patients with RA partici-
pating in ARAD has decreased over time. Compared
with patients who joined ARAD at its inception, those
who joined the registry in more recent years had a lower
probability of commencing GCs and a greater probability
of ceasing GCs. Care needs to be taken when commencing
oral GCs because it is often difficult to cease therapy once
started, and bDMARD use has only a modest impact on
this. Consideration of intramuscular and intra-articular
GCs may help to offset oral GC use.
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5 GC Use- The Patient Perspective 
 
This chapter addresses the second aim of the thesis: 
 
To better understand the benefits and harms of glucocorticoid use from the patient 
perspective  
5.1 Introduction 
In this chapter, the focus of the work moves from investigating how GCs are used in RA, 
to examining the benefits and harms of treatment from the patient perspective. As a 
starting point, it explores the need for a patient reported outcome measure (PRO) to 
capture the benefits and harms of GC use from the patient perspective, by searching 
the literature for whether a GC PRO has already been developed. Having established 
that such a PRO has not already been reported in the literature, the chapter goes on to 
explore the benefits and harms of GC use from the patient perspective with a descriptive 
exercise to establish the types of GC AEs reported in RCTs, and a quantitative survey 
presented as a published manuscript. The work in this section of the thesis has also 
contributed to the OMERACT GC working group, described in more detail in the Thesis 
Introduction. Complementary work undertaken by other members of the OMERACT GC 
working group is described in the OMERACT 2016 (218) and 2018 (83) conference 
papers, which are included in Appendix and Appendix. 
 
Establishing whether a GC PRO has already been developed 
As an initial step, a systematic literature review (SLR) was performed to determine if a 
PRO for capturing the effects of GC use had already been published. This involved a 
librarian-assisted search, which was carried out in OVID MEDLINE (1946 to February, 
Week 3, 2016) and OVID EMBASE (1974 to February 26, 2016). The search terms are 
shown in Table 5.1, with the search (1 OR 2 OR 3 OR 4 OR 5) AND 6 AND (7 OR 8 OR 9 
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Table 5.1: Search terms used to identify any pre-existing PROMs for GC AEs 
OVID MEDLINE OVID EMBASE 
1. exp Adrenal Cortex Hormones/  1. exp corticosteroid/   
2. corticosteroid*.mp.  2. corticosteroid*.mp.  
3. glucocorticoid*.mp.  3. glucocorticoid*.mp.  
4. glucocorticosteroid*.mp. 4. glucocorticosteroid*.mp.  
5. steroid*.mp. 5. steroid*.mp.  
6. patient report*.mp.  6. patient report*.mp. 
7. (adverse adj2 effect*).mp.  7. (adverse adj2 effect*).mp.  
8. (adverse adj2 event*).mp. 8. (adverse adj2 event*).mp.  
9. (adverse adj2 outcome*).mp.  9. (adverse adj2 outcome*).mp.  
10. (adverse adj2 reaction*).mp.  10. (adverse adj2 reaction*).mp.  
11. (side adj2 effect*).mp. 11. (side adj2 effect*).mp. 
 
Titles and abstracts of 146 articles were screened, and seven papers were chosen for 
full-text review. No PRO for systemic GC use was identified; however, two articles 
described the Inhaled Corticosteroid Questionnaire (ICQ)(219, 220), a PRO for inhaled 
GC use (218). The ICQ contains 57 items across 15 categories; 38 items identified 
inhalation-related AEs affecting the oropharynx, taste, and voice, and 19 items were 
related to systemic AEs of inhaled GC including mood, skin/hair/nails, perspiration, and 
tiredness, among others. Given many of the items in the ICQ were specific to inhaled GC 
preparations, it was felt that a PRO to capture the effects of systemic GC exposure is still 
required. 
 
Exploring GC AEs reported in selected RCTs  
Having established that a GC PRO has not yet been published, it was deemed important 
to look more closely at which AEs have been reported in published randomised 
controlled trials (RCTs) of GC use and whether there are differences according to the 
disease population being studied. Together with another member of the OMERACT GC 
working group (L. Lai), an exploratory exercise was carried out, using the studies 
included in four SLRs of chronic inflammatory diseases for which GC treatment is 
commonly used: 1. polymyalgia rheumatica (PMR; 9 RCTs)(221), 2. Crohn’s disease (14 
RCTs)(222), 3. ulcerative colitis (UC; 6 RCTs) (223) and 4. RA (28 RCTs) (224). Each study 
included in the four SLRs was reviewed and GC AEs were extracted by two reviewers (R. 
Black & L. Lai). There were 63 different AEs, fitting into 11 different categories reported 
across all the RCTs reviewed (Figure 5.1) (218). The percentage of RCTs in each SLR that 
reported at least one GC AE from each category was determined (Figure 5.2). There 
were no central nervous system AEs reported in the PMR RCTs and no cardiovascular or 
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ocular AEs reported in the UC RCTs. The collection of GC AEs in published RCTs looking 
at GC use in inflammatory diseases was inconsistent, again demonstrating the need for 
a GC PRO.  
 
Figure 5.1: AEs reported in RCTs of GC use in inflammatory conditions 
 
GIT=gastrointestinal tract, MSK=musculoskeletal, CNS=central nervous system, Psych= psychiatric, Abx=antibiotics, 
UTI=urinary tract infection, BP=blood pressure, HTN=hypertension, MI=myocardial infarction, CCF=congestive cardiac 
failure, BSLs=blood sugar levels, #s=fractures, BMD=bone mineral density 
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Figure 5.2 Percentage of RCTs reporting each GC AE Category in 4 Inflammatory Diseases 
 
PMR=polymyalgia rheumatica, GIT=gastrointestinal tract, MSK=musculoskeletal, CNS=central nervous system, 
Psych= psychiatric 
 
A cross-sectional patient survey of the benefits and harms of GC use 
Having established that a GC PRO has not yet been developed and that published RCTs 
are inconsistent in their collection of GC AEs, the next stage was to explore the benefits 
and harms of GC use from the patient perspective. This work also investigates whether 
the symptoms patients attribute to GC use are likely to be due to GC use rather than the 
disease being treated or other medications. This section is presented as a published 
manuscript and describes a cross-sectional survey looking at GC AEs experienced by two 
international patient populations. It captured which AEs are considered the ‘worst’ by 
patients, whether patients feel the benefits of GCs outweigh the AEs, and whether GCs 
help their disease “a lot,” “a little,” “not sure,” or “not at all”. The survey was initially 
administered to an Australian cohort of rheumatology outpatients who had used GCs 
within the past 12 months and included patients with various rheumatic diagnoses. In 
order to assess whether the AEs patients attribute to GC use might actually be due to 
other medications or the underlying disease, the survey was also administered to a US 
cohort of RA patients who were both users and non-users of GCs, allowing for a 
comparison of reported AEs between these groups. AEs identified as “worst” by GC 
users included skin thinning/easy bruising, sleep disturbance, mood disturbance, and 
change in facial shape. The comparison of AEs between GC users and non-users 
confirmed that most GC AEs are more frequently reported by GC users, suggesting that 
patients are reliably attributing AEs to GC use.  It was noted that many of the AEs that 
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are important to patients are not easily measured in the clinic or research setting, 
reinforcing the need for a GC PRO. 
 
A large body of research, including the author’s work described above, has now been 
carried out by the OMERACT GC working group in preparation for developing a core 
domain set, which is the first step in the development of a GC PRO (83, 218). This work, 
including that presented in the manuscript below (225), has shed light on the patient 
perspective of GC use. Many of the AEs that are important to patients, occur commonly 
but are not easily measured. Reassuringly, AEs commonly attributed to GCs are 
significantly more frequent in those exposed to GCs compared to those unexposed, 
suggesting that patients are correctly attributing their symptoms to GC use. In addition 
to the physical and psychological symptoms commonly identified in quantitative 
studies, qualitative work carried out by other members of the OMERACT GC working 
group has revealed outcomes relating to participation and contextual factors are also 
very important to patients (83, 218).  
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A Survey of Glucocorticoid Adverse Effects and Benefits
in Rheumatic Diseases
The Patient Perspective
Rachel J. Black, MBBS,*† Susan M. Goodman, MD,‡ Carlee Ruediger, PhD,§ Susan Lester, BSc (Hons),§
Sarah L. Mackie, PhD,|| and Catherine L. Hill, MD*†§
Objective: The aim of this study was to explore, from the patient's per-
spective, the beneficial and adverse effects (AEs) of glucocorticoids
(GCs) in patients with rheumatic diseases, to be used in the development
of a patient-reported outcome measure.
Methods: A cross-sectional survey, capturing benefits and AEs of GC
use, was administered to 2 groups of patients: (1) those attending a tertiary
rheumatology clinic with various rheumatic diseases who had used GCs
within the past year and (2) patients from the Hospital for Special Surgery
rheumatoid arthritis database.
Results: Cohort 1 had 55 GC users, and cohort 2 had 95 GC users and 29
nonusers. The majority of GC users in both cohorts reported at least 1 AE
(100%, 86%). The AE prevalence per person was 50% higher in cohort 1
compared with GC users in cohort 2 (7.7 vs. 5.3; AE ratio, 1.5; 95% confi-
dence interval, 1.3–1.7) and 2-fold greater in cohort 2 GC users compared
with GC nonusers (5.3 vs. 2.6; AE ratio, 2.0; 95% confidence interval,
1.6–2.6). In both cohorts, AEs identified as “worst” by GC users included
skin thinning/easy bruising, sleep disturbance, mood disturbance,
and change in facial shape. Most felt GCs helped their disease “a
lot” (78%/62%) and that the benefits were greater than the AEs (55%/
64%). Many AEs were more frequent in GC users than in nonusers.
Conclusions: Patients receiving GC therapy for rheumatic conditions re-
port a large number of AEs and those that have the greatest life impact are
often difficult for physicians to measure. These results will inform the de-
velopment of a patient-reported outcome measure to capture the effects of
GCs from the patient's perspective.
Key Words: adverse events, glucocorticoids, patient-reported outcomes,
rheumatic diseases, rheumatoid arthritis
(J Clin Rheumatol 2017;23: 416–420)
G lucocorticoids (GCs) are frequently used to treat rheumaticconditions including inflammatory arthritis, connective tissue
disorders, vasculitis, and polymyalgia rheumatica.1 Although they
are effective anti-inflammatory agents, they are also associated with
many potential adverse effects (AEs) such as skin thinning, easy
bruising, weight gain, osteoporosis, diabetes, hypertension, infec-
tion, and cataract. However, not all patients exposed to GCs will
develop AEs, and there is currently no standardized measure of
the benefits and AEs that are important to patients. The European
League Against Rheumatism (EULAR) Taskforce on GC therapy
has published 2 systematic reviews concluding that there is a need
to systematically capture GC AEs in a standardized manner.2,3
The EULAR recommendations for monitoring GCAEs in clinical
trials and daily practice suggested that new tools be developed for
assessing adverse events.4 This has led to the very recent develop-
ment of the Glucocorticoid Toxicity Index (GTI), which measures
the physiological AEs (clinical signs and biomarkers) of GC use.5
The GTI focuses on items that are measurable in the clinic such as
glucose tolerance, body mass index, and blood pressure.
Increasingly, a patient's experience of treatment and care has
been recognized as an important quality indicator. This has led to
an expansion in the development and application of questionnaires
to measure health and illness from the patient's perspective. Patient-
reported outcome measures (PROMs) provide unique insight into
the way patients perceive their health and the impact that treatments
have on their quality of life.6,7 Patient-reported outcome measures
involve patients in clinical decision making, can improve
doctor-patient communication about treatment, and ultimately
lead to better patient outcomes.7 At present, there is no PROM
to measure the risks, benefits, and experience of systemic GC use
from the patient's perspective.8 Patients may perceive important ef-
fects differently than physicians,9 making it important to understand
both the impact of GC use from the patient's perspective and the
physiological impact measured by the GTI.
The first step in developing a PROM for the impact of GCs is
to undertake qualitative and quantitative pilot work that provides
insight into the aspects of GC treatment that are important to pa-
tients, so that these can be captured as items in any future mea-
surement tool. The aim of this pilot study was to determine the
AEs related to GCs in 2 groups of GC users and to explore which
GC effects are important to patients. A secondary aimwas to com-
pare AEs reported by rheumatoid arthritis patients exposed and
not exposed to GCs.
METHODS
A cross-sectional, questionnaire-based survey was carried
out in 2 cohorts, in Australia and the United States. In Australia,
the studywas approved byTheQueenElizabethHospital HumanRe-
search Ethics Committee (reference no. HREC/14/TQEHLMH/209).
In theUnited States, the cohort was approved by theHospital for Spe-
cial Surgery Ethics Review Board (reference no. 2014-234-CR2).
Participants
Participants in cohort 1 (Australian cohort) attended a ter-
tiary rheumatology clinic with various rheumatic diseases and
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were taking an oral GC currently or within the past 12 months. Po-
tential participants were identified from the departmental elec-
tronic outpatient letters, which are sent to the patient's general
practitioner after each outpatient visit and include a summary of
the diagnoses andmedications. All letters from the past 12 months
were assessed by 2 reviewers (R.J.B., C.R.), and a random selec-
tion of eligible patients was mailed out a participant information
sheet, consent form, and a copy of the questionnaire with a reply
paid return envelope. Cohort 2 (US cohort) was from the Hospital
for Special Surgery rheumatoid arthritis (RA) database and in-
cluded both GC users and nonusers. Cases included in the database
were identified from the Hospital for Special Surgery practice re-
cords by International Classification of Diseases, Ninth Revision
code 714.0 and confirmed by chart review. Cases meeting the
American College of Rheumatology/EULAR criteria for RAwere
recruited at a clinic visit or via mail and were included after giving
consent, at which time they completed a brief survey and agreed to
be contacted for further studies. The questionnaire was distributed
to patients on the database with a valid e-mail address.
Questionnaire
A pilot questionnaire was developed in order to explore
patient-reported GC AEs and assess the risks and benefits of
GCs from the patient's perspective. It included a checklist of 19
known AEs and an open-ended question about presence of “other
GC side effects.” The questionnaire was designed to be as inclu-
sive as possible, while balancing the burden of data entry by keep-
ing the checklist relatively concise. Checklist items included AEs
cited frequently in the literature, as well as those occurring fre-
quently in the authors' clinical experience. In addition, all partici-
pants were asked to rate the 3 “worst” AEs. Participants exposed
to GCs were asked to indicate whether GC therapy helped “a
lot,” “a little,” “not sure,” or “not at all” and whether the AEs they
experienced were worse than the benefits of treatment (yes/no/not
sure). The questionnaire was not developed to be a PROM itself,
but rather as a format by which to capture information that will
inform the development of a PROM in the future.8 (A copy of
the questionnaire can be found in file, Supplemental Digital
Content 1, http://links.lww.com/RHU/A76.)
Analysis
Descriptive statistics were used to summarize cohort demo-
graphics and the frequency of the individual AEs on the checklist
as well as those considered to be the worst AEs. The median num-
ber of AEs experienced by each patient (AE prevalence) was
compared between cohorts using Poisson regression, and the
number of patients to report at least 1 AE was analyzed using χ2
analysis. The degree to which participants felt GCs helped their
condition was assessed by comparing the ordinal trend between
groups using the Cochran Armitage exact test. A χ2 analysis was
carried out for the comparison of GC AEs and benefits. Within co-
hort 2, AEs reported by GC users and GC nonusers were compared
by Fisher exact test. All analyses were carried out in R
version 3.2.3.10
RESULTS
In cohort 1 (Australia), 88 questionnaires were distributed,
and 55 (63%) were returned. In cohort 2 (United States), there were
227 questionnaires distributed to those with a valid e-mail address,
with 124 (55%) returned. All patients in cohort 1 were GC users,
and in cohort 2, 95 (77%) had ever used GCs (GC users), and 29
(23%) had never used GCs (GC nonusers). Demographics and di-
agnoses are summarized in Table 1. For cohort 1, the 33 patients
who declined to participate were younger (median age, 63 years
[interquartile range {IQR}, 51–75 years vs. 68 years [IQR, 60–-
76 years]), and a greater proportion was female (27/33 [82%]
vs. 39/55 [71%]). For cohort 2, the 103 patients who did not par-
ticipate were also slightly younger (median, 60 years [IQR, 52–-
70 years] vs. 63 [IQR, 53–71 years]), with a similar proportion
of females (91/103 [88%] vs. 103/124 [83%]). Rheumatoid arthri-
tis duration was similar in nonparticipants (median, 9.5 years
[IQR, 4.5–18.0 years] vs. 9.6 years [IQR, 5.5–17.5 years]), and
there were fewer GC users at the time of the survey (23/103
[22%] vs. 35/124 [28%]).
The AE prevalence per person was 50% higher in cohort 1
compared with GC users in cohort 2 (7.7 vs. 5.3; AE ratio, 1.5;
95% confidence interval, 1.3–1.7) and 2-fold greater in cohort 2
GC users compared with GC nonusers (5.3 vs. 2.6; AE ratio, 2.0;
95% confidence interval, 1.6–2.6). All patients in cohort 1 reported
at least 1 GC AE compared with 86% of GC users in cohort
2 (P = 0.002).
The frequency of patient-reported AEs and worst AEs are
shown in the Figure 1. Themost frequent AEswere similar among
patients in cohort 1 (thin skin/easy bruising, weight gain, sleep
disturbance, and stomach upset/gastric reflux) and GC users in co-
hort 2 (sleep disturbance, thin skin/easy bruising, and weight
gain). The most frequent AEs in cohort 2 GC nonusers were sleep
disturbance, stomach upset/gastric reflux, and muscle weakness.
Worst AEswere dependent on the AE frequency and included thin
skin/easy bruising (9/45), weight gain (9/36), and sleep disturbance
TABLE 1. Baseline Demographics and Diagnoses
Demographics
Cohort 1 (n = 55)
(Australia)
Cohort 2 (n = 124) (United States)
GC Users (n = 95) GC Nonusers (n = 29)
Age, median (IQR), y 68 (33–89) 63 (52–72) 63 (53–70)
Sex, female, n (%) 39 (71) 77 (81) 26 (90)
Diagnosis n (%)
Connective tissue disease 14 (25)
RA 14 (25) 95 (100) 29 (100)
Polymyalgia rheumatica 14 (25)
Giant cell arteritis 5 (9)
Other vasculitis 3 (5)
Other inflammatory arthritis 2 (4)
Other 3 (5)
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(9/30) in cohort 1. Theworst AEs for GC users in cohort 2 included
weight gain (13/40), sleep disturbance (8/49), stomach upset/gastric
reflux (8/38), andmuscleweakness (8/34). Glucocorticoid nonusers
noted swelling of the feet or ankles (4/6), weakness of muscles (3/
8), increased appetite (2/3), and thrush in the mouth (2/2) as the
worst AEs. Additional AEs attributed to GCs in either cohort are
shown in the Figure, Supplemental Digital Content 2, http://links.
lww.com/RHU/A77.
In both GC use cohorts, most (78% cohort 1/62% cohort 2 GC
users) felt GCs helped their disease “a lot,” 11%/21% felt they
helped “a little,” 9%/8% were “not sure,” and 2%/8% felt GCs
did not help at all, with no difference between groups (ordinal
P = 1.0). Most participants in cohorts 1 (55%) and 2 (64%) felt
the benefits of treatment were greater than the AEs, with no differ-
ence between groups (P = 0.67). In cohort 2, AEs including weight
gain, thin skin or easy bruising, high blood sugars, broken bones,
change in shape of face, change in shape of body, and increased ap-
petite were more frequently reported by GC users compared with
GC nonusers (P < 0.05) as shown in Table 2.
DISCUSSION
This study has demonstrated that many AEs that are impor-
tant to patients are more common in GC users compared with
nonusers and include symptoms that are difficult to capture using
conventional physiological measures. In addition, a difference in
the AE rate among cohort 1 (mixed rheumatic diagnoses) and
GC users in cohort 2 (RA) was detected, possibly reflecting the
different demographics, diagnoses, and unmeasured differences
in the dose and duration of GC treatment.
Many studies looking at GC AEs have focused on AEs that
are easier to measure such as osteoporosis, fractures, and infec-
tion. However, few studies have also captured patient-reported
GC AEs. In a cross-sectional study of UK patients with asthma
(n = 233), 88% reported 1 or more AEs, with bruising (67%)
and weight gain (67%) being the most common.11 In a French co-
hort study of 80 participants on long-term systemic GCs, 71% re-
ported 1 or more AEs, with change in face shape reported as the
most distressing (39%).12 A cross-sectional study of UK patients
with asthma, chronic obstructive pulmonary disease, and fibrosing
FIGURE 1. Frequency of glucocorticoid adverse effects and worst adverse effects in (A) cohort 1 GC users, n = 55, and (B) cohort 2 GC users,
n = 95, and (C) cohort 2 GC nonusers, n = 29.
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alveolitis (n = 367) found that bruising (73%) and muscle weakness
(60%) were the most common GC AEs.13 AUnited Kingdom–based
case-control study of polymyalgia rheumatica and giant cell arteritis
found that 23 (66%) of 35 participants reported 1 or more AEs, with
weight gain (26%) and skin changes (26%) being themost common.14
In the largest study to date, Curtis et al.15 included a popula-
tion cohort of 2167 long-term GC users from the United States, of
which 90% reported at least 1 from a list of 8 potential AEs. The
most common GC AEs included weight gain, skin bruising or
thinning, and sleep problems, similar to the current study. However,
the current study examined 19 rather than 8 items, in addition to a
free-text question to capture additional AEs attributed to GC use
by patients. The current study also differed from the previous study
in its comparison of AEs reported by RA patients with and without
GC therapy and in that patients were asked to prioritize the 3
“worst” AEs. Lastly, in the current study, the survey was adminis-
tered in 2 different English-speaking countries, which is important
for cross-cultural generalizability.
Another cross-sectional study looking at GC AEs that are
important to patients was recently carried out in a novel cohort
of online health users in the United Kingdom.16 In this popula-
tion, weight gain was deemed the most important AE, followed
by insomnia and moon face. The design and unique setting of this
study provide additional insight into the patient experience of GC
AEs. The results complement the findings of this study and will
also be useful in the development of a future PROM.
Limitations of the study include potential biases associated
with survey-based research. There may be a response bias, with
fundamental differences in the experience of responders and non-
responders; indeed, in cohort 2, fewer GC nonusers responded to
the survey. Also in cohort 2, only thosewith valid e-mail addresses
were included, and there may be differences between people who
use technologies and those who do not. There is also the potential
for recall bias, with those who received more recent GC therapy
more likely to recall a greater number of AEs. Other limitations
of this study include the small sample size and that the questionnaire
was available only in English. Although the checklist was created to
capture many common GCAEs, some AEs, such as infections other
than oral and vaginal thrush, were not included in order to minimize
any burden of data entry. The free-text section was included to cap-
ture other AEs not on the checklist; however, thesemay have been re-
ported less than those visible on the checklist.
Strengths of this study include its inclusion of 2 different co-
horts and its comparison of AEs among GC users and nonusers
from the same cohort. The results of this study will be used, in
conjunction with ongoing qualitative work in different disease co-
horts, to develop potential items for inclusion in a PROM. These
potential items will then be compiled, and patient and clinician ex-
perts will be engaged to determine the most appropriate items to
be included in the final PROM,which will then be properly devel-
oped and validated. Such a PROM will provide patients with an
effective means by which to communicate with their treatment
team about the impact of GC treatment.
CONCLUSIONS
This cross-sectional study has increased our understanding
of the impact of GC therapy from the patient's perspective and is
the first step in the development of a PROM. Patient-reported
GC AEs were common among GC users; however, the benefits
of treatment were felt to outweigh the AEs. In addition, many
patient-reported AEs were more frequent among RA GC users
than nonusers.
KEY POINTS
• Patient-reported GC AEs occurred in 86% to 100% of GC users.
TABLE 2. Differences Between AEs Reported by GC Users and GC Nonusers in Cohort 2










Weight gain 40 55 4 25 0.007a
Thin skin or easy bruising 44 51 4 25 0.002a
High blood sugars 18 77 1 28 0.043a
Weakness of muscles 34 61 8 21 0.050
High blood pressure 17 78 3 26 0.400
Depression 19 76 4 25 0.590
Mood disturbance 24 71 5 24 0.460
Thin bones or osteoporosis 29 66 3 26 0.031
Broken bones 15 80 0 29 0.021a
Change in shape of face 20 75 0 29 0.004a
Change in body shape 27 68 1 28 0.004a
Sleep disturbance 49 46 9 20 0.059
Increased appetite 32 63 3 26 0.017a
Stomach upset or gastric reflux 38 57 9 20 0.510
Swelling of feet or ankles 38 57 6 23 0.076
Thrush in the mouth 13 82 2 27 0.520
Cataracts of eyes 17 78 7 22 0.440
Osteonecrosis of the hip 2 93 1 28 0.550
For women, vaginal thrush 8 69 2 24 1.000
aStatistically significant difference between GC users and GC nonusers (P < 0.05).
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• Many GCAEs that are important to patients are poorly captured
by current physiological measures, including thin skin and easy
bruising, sleep disturbance, and stomach upset/gastric reflux.
• Most patients felt that GCs are effective at controlling their dis-
ease and that the benefits of treatment outweigh the AEs.
• Many patient-reported AEs were more frequent among RAGC
users than nonusers.
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STEROID QUESTIONNAIRE  Page 1 of 4 
Patient’s perceptions of glucocorticoid therapy 
QUESTIONNAIRE 
Thank you for completing this questionnaire about steroid (prednisolone) treatment. 
It is important to remember that not all patients experience side effects with steroids, 
and steroids are never commenced unless required to treat your illness. 
If you have any questions, the study co-ordinator is happy to help you fill in the 
questionnaire. 
If you are unsure about exact dates, please fill in as much as you are able  
(for example, month and year or year alone). 
NAME ………………………………………………………... 
Date ………………………………………………  /  /    
DD/MM/YYYY 
DEMOGRAPHICS 
Date of Birth …………………………………………..  /  /    
DD/MM/YYYY 
Gender …………….....   Female 
 Male 
SUPPLEMENTAL DIGITAL CONTENT 1









When did you start on prednisolone tablets? 
                   START DATE:     /  /                                                      
                                                DD/MM/YYYY 
              STOP DATE:   /  /               OR    still taking                                              
                                         DD/MM/YYYY 
What dose of prednisolone tablets did 
you start on? …………mg/day OR    don’t know 
Were you given any steroids through a 
drip?  Yes No 
What is your current dose of 
prednisolone? …………mg/day 





Are you currently taking a tablet to 
lower your cholesterol?  Yes No Don’t know 
Are you currently taking a tablet for 
diabetes?  Yes No Don’t know 
       
 
 




Are you currently taking any 
medications to treat osteoporosis?  Yes No Not sure 
  Alendro, Fosamax (alendronate)    
  Fosamax Plux (Alendronate + Vitamin D)    
  Caltrate, Citrocal (Calcium)    
  Calcijex, Calcitriol, Kosteo, Rocaltrol, 
Sitriol (calcitriol) 
 
   
  Vitamin D (Ostelin)    
  Didrocal, Didronel (etidronate)    
  Actonel (risedronate)    
  Actonel combi ( Risedronate + calcium)    
  Evista (raloxifene)    
  Protos (Strontium ranelate)    
  Forteo (teriparatide)    
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Have you ever been told by a doctor that you have had any of the following? 
 Yes No Not sure 
Diabetes    
Osteoporosis    
High blood pressure    
Asthma    
Emphysema/Chronic Bronchitis    
Ischaemic heart disease    
Heart attack    
Stroke    
Angina    
High cholesterol    
Cataracts    
Glaucoma    
 
 
Do you think that your steroid treatment (prednisolone) has helped you? (please 
circle) 
Not at all  A little A lot Not sure 
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HAVE YOU HAD ANY OF THE FOLLOWING SIDE EFFECTS SINCE 
COMMENCING ON STEROID (PREDNISOLONE) TREATMENT? 
 Yes No Don’t know 
Weight gain    
Thin skin or easy bruising    
High blood sugars    
Weakness of muscles     
High blood pressure    
Depression    
Mood disturbance    
Thin bones or osteoporosis    
Broken bones Which bone was 
broken?..................................   
 
 
Change in shape of face    
Change in body shape    
Sleep disturbance    
Increased appetite    
Stomach upset or gastric reflux    
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Swelling of feet or ankles    
Thrush in the mouth    
Cataracts of eyes    
Hip problem (also called 
avascular necrosis of the hip)    
For women, vaginal thrush    
  None of the above 
 
 
If you have other side effects, while on steroid treatment please list them below: 
 
             
             
              
 
If you have had side effects, while on steroid treatment, which were the worst side effects that you 
had and why. Please list them below: 
 
1.             
             
2.             
             
3.              
With regard to steroid treatment, do you think the side effects were worse than the 
benefit from the steroids? 
Yes  No Not sure 
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6 GC Use- The Risk of Developing Cataract and Glaucoma in RA 
 
This chapter addresses aims 3 and 4 of the thesis: 
 
To determine whether the risk of cataract and glaucoma associated with 
glucocorticoid use in patients with rheumatoid arthritis has been adequately 
quantified in the current literature  
 
To quantify the risk of GC exposure and the development of cataract and glaucoma 
in RA and to explore the risk associated with different patterns of GC exposure, 
including dose, timing of dose and cumulative dose  
6.1 Introduction 
GC related eye disease is a potential harm of GC use that has previously received limited 
attention. This chapter looks at cataracts and glaucoma, with the aim of better 
quantifying the risks associated with GC use, dose, timing of dose and cumulative dose. 
These vision-threatening conditions are highly prevalent worldwide and account for 
>50% of blindness (96). They can have a significant impact on the lives of those affected 
and are associated with significant financial costs to the healthcare system (97). The 
extent to which systemic GC use contributes to the development of cataracts and 
glaucoma is not clear, with conflicting results among studies which try to quantify this. 
RA was selected as an ideal population in which to explore this question, as 60% of 
patients with this inflammatory condition are exposed to GCs, with different patterns 
of use seen. 
 
The first manuscript in this section of work describes a systematic literature review (SLR) 
and meta-analysis addressing the association between systemic GC use and the risk of 
developing cataract and glaucoma in patients with RA. There were three RCTS reporting 
cataract and glaucoma, five cohort studies reporting cataract, one reporting PSCs 
specifically, and two reporting glaucoma. There were also five cross-sectional studies 
reporting PSCs. Data on the effects of dose and duration of therapy were very limited. 
The study concluded that the association between GC use and the development of 
cataract and glaucoma in RA is not clear from the current literature and that future well 
designed observational studies are needed to address this evidence gap. 
 
The second manuscript goes on to address the evidence gaps identified in the SLR and 
describes a longitudinal cohort study which uses data from CPRD to quantify the risk of 
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developing cataract and glaucoma associated with GC use. In addition, it investigates 
the influence of the timing of GC dose and cumulative dose using different time-varying 
models of GC exposure. As shown in Chapter 3, GC use in RA varies greatly and it was 
therefore important to select models that capture different time-varying patterns of GC 
use in order to properly understand the risk of these potential harms. This work 
quantifies the risk of developing cataract and glaucoma associated with GC use in RA. 
Current GC use was associated with a 60% increased risk of glaucoma, and double the 
risk of cataracts, with risk increasing with age. It also investigates the timing of GC dose, 
with a current dose of 10mg associated with a 16% increased risk of developing 
cataracts, compared to no GC use.  A dose of 10mg (compared to no GC use) six-months 
prior to cataract diagnosis was associated with a 13% increased risk, with the greatest 
risk of 26% seen with a 10mg dose one-year prior to diagnosis. Current dose was not 
associated with the development of glaucoma, whereas a 10mg dose compared to no 
GC use at three-months and one-year prior to glaucoma diagnosis was associated with 
a 4% and 5% increased risk respectively. Cumulative doses of more than 1000mg were 
associated with a 60% increased risk of cataracts compared to no GC use and cumulative 
doses more than 4000mg were associated with a 3-fold increased risk of cataracts and 
a 50% increased risk of glaucoma compared to no GC exposure.  
 
As the first study to accurately quantify the risk of cataracts and glaucoma in RA patients 
treated with oral GCs, these results make a significant contribution to the existing 
literature, which was previously sparse and inconclusive for RA populations and 
conflicting in other diseases. Careful consideration was given to the study design and 
selection of analyses, with CPRD chosen as a large real-life longitudinal cohort, in which 
time-varying analyses could be performed.  The results expand current knowledge 
regarding GC-associated eye diseases, quantifying the risks related to GC use, dose, 
timing of dose and also cumulative dose, as a combined measure of both dose and 
duration.  
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Glucocorticoids (GCs) are often used to treat Rheumatoid Arthritis (RA) despite their many
side effects and the availability of other effective therapies. Cataract and glaucoma are
known side effects of GCs but the risk of them developing in the setting of GC use for RA is
unknown. The aim was to perform a systematic review and meta-analysis to determine the
association between GCs and the risk of developing cataract and/or glaucoma in RA.
Methods
A systematic search was carried out using MEDLINE, EMBASE, and Web of Science. All
RCTs comparing GC use to non-use in RA populations were sought. Observational studies
reporting cataract and/or glaucoma amongst GC users and non-users were also included.
Data extracted included incidence/prevalence of cataract and/or glaucoma in each arm,
dose and duration of therapy. Two independent reviewers performed quality assessment.
Results
28 RCTs met eligibility criteria, however only 3 reported cataracts and glaucoma, suggesting
significant under-reporting. An association between GC use and the development of cata-
racts in RA patients was seen in observational studies but not RCTs. There was no statisti-
cally significant association between GC use and the development of glaucoma, although
data were sparse. There were insufficient data to determine the impact of dose and duration
of therapy.
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Conclusion
The current literature suggests a possible association between GC use and the develop-
ment of cataract. However, this risk cannot be accurately quantified in RA from the available
evidence. RCTs have not adequately captured these outcomes and well-designed observa-
tional research is required.
Introduction
Cataract and glaucoma were first described as side effects of systemic GC therapy as early as
1953[1, 2]. In particular, posterior subcapsular cataracts (PSCs) are a subtype of cataracts that
occur more frequently in GC-exposed patients [1]. Similarly, GC exposure can lead to steroid-
induced glaucoma, a type of open angle glaucoma. These conditions can lead to visual
impairment, resulting in significant disability and cost to the healthcare system [3]. As GCs
remain widely prescribed in rheumatoid arthritis (RA) and many other inflammatory diseases
[4, 5], any increased risk might lead to a significant public health burden.
EULAR guidelines advocate that clinicians inform their patients of the risk of side effects
associated with GCs before commencing treatment [6]. However, for cataract and glaucoma,
the magnitude of risk is rarely reported and current literature has not been reviewed to deter-
mine if the risk can be accurately quantified. Specific questions, such as how this is influenced
by dose and duration of therapy, also have not yet been addressed. RA was the first condition
to be treated with GCs in 1948 [7] and it was also the first condition in which PSCs were
described as AEs of GC use in 1950 [1]. There are multiple randomised controlled trials
(RCTs) of GC use in RA, and long-term use has been looked at in many observational studies,
making it an ideal setting to explore these questions.
The aim was to perform a systematic literature review and meta-analysis of RCTs and
observational studies examining the association between GC use and the risk of cataract and
glaucoma in patients with RA compared to patients with RA not exposed to GCs. Secondary
aims were to determine whether there is an association with dose and duration of GC therapy.
Materials and Methods
Search strategy
A systematic search was conducted using MEDLINE, EMBASE and Web of Science for articles
published to January 2016. There was no review protocol for this systematic review. Separate
search strategies were conducted for RCTs and observational studies. RCTs fulfilling the fol-
lowing criteria were included: 1) RA population 2) Exposure to systemic (oral, intramuscular
or intravenous) GC therapy in one arm and non-exposure (no treatment or placebo) in at least
one comparator arm. Studies comparing DMARD(s) plus GC in one arm and the same
DMARD(s) without GC in the comparison arm were also included. Inclusion criteria for
observational studies were: 1) RA population, 2) Use of a cross-sectional, case-control or
cohort study design 3) Reporting of the number or rate of cataracts and/or glaucoma in GC-
exposed and non-exposed patients. Although cross-sectional studies do not provide informa-
tion on causality, they were included in this review in order to capture information from about
PSCs from early studies conducted in the 1960s. Studies conducted exclusively in populations
other than RA (including early inflammatory arthritis, undifferentiated polyarthritis and JIA)
were excluded. If RA was one of several indications reported, the study was only included if
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the RA population was reported separately from the other populations. Exposure was
restricted to systemic GC therapy (oral, intramuscular, intravenous), and studies reporting
only topical, intra-articular, intra-ocular or other non-systemic routes of steroid administra-
tion were excluded. In instances where two studies reported on the same cohort, the earlier of
the two studies was retained unless the latter reported on cataracts and/or glaucoma.
Search terms are listed in the online supporting information (S1 Table). Search filters for
RCTs were based on the Cochrane Highly Sensitive Search Strategy for identifying random-
ized trials in MEDLINE: sensitivity-maximizing version [8].The search filters for observational
studies was based on the Scottish Intercollegiate Guidelines Network search filters for observa-
tional studies [9].
Study Selection and Data extraction
The initial study selection was based on review of title and abstract. Studies in non-RA popula-
tions were excluded at this stage, as were those with designs other than RCTs, cohort, case con-
trol or cross-sectional studies. Only articles published in English were selected due to lack of
access to a translation service. Full text manuscripts of all remaining articles were reviewed for
eligibility based on the inclusion and exclusion criteria. Hand searching of references of all
papers obtained through the above search and relevant review articles was also carried out.
Abstract only publications and unpublished studies were not considered. A random sample of
20 RCTs was selected for independent full-text review by the second reviewer (CH). Each
study was assessed in regards to eligibility criteria and the rate of agreement with the first
reviewer (RB) was then determined.
Data extraction was performed by a single reviewer using an electronic data collection
form. Information was extracted regarding: 1. The RA population including age, gender and
disease duration, 2. The exposure including the definition of GC use, dose and duration of
therapy, 3. The comparator arm including whether this was placebo or non-GC exposure, and
4. The outcome of cataract and glaucoma in each arm, how this was obtained and whether this
was reported as point prevalence, prevalence, incidence or incidence rate.
Quality Appraisal
Both reviewers (RB, CH) performed an independent assessment of the quality of all included
studies. Discrepancies were discussed and resolved by consensus. The Cochrane Risk of Bias
Assessment tool [10] was used to assess the quality of all included RCTs reporting cataract
and/or glaucoma. Cohort studies were assessed using the Newcastle Ottawa Scale[11] and each
of the cross-sectional studies was assessed for selection bias, detection bias, attrition bias, and
reporting bias, based on the Cochrane Handbook common classification scheme for bias[12].
No case control studies meeting eligibility criteria were identified in the search. The RCTs and
cross-sectional studies were assessed as low, high or uncertain risk, however the cohort studies
were assessed as either being low or high risk due to differences in the scales used.
Meta analysis
Although data were limited, meta-analyses were performed as a means of summarising the
data available. Cross sectional studies were not considered in the meta-analysis due to their
inability to assess causality. Random effects meta-analyses were performed for each outcome:
all cataracts and glaucoma. While other methodologies for dealing with zero events and sparse
data were considered [13–15], risk difference (RD) was selected as the effect size because many
studies had zero events in one arm, and odds ratios and relative risks are not defined in this
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setting. Statistical heterogeneity was assessed using the I2 statistic, where I2>50% represents
significant heterogeneity. Meta analyses were carried out using the Metafor package in R [16].
Effect of dose and duration of GC exposure and visual outcomes
A description, rather than formals analysis of the effect of dose and duration of GC use on the
development of cataract and glaucoma was carried out due to the scarcity of studies addressing
this.
Comparing the reporting of cataracts in RCTs, to population-based
incidence of cataracts
Concerns that cataracts were not being captured or reported in RCTs, early in the course of
this review, led to a secondary aim to compare the RCT incidence with the expected incidence
of cataracts based on general population rates derived from The Blue Mountains Eye Study
(BMES) [17]. For comparison with RA RCTs, the expected population cumulative incidence
of cataracts over 1 and 2 years was estimated for patients aged less than 75 years from the
reported BMES 5-year incidence, under the constant hazards assumption.
Results
Randomised Controlled Trials
95 RCTs were identified for full-text review and 28 RCTs were ultimately included after apply-
ing eligibility criteria (Fig 1). There was initial agreement for 19/20 articles selected for assess-
ment by the second reviewer. Disagreement occurred for one article because the results of this
study had already been reported earlier in another paper that had not been included in the ran-
dom sample. Once this issue was made known to the second reviewer, there was full consensus
for all articles. These papers are summarised in the supporting information (S2 Table).
Cataracts and glaucoma were reported in only 3 of the 28 RCTs (Table 1), each of 2 years’
duration. The initial 28 RCTs evaluated treatment with oral, intramuscular and intravenous
GCs, however the final three studies all assessed oral exposure. These three studies reported all
cataracts rather than the PSC subtype. One study, Williams et al [18], was excluded because it
did not report whether the single observed glaucoma case occurred in the GC or control
group. The remaining 24 RCTs did not mention cataracts and/or glaucoma in either the meth-
ods or the results. The protocols for all three RCTs reporting incident eye disease included
either recording specific known GC-associated AEs using a standardised list [19, 20] or oph-
thalmological examinations [20, 21]. There were no significant differences in the risk of devel-
oping cataracts for GC-exposed versus unexposed RA patients, either individually by trial, or
collectively in the meta-analysis (RD 0.01 events/patient, 95% CI -0.01–0.03), Fig 2 (A RD of
0.01 equates to an additional 10 cataracts for every 1000 patients exposed to GCs compared to
those unexposed). Similarly, there were no significant differences in the risk of developing
glaucoma for GC-exposed versus unexposed RA patients, either individually by trial, or collec-
tively in the meta-analysis (RD 0.01 events/patient, 95% CI -0.02–0.04), Fig 2.
Comparing the reporting of cataracts in RCTs to population-based
incidence of cataracts
Of the 28 RCTS comparing GC use to non-use in RA, there were a total of 13 cataracts
reported in only 3/28 studies (11%). The remaining 25 studies did not report cataracts in their
results, nor did they set out to do so in the their methods. Across all 28 RCTs there was a total
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of 4604 person years, giving a combined cataract incidence rate of 2.8 per 1000 person years
(pyr).
Considering incidence only in the three studies that reported cataracts, the random effects
estimate of the combined incidence rate (IR) was 11/1000pyr (95%CI 3-43/1000pyr), although
the IRs ranged considerably from 2.1/1000pyr [19] to 12.3/1000pyr [20] to 26.5/1000pyr [21].
This heterogeneity is likely related to the different methods used to detect cataract, with oph-
thalmological examination detecting a greater prevalence of cataracts.
Fig 1. Flow charts depicting selection of A. Randomised Controlled Trials and B. Observational Studies.
doi:10.1371/journal.pone.0166468.g001
Table 1. RCTs comparing GC use to non-use in RA and number of reported cataracts and glaucoma.
First Author, Duration of
study
Country Mean Age (%
Female)
Arms of RCTs (n) Outcome Reported & method of detection
Year
Bakker [19], 2 years The Netherlands 54 MTX + PNL 10mg
(117)
Incident cataract and glaucoma-standard list of AEs




2 years The Netherlands 62 PNL 10mg (40) Incident cataract and glaucoma- standardised list of AEs,
ophthalmologic expertise requested when necessary
2002 (64%) Placebo (41)
Wassenberg
[21],
2 years Germany, Austria,
Switzerland
52 Gold or MTX
+ PNL 5mg (93)
Incident cataract and glaucoma- ophthalmologic exams at
the beginning and end of the study
2005 (70%) Gold or MTX
+ placebo (96)
RCTs = Randomised Controlled Trials, GC = glucocorticoid, RA = rheumatoid arthritis, n = number, PNL = prednisolone, MTX = methotrexate,
AEs = Adverse Events
doi:10.1371/journal.pone.0166468.t001
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Fig 2. Meta analysis forest plots of RCTs and cohort studies reporting all cataracts, cohort studies
reporting PSCs and RCTs and cohort studies reporting glaucoma.
doi:10.1371/journal.pone.0166468.g002
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The cumulative two-year incidence in the 3 studies of this duration reporting cataract was
2.0% (95% CI 0.6–6.6). The expected population cumulative incidence (in participants youn-
ger than 75 years), estimated from the BMES population [17], is 6% over 1 year and 12% over
two years. Given that the median duration of the 27 RCTs was one year, this suggests that cata-
racts were expected in RCTS in which they were not reported, suggesting a substantial six-fold
under-reporting of cataracts in the clinical trials.
Observational studies
A total of 10 observational studies met eligibility criteria for the final review. Five were cohort
studies, of which two were prospective and three retrospective. The remaining five were cross-
sectional (Fig 1).
a) All Cataracts (Reported in 5 cohort studies). Amongst the cohort studies, Gullberg
et al [22] reported PSCs as well as all cataracts. However, the remaining cohort studies
reported all cataracts only and not PSCs [23–26]. The methods for identifying and defining
cataracts varied between studies, as did the definitions of GC use (Table 2).
In contrast to RCTs, four of the five cohort studies reported a significantly increased risk of
cataracts in GC-exposed patients, and collectively the combined risk difference was 0.07 events
per person (95%CI 0.04–0.10), Fig 2, which is equivalent to an additional 70 cataracts seen per
1000 patients in those exposed to GCs. The odds ratio, which could also be meaningfully esti-
mated from this data, was 2.1 (95%CI 1.5–2.9). While there was considerable variation in age,
disease duration, dose and duration on GCs between these studies (Table 2), there was surpris-
ingly little statistical evidence of heterogeneity between the effect sizes (RD I2 = 6.2%).
In regards to dose and duration of therapy, Huscher et al [25] looked at patterns of gluco-
corticoid induced side effects and found two distinct patterns including ‘linear risk’, where
risk of developing an AE increased with dose in a linear fashion and ‘threshold risk’ where the
increased risk only occurred after a threshold dose was reached. They found that both cataract
and glaucoma fit the threshold pattern with a threshold dose of 5mg per day for cataract and
7.5mg per day for glaucoma in patients on GCs for more than 6 months. Mazzantini et al [26]
did not find any difference in cataract prevalence between those treated with GCs for<2
years, 2–5 years or >5years.
b) Posterior Supcapsular Cataracts (PSCs) (Reported in 5 cross-sectional studies and 1
cohort study). PSCs were reported in five cross-sectional studies published between 1960
and 1969. In all five studies, an RA population, including those exposed and unexposed to GC
treatment, underwent ophthalmological examination. In 4/5 of these studies[1, 27–29], PSCs
were only seen in those exposed to GCs, and in the remaining study by Williamson et al [30], 1
PSC was seen amongst 159 unexposed to GCs compared to 10/148 exposed (Table 3). PSCs
were also reported in a retrospective cohort study by Gullberg et al [22], with a risk difference
of 0.20 events per patient (95%CI 0.08–0.33), equivalent to an additional 200 PSCs for every
1000 patients exposed to GCs.
In regards to dose and duration of GC therapy, Black et al reported that PSCs were not seen
in six patients who took prednisolone equivalent doses of<10mg per day or in nine patients
who had been taking GCs for less than one year [1]. Giles et al [27] also found that PSCs did
not occur in three patients that received GCS for less than one year. However they did occur in
four of the 19 patients taking <10mg per day for6 months. The prevalence of PSCs
increased with GC dose, with PSCs seen in 4/12 patients on 10-15mg/day and in 6/7 patients
on>15mg per day. Furst et al compared the prednisolone equivalent average daily dose and
duration of therapy in those with PSCs to those without and found no significant difference in
duration of therapy but a higher average dose of 11.5mg in those that developed PSCs
Glucocorticoid Associated Cataract and Glaucoma Risk in RA
PLOS ONE | DOI:10.1371/journal.pone.0166468 November 15, 2016 7 / 15
























Black [1], Cross-sectional, <30 = 3, 30–
39 = 9,
37/67 1-3y = 20, Not defined <1y = 9, <10mg = 6, PSC
1960 40–49 = 24, (55%) 4-6y = 13, 1-4y = 22, 10-15mg = 22, Ophthalmologist
Point prevalence 50–59 = 16, 7-9y = 12, >4y = 13 >15mg = 16
60 = 11 >9y = 18(63)
Giles [27], Cross-sectional, <30 = 3, 45/62 1-3y = 15, Sustained
GC
<1y = 3, <10mg = 19, PSC
1962 30–39 = 8, (73%) 4-6y = 12, use for 1-4y = 18, 10-15mg = 12, Ophthalmologist
Point prevalence 40–49 = 20, 7-9y = 11, 6months >4y = 17 >15mg = 7
50–59 = 26, >9y = 24
(62) 60 = 5
Crews [28], Cross-sectional, Patients with
PSC





1963 40–49 = 2, 50–
59 = 7,
PSC PSC Ophthalmologist
Point prevalence 60–69 = 8, 70–
79 = 1




(86) Not Reported Not
reported
Not reported
Furst [29], Cross-sectional, Not Reported Not Reported Not reported GC use for Patients
with
Patients with PSC
1966 minimum of PSC PSC Ophthalmologist









Cross-sectional*, GC-users 243/307 GC-users Not defined Mean
3.15y
Mean PSC
1969 Mean 52.5 (79%) Mean 8.95y SD
+/-2.45
10.89mg Ophthalmologist
Point prevalence SD +/-11.5 SD +/- 6.35 SD +/-4.8
Range 18–80 Non-users
(307) Non-users Mean 6.55y







Mean 58 100/130 Mean 11 y Not defined Patients
with
Patients with PSC and all











Glucocorticoid Associated Cataract and Glaucoma Risk in RA
PLOS ONE | DOI:10.1371/journal.pone.0166468 November 15, 2016 8 / 15
compared to 8.8mg in those that did not. However, they did not report whether this difference
was significant. Williamson also reported an increased prevalence with longer duration of
therapy, with no PSCs seen in the 65 patients on GCs for less that two years compared to seven
of the 52 patients on GCs for more than two years (p<0.01) [30].
c) Glaucoma (Reported in2 cohort studies and 1 cross-sectional study). Of the observa-
tional studies that fulfilled the eligibility criteria for this search, three studies reported glau-
coma [23, 25, 30]. No significant association was seen between GC use and glaucoma amongst
the 2 cohort studies [23, 25] with a combined risk difference of 0.00 (95% CI -0.01–0.02). In
the cross-sectional study, Williamson et al [30] reported 1 case of glaucoma amongst 148 GC





























GC-users 170/244 GC-users Received GC Mean 6.9y Mean 8.0mg Not Stated





Non-users enrolment 23.4 ophthalmoscope
(244) Non-users Mean 13.8y (excluded if examination at
each




exposure) referral if needed
Saag [23], Retrospective
cohort,
GC-users 168/224 GC-users Near Not
reported
Mean 6.1mg Not Stated
1994 Mean 51.8 (75%) Mean 4.9y continuous SD +/-3.1mg Clinical records
Incidence SD +/-12.7 SD+/-6.3, (<1mth off)
(224) Non-users Non-users steroids
Mean 51.7 Mean4.9y for>1y at









<5mg = 101, Not Stated
2009 <5mg = 60.9 <5mg = 82% <5mg = 9.7y, the past 12m 5–7.5mg = 281, Self reported
Point prevalence 5–
7.5mg = 60.4
5–7.5mg = 77% 5–
7.5mg = 13.2y,
for >6m >7.5mg = 90





GC-users GC-users GC-users GC use Mean 8y Mean 4.1mg Not Stated
2010 Mean 66.7 65% Mean 16.8y continuously SD +/-6y SD+/-1.2mg Clinical records
Prevalence SD +/-11.7 Non-users SD +/-6.3y for >6m and Range 1-
20y
Range 4-6mg
(365) Range 26–89 74% Non-users <10y
Non-users Mean 16.3y
Mean 66.1 SD +/-6.1y
SD+/-12.3
Range 28–90
*Some patients followed up prospectively with repeat ophthalmological examinations performed two or more times at 3 or 6 months intervals.
n = number, PSC = posterior supcapsular cataract, GC = glucocorticoid, d = day, m = month, y = year, SD = standard deviation
doi:10.1371/journal.pone.0166468.t002
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Quality Assessment
The quality assessment of all studies is shown in Fig 3. Among RCTs, the risk of bias was low
for most criteria (Fig 3A). Conversely, for the cohort studies, there was a high risk of bias in
some categories, particularly regarding the exclusion of prevalent eye disease (Fig 3B).
Amongst the cross-sectional studies, the risk of bias was uncertain for most categories (Fig
3C).
Discussion
RA is an ideal patient group in which to look for long term adverse effects of GCs. RA was the
first condition to be treated with GCs [7]and it was also the first condition in which PSCs were
described as AEs of GC use [1]. More recently GCs have been shown to have a disease modify-
ing effect in RA [31], resulting in more continuous patterns of use compared to other indica-
tions such as asthma and IBD for which GCs are often used intermittently. RA patients may
differ in their risk of developing GC induced eye diseases compared to other populations such
as those with IBD and spondyloarthropathies, which are more frequently associated with uve-
itis and topical GC use, other known risk factors for developing cataract and glaucoma [32]. It
is therefore important to understand how systemic GC use affects the risk of developing cata-
ract and glaucoma in RA patients.
This review has found that there is limited literature addressing the association between sys-
temic glucocorticoid use and the risk of cataract and glaucoma in patients with RA. In contrast
to the RCTs which showed no association between GC use and all cataracts (RD 0.01, 95%CI
-0.01–0.03), an association was observed in the observational cohort studies [22–26], with a
estimated risk difference of 0.07, 95%CI 0.04–0.10. The RCT and observational literature
regarding glaucoma was particularly limited as was that addressing the effect of dose and dura-
tion of GC therapy. There were no studies addressing the impact of comorbidities known to be
associated with increased risk of cataract or glaucoma, or the visual outcome of GC-induced
cataract or glaucoma. PSCs often require surgery at an earlier stage than other cataract types
[33] and whilst this has not been addressed in the context of GC use, it certainly raises concern
and highlights the need for future studies in this area.
Although well described as side effects of GC use in review articles and books [34–38], cata-
racts have been reported in only three of the 28 RCTs comparing GC use and non-use in RA
populations (in either arm of the study). Through comparison to general population cumula-
tive incidence rates derived from the BMES, it is apparent there is significant under-reporting
of cataracts in RA glucocorticoid clinical trials, making any estimates of GC-associated risk
less reliable. Ideally, future RCTs comparing GC use to non-use would endeavour to accurately
capture this information with regular ophthalmology assessments.
Table 3. Cross-sectional Studies Reporting Posterior Subcapsular Cataracts (PSCs).
Study GC-Exposed GC-Unexposed
Author, Year Number of patients Number of PSCs Number of patients Number of PSCs
Black [1], 1960 44 17 19 0
Giles [27], 1962 38 14 24 0
Crews [28], 1963 52 18 34 0
Furst [29], 1966 57 6 48 0
Williamson [30], 1969 148 10 159 1
GC = glucocorticoid, PSCs = Posterior Subcapsular Cataracts
doi:10.1371/journal.pone.0166468.t003
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Whilst this review focussed specifically on studies in RA populations, it is interesting to
consider how the extent of GC-associated risk compares with studies in other populations,
and between the sub-types of cataract. In the BMES Australian general population there was
an association between current GC use and PSCs (OR 4.11, 95%CI 1.67–10.08) and nuclear
cataracts (OR 3.45, 95% CI 1.26–9.43) but not cortical cataracts (OR 1.08, 95%CI 0.44–2.64)
[33]. In comparison, the Beaver Dam Eye Study found an increased incidence of cortical
cataracts associated with GC use in the American general population (OR 2.59, 95%CI
1.45–4.62) but not PSCs (OR 1.27, 95%CI 0.42–3.86) or nuclear cataracts (OR 1.41, 95%CI
0.77–2.56) [39]. This is in contrast to other studies that have shown a strong association
between GC use and PSCs in other populations including asthma and renal transplantation
[33, 40–43]. Unfortunately, despite the observation that PSCs occurred with GC use
reported in earlier cross-sectional studies, more recent RA studies have not reported spe-
cific cataract type.
Fig 3. Quality Assessment of A. Randomised controlled trials and C. Cross sectional studies using the Cochrane Risk of Bias Assessment Tool (high risk,
low risk of uncertain risk) and B. Cohort studies using the Newcastle Ottawa Scale (high risk or low risk).
doi:10.1371/journal.pone.0166468.g003
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Impact of Dose and Duration of GC Therapy
The impact of dose and duration of GC therapy on the development of cataract and glaucoma
remains unanswered. Whilst some of the observational studies in this review suggest an associ-
ation between GC use and dose and duration of therapy, they do not adequately quantify the
risk in a way that can be translated into clinical practice when discussing the risks and benefits
of GC treatment for RA. Many of the observational studies that comment on dose and dura-
tion were insufficiently powered, or not appropriately designed, to determine an accurate asso-
ciation between different doses and durations of therapy. A striking association between GC
use and the development of PSCs was described in early cross-sectional studies carried out in
the 1960s, however an association with cataracts was not seen in more recent RCTs. Whilst
under-reporting partly accounts for this, another possible explanation is that GC exposure
(dose and duration of therapy) has declined over time with the increasing use of concurrent
DMARDs, highlighting the need for this to be explored in future studies.
Strengths and limitations
The main strength of this review is the systematic approach used to identify all relevant studies
published since 1950 and the use of two reviewers to confirm eligibility criteria. The main limi-
tation of this review is the small number of studies meeting eligibility criteria, making it impos-
sible to draw meaningful conclusions. Although cross-sectional studies cannot assess causality,
their inclusion allowed a comprehensive summary of the complete literature on this subject.
The results are reported by study design and thus this does not detract from the study findings.
The heterogeneity of studies was significant, particularly in regards to the methods used to
detect cataracts and glaucoma. Only one of the RCTs and two of the cohort studies used exam-
inations to detect cataracts, and the remainder relied on patient reports or case note review.
There was additional heterogeneity in the definitions of GC exposure. This heterogeneity
made it impossible to draw any quantitative conclusions regarding the risk of GC use and the
development of cataract and glaucoma in RA patients. The observational studies had a high
risk of bias, with only one [25] controlling for comorbidities known to be associated the devel-
opment of cataract and glaucoma and potentially associated with GC exposure [44–46].
The current literature leaves many questions unanswered in regards to GC use and the
development of cataract and glaucoma. Although RCTs often represent the highest level of evi-
dence for efficacy, they are not ideal for examining long-term drug adverse effects. They also
do not reflect the patterns of GC use seen in routine practice. In order to adequately address
the questions in this review, a well designed observational study that is large enough and of suf-
ficient duration to capture rare events is required. Ideally, such a study would be conducted in
a real-life setting so that the impact of age and comorbidities could also be determined. Data
on dose and duration of GC use would need to be accurately captured and appropriate meth-
odologies employed to fully understand the interactions between dose, duration and recent-
ness of treatment. Cataracts and glaucoma become increasingly prevalent with age and
commonly occur without exposure to systemic GCs. They range in severity from asymptom-
atic to visually disabling, making it important to clearly define the clinical relevance of cata-
ract/glaucoma in future studies.
Conclusions
In conclusion, observational studies, but not RCTs, suggest an association between GC use
and the development of cataracts in RA patients. This relationship has not been adequately
quantified, nor have the effect of dose and duration of therapy, visual outcomes and the impact
of comorbidities been addressed. Confidence in RCT and observational estimates are limited
Glucocorticoid Associated Cataract and Glaucoma Risk in RA
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by under-reporting, and heterogeneity and bias, respectively. There is no robust literature
regarding GC use and the development of glaucoma in RA patients. These findings highlight
the need for future well conducted observational studies targeting the unanswered questions
as well as improved capture of these outcomes in future RCTs.
Supporting Information
S1 Table. Search terms used for RCTs and Observational Studies in each of the databases.
(DOCX)
S2 Table. RCTs comparing GC use to non-use in RA and number of reported cataract and
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Background: Cataracts and glaucoma are recognised glucocorticoid (GC) adverse 
effects. However, the impact of GC use, dose and timing of dose on the development 
of cataracts and glaucoma has not been well quantified. 
Objectives: To determine the association between: 1. GC use 2. GC dose and the lag 
effect of GC dose, and 3. Cumulative GC dose and the development of incident 
cataract and glaucoma in patients with incident RA. 
Methods: Data were used from the Clinical Practice Research Datalink (CPRD), a large 
UK primary care database derived from electronic medical records (Jan 1992-  Dec 
2017). Incident RA patients were identified using a validated algorithm. Three GC 
exposure models assessed the impact of: 1. Current GC exposure, 2. Current dose 
(prednisolone daily dose equivalent) and lagged dose (at 1, 3, 6 months, 1 & 2 years) 
and 3. Cumulative dose, all as time-varying covariates. Each outcome was analysed 
separately using parametric log-logistic and Weibull survival models respectively. To 
improve the model fit, a square root (sqrt) transformation of dose was used for 
cataract Model 2. Smoking, gender and uveitis were included as covariates in the 
model and age was used as the timescale. Comorbidities on the causal pathway, such 
as diabetes, obesity and hypertension, were not included.  
Results: There were 22607 patients with incident RA (median age 66, IQR 37, 84, 68% 
female), of whom 241 had cataracts and 164 had glaucoma on or before baseline and 
were thus excluded. Median duration of follow up was 8.7 years (IQR 1.8, 19.8) and 
39% were ever GC users during follow up. The incidence rate, per 1000 patient-years, 
was 12.3 (95% CI 11.8, 12.9) for cataracts and 3.1 (95% CI 2.8, 3.4) for glaucoma, which 
increased with age. GC use was associated with both cataracts (OR 2.25, 95%CI 1.89, 
2.68) and glaucoma (HR 1.60, 95%CI 1.26, 2.02). In the multivariable lagged dose 
analysis, an increase in current dose from 0-10mg was associated with an increased 
risk of cataract (OR 1.59, 95%CI 1.08, 2.33), with dose 1-year prior having the greatest 
effect size for cataracts (OR 2.08, 95%CI 1.45- 3.00).  For glaucoma, each 10mg 
increase in GC dose at 3-months prior (HR 1.54, 95% CI 1.13, 2.10) and 1-year prior (HR 
1.60, 95% CI 1.20, 2.14) were important. Compared to no GC use, cumulative GC doses 
more than 1000mg were associated with cataracts (OR 1.63, 95%CI 1.26, 2.10), with an 
increased risk seen with higher cumulative doses more than 4000mg (OR3.15, 95%CI 
2.56, 3.88). Compared to no GC use, there was an increased risk of glaucoma 
associated with cumulative doses greater then 4000mg (HR 1.47, 95%CI 1.07, 2.02). 
Conclusions: The quantification of the risk associated with GCs and the development 
of cataract and glaucoma is of clinical utility in daily practice. EULAR guidelines 
recommend patients are informed of the risks and benefits of GC treatment prior to 
commencement, however the risk of these potential side effects had not previously 
been quantified. This information will allow patients to make better informed 






Cataracts and glaucoma are well recognised as the main ophthalmic adverse effects 
(AEs) associated with glucocorticoid (GC) use. These conditions can lead to visual loss 
and account for significant disability and cost to the healthcare system(1, 2). Multiple 
mechanisms linking GC use to the development of cataracts and glaucoma have been 
proposed (3, 4), however much of the literature focuses on topical GC use, with less 
understood about the effects of systemic GC use on the eye.  The impact of oral GC 
use on the development of cataracts, but not glaucoma, has been previously reported 
in disease-specific and general populations (5-10).  However, the estimates in these 
studies ranged from a less than three-fold increase in risk to a greater than eight-fold 
increased risk due to significant heterogeneity in the design of the studies, including 
different definitions of cataracts and differing methods for identifying them. The 
impact of dose, the timing of when a dose is given and the cumulative effects of dose 
also remain unquantified (11). 
 
GCs are frequently used in the treatment of rheumatoid arthritis (RA), with 
approximately 50-60% of RA patients found to be ever-users(12-14). International 
guidelines recommend the risks and benefits of GC treatment are discussed with 
patients prior to therapy (15), however an informed risk-benefit assessment is difficult 
when the risks have not been adequately quantified. Dosing patterns have been 
shown to vary greatly for patients with RA (12), making it necessary to explore the 
impact of differing GC exposure patterns on the development of cataracts and 
glaucoma. 
 
The primary aim of this study was to examine the association between GC use and the 
development of cataracts and glaucoma in RA patients. Specific objectives were to 
examine time-varying models of: 1) current GC use (yes/no), 2) current or lagged GC 





Clinical Practice Research Datalink (CPRD) is an automated database that contains 
pseudonymised, prospectively collected electronic medical records (EMRs) from 
registered UK general practices. In the UK, healthcare is centralised through general 
practice and EMRs are maintained and updated within practices. The EMRs contain all 
primary care details as well as information about referrals. Studies have found the 
data held by CPRD to be representative of the UK population in terms of age and 
gender structure (16, 17). Validation studies have demonstrated good completeness 
and accuracy of the data, particularly for chronic diseases (18, 19). CPRD has its own 
internal quality measures at the patient and practice level, including acceptability flags 
based on contiguity and quality of patient data, and an up to standard date for 
practices based on continuity of data recording (20). UK primary care electronic 
medical records use a unique coding system with Read codes identifying medical 
diagnoses and Product codes to identify medications (21). Medical and Product 
Browsers available to generate Read and Product code lists.   
 
Data were obtained from CPRD for the period from 1st January 1992- 31st December 
2017. Patients with RA were identified using a validated algorithm, shown to have a 
sensitivity of 84% and a specificity of 86% when compared to the American College of 
Rheumatology 1987 revised RA classification criteria (22). The RA diagnosis date was 
defined as the date of the first RA code in patients with validated RA. Each patient had 
a cohort entry date defined as the date at which all of the following criteria were met: 
their practice was classified as up to standard, the patient was currently registered 
with the practice and the study period had started (1st Jan 1992).  Patients with 
incident RA were identified as those with an RA diagnosis date on or after their cohort 
entry date, at least 12 months of data recorded prior to diagnosis and no record of 
disease modifying anti-rheumatic drug (DMARD) use, including prior to their RA 
diagnosis date. Those aged less than 18 years were excluded.  
 
Outcome variables 
Cataract and Glaucoma codes were identified using the Read code dictionary. A 
number of cataract and glaucoma codes have been previously validated (23), however 
these validated code lists included 13 cataract codes and 13 glaucoma codes, far fewer 
than those identified in Medical Browser  search. Therefore, an expanded list was 
selected for this study. Codes for cataract and glaucoma with congenital, post 
traumatic and surgical causes were excluded as well as those identified as being 
secondary to another medical condition. Code lists are available in data supplement 
Table S1. Those with a cataract code on or before baseline were excluded from the 
cataract analyses, with the same process applied to the glaucoma analyses. 
 
Glucocorticoid use exposure variables  
Oral GC use was identified using the Product codes for prednisolone, cortisone, 
hydrocortisone, triamcinolone, methylprednisolone, dexamethasone, 
bethamethasone, budesonide and deflazacort. A previously developed prescription 
algorithm was used to prepare the data for analysis(12, 24, 25). Dosages were 
converted to a prednisolone-equivalent (PEQ) daily dose. Those with a GC prescription 
greater than a pre-defined maximum PEQ dose of 100mg per day were excluded. For 
each patient, episodes on and off GCs were created for the complete follow up period, 
with a prednisolone equivalent daily dose for each episode on GCs. A binary indicator 
of GC use (on/off) and a continuous measure of GC dose (mg PEQ) were therefore 
time varying variables. 
 
Analyses 
All analyses were performed in Stata v13 (StatCorp LLC, Texas, USA). Descriptive 
statistics were used to determine the characteristics of the incident RA cohort.  
Cataract and glaucoma analyses were run separately. The incidence rate per 1000 
patient years by age and gender was tabulated, and cumulative incidence (Kaplan-
Meier failure function) and the smoothed hazard function were plotted for both 
cataract and glaucoma.  
The relationships between GC exposure and cataract or glaucoma outcome were 
analysed by time-to-event (survival) regression analysis. Follow up began on the date 
of RA diagnosis and ended when the patient first developed the outcome of interest, 
or censored when the patient left the practice, died, the study period finished (31st 
Dec 2017) or on the date data was last collected from the practice, whichever 
occurred first. Age was used as the timescale in all analyses.  
 
Non-parametric Cox regression models were initially considered for the analysis, but 
the proportional hazards assumption was clearly violated for the glaucoma data, and 
ultimately parametric survival models were selected for the analysis. Selection of the 
appropriate model was based on the shape of the underlying hazard function, and 
both the Akaike information criterion (AIC) and Bayesian information criterion (BIC). 
 
Three separate GC exposure models were analysed for both cataracts and glaucoma: 
1. Current GC use (on/off), 2. GC dose at pre-specified lagged intervals, and 3. 
Cumulative GC dose. The lagged dose multivariable models looked at current PEQ 
dose, dose at 1 month, 3 months, 6 months, 1 year and 2 years prior to the 
development of cataract or glaucoma. Prior to this analysis, the relationship between 
current dose and outcome was evaluated using Tukey ladder of powers fractional 
polynomial transformations, and the square root of dose was selected as an 
appropriate transformation to linearize the relationship between GC dose and 
cataracts. However, no transformation was needed for glaucoma as the relationship 
between dose and glaucoma was linear. The cumulative dose models looked at the 
total additive GC exposure from the date of diagnosis. For ease of interpreting the 
results, the cumulative dose was categorised (0mg, 1-125mg, 126-250mg, 251-500mg, 
501-1000mg, 1001-2000mg, 2001-4000mg and >4000mg PEQ). 
 
Covariates 
Risk factors for cataract and glaucoma were identified from the literature. Many, 
including diabetes mellitus, hypertension and obesity were not included as covariates 
in the analysis as they are on the causal pathway for the association between 
exposure and outcome. For example, hypertension is a risk factor for cataract and 
glaucoma, however GC use can lead to hypertension, which can in turn increase the 
risk of developing cataracts or glaucoma. Risk factors not on the causal pathway, that 






Of the 36,000 patients identified using the RA validation algorithm, 22,607 met criteria 
for incident RA, with Figure 1 depicting how the cohort was derived.  Characteristics of 
the incident RA cohort (median age 66; 68.2% female) are shown in Table 1. The 
overall incidence rate of cataracts was 12.33 (11.75, 12.94) per 1000 patient years, 
with a lower incidence rate of 3.10 (2.82, 3.40) per 1000 patient years seen for 
glaucoma. The incidence rate increased with age for both cataracts and glaucoma as 
shown in data supplement Table S2. 
 
The cumulative incidence and smoothed hazards function by age for both cataracts 
and glaucoma are shown in Figure 2. The cumulative incidence curve may be 
interpreted as the probability that a patient will develop cataracts or glaucoma by a 
certain age. For cataracts (Figure 2A), the cumulative incidence rises steeply from age 
65, reaching ~50% by age 80. For glaucoma (Figure 2B), the steepest part of the curve 
also occurs from age 60, however the cumulative incidence is far less than that of 
cataract, reaching just over 10% by age 80. The smoothed hazards function was 
unimodal for both cataracts (Figure 2C) and glaucoma (Figure 2D). 
 
Model Selection 
Initial analysis was performed by semi-parametric cox proportional hazards regression, 
with GC use as the exposure variable (Model 1). However, there was evidence of 
violation of the proportional hazards assumption for the cataract data (p = 0.0007), 
but not for glaucoma (p = 0.13). Based on the AIC and BIC criteria (Table S3), the log-
logistic parametric survival model was the best fitting parametric survival model for 
the cataract data, which was also consistent with the shape of the hazards function 
(Figure 2C). The loglogistic survival model is an accelerated failure time (AFT) model in 
which the exponentiated coefficients represent the time (in this case, age) ratio at 
outcome onset between comparator groups. This model also has the property of 
proportional odds, and therefore the odds ratio for survival (or cumulative failure) 
between comparator groups is constant over time. There was no evidence that the 
proportional odds assumption was violated for any of the model covariates, as 
assessed by covariate interaction with the gamma (shape) parameter. 
Because the proportional hazards assumption held for the glaucoma data, a Weibull 
parametric survival model was used for the glaucoma data. In addition to a 
proportional hazards model, this also has representation as an AFT model, and 
therefore results for glaucoma can be compared to those for cataracts. 
 
The suitability of the models selected for the analyses is shown in data supplement 
Figure S1, where the predicted survival from the log logistic model (with no covariates) 
is plotted against the observed Kaplan Meier (KM) survival curve for cataract, and the 
predicted survival from the Weibull model is plotted against the observed KM curve 
for glaucoma. For both the cataract and glaucoma models, there was a good fit, with 
the predicted models lying within the 95% confidence intervals of the observed plot. 
 
GC Exposure Models- Cataracts 
The results of the three different exposure models for cataracts are shown in Table 2. 
In the first model, current GC use was associated with cataracts (OR 2.25, 95%CI 1.89, 
2.68), as was baseline uveitis (OR 8.73, 95% CI 4.11, 18.52). The AFT loge coefficient, 
which for small values is approximately equal to the proportional reduction in age of 
onset, was -0.098 (95% CI 0.12, -0.076) for GC use, indicating that cataracts occurred 
at a 10% earlier age in GC users compared to non-users. The second model examined 
the effect of current and lagged GC dose, for which a square root transformation was 
performed, as described in the methods. For ease of interpretation, the results are 
presented as ORs for an increase in dose from 0-10mg.  There was an association 
between current GC dose (OR 1.59, 95%CI 1.08, 2.33), meaning that an increase in GC 
dose from 0-10mg PEQ was associated with a 60% increase in the odds of developing 
cataracts.  There was also a significant association with an increase in GC dose from 0-
10mg at 6 months (OR 1.49, 95%CI 1.02, 2.17), with the greatest association seen at 1 
year prior to the diagnosis of cataracts (OR 2.08, 95%CI 1.45, 3.00). In the third model, 
prior cumulative GC dose was analysed, showing that cumulative doses 1000-2000mg 
were associated with the development of cataracts (OR 1.63, 95%CI 1.26, 2.10), with 
similar odds for 2000-4000mg, whereas the odds increased further with cumulative 
doses greater than 4000mg (OR 3.15, 95%CI 2.56, 3.88). 
 
GC Exposure Models-Glaucoma 
The results of the three GC exposure models for glaucoma are shown in Table 3. In 
Model 1, current GC use (HR 1.60, 95%CI 1.26, 2.02) and baseline uveitis (HR 4.69, 
95%CI 2.42, 9.09) were associated with glaucoma. The AFT for GC use was -0.122 
(95%CI -0.188, -0.055), indicating that glaucoma developed at a 12% younger age in 
GC users compared to non-users. In Model 2, glaucoma risk was associated with a 0-
10mg increase in GC dose at 3 months (HR 1.54, 95%CI 1.13, 2.10) and 1 year (HR 1.60, 
95%CI 1.20, 2.14), but not at 6 months. In Model 3, cumulative doses greater than 
4000mg were associated with the development of glaucoma (HR 1.47, 95%CI 1.07, 
2.02), however there was no association with lower cumulative doses below 4000mg. 
 
Mean difference in Age of Onset with GC Use 
The results of the AFT models can be expressed in different ways, one of which is the 
mean age difference (in years) for the outcome onset. For example, in Model 1, the 
mean age of onset of cataract or glaucoma with GC use was estimated by prediction of 
the marginal effects, averaged over all covariates (Figure 3). Cataracts occurred an 
average of 8.4 years (95%CI -10.3, -6.6) earlier with GC use compared to non-use. The 
effect of GC use on glaucoma age of onset was even greater, occurring an average of 
15.2 years (95%CI -23.6, -6.9) earlier with GC use compared to non-use. Uveitis had 
the greatest impact on age of onset for both cataract and glaucoma, bringing forward 




This study confirms that oral GC use is associated with the development of cataracts 
and glaucoma in patients with RA. For cataracts, the results of Model 1 have shown an 
OR of 2.25 (95%CI 1.89, 2.68) for current exposure, which is comparable to the results 
of a previous meta-analysis, where the OR for GC exposure in RA observational studies 
was found to be 2.1 (95%CI 1.5–2.9)(11). The same meta-analysis, found no such 
association between GC exposure and cataracts in randomised controlled trials, 
reinforcing the message that long-term observational studies in real-life populations 
play an essential role in quantifying safety outcomes.  
 
The relationship between GC use and the development of cataracts has previously 
been explored in general and diseases specific populations, but with significant 
heterogeneity in estimates and study design. Many of these studies used ophthalmic 
examination to define cataracts, dividing them into three common subtypes including 
posterior subcapsular cataracts (PSCs), nuclear cataracts and cortical cataracts. In The 
Blue Mountains Eye Study (BMES) 3654 Australians aged 49 years or older were 
examined between 1992– 1994, 2335 were re-examined after five years and 1952 
were re-examined after 10 years. Current oral GC users at baseline had a greater risk 
of developing PSCs(OR 4.11; 95% CI 1.67–10.08) and nuclear cataracts (OR 3.45, 95% 
CI 1.26 –9.43) but not cortical cataracts (5). Conversely, in the Beaver Dam Eye Study 
(BDES) adults aged 43 to 86 years were examined between 1988-1990 and again 5 
years later. In contrast to the BMES, oral GC use was associated with an increased risk 
of cortical cataracts (OR 2.59, 95%CI 1.45-4.62) but not nuclear cataracts or PSCs (6). In 
the Lens Opacities Study, cases (cataracts) and controls were taken from a general 
ophthalmology outpatient clinic, with oral GCs found to be a risk factor for PSCs only 
(OR 5.73, 95%CI 2.14, 15.3) (7). In the Italian-American Cataract Study Group, patients 
were recruited from the three ophthalmic clinics in Parma, Italy, from 1987 -1989. 
They did not analyse oral and topical GCs separately, and cortisone given orally or as 
eye drops was associated with an increased risk or PSCs (OR 8.39, 95%CI 3.42-20.61) 
but not with other cataract types (8). In a cross sectional disease-specific study of 
asthma patients, PSCs diagnosed by at an ophthalmological examination were 
associated with current prednisolone dose (coef 0.43, P<0.002) but non-PSC opacities 
were not (9). Renal transplant recipients at Princess Alexandra Hospital, Australia 
between 1982-1988 were examined before and after treatment. High dose versus low 
dose GC treatment was associated with an increased risk of cataracts (χ2= 8.097; df= 1, 
P<0.01)(10). 
 
Current knowledge about the relationship between oral GC dose and the development 
of cataracts and glaucoma has been extended by the results of Models 2 & 3. In Model 
2, the effect of current dose on the development of cataracts was quantified, with a 
60% increase in risk associated with a dose increase from 0-10mg PEQ. This model also 
demonstrated that doses taken 1 and 3-months prior to diagnosis were not associated 
with cataract development but a dose increase from 0-10mg PEQ 6-months prior was 
associated with a 50% increase in risk, with a doubling of the risk seen wat 12-months 
prior. The lack of association with doses at 1 and 3-months may be due to a 
correlation between current dose and dose at these time points, such that they are 
not significant when included in the same multivariable model. It is also interesting to 
consider how current dose and doses 6 and 12 months prior could mechanistically 
lead to cataract development. One explanation might be that current dose is 
important in accelerating cataract development in patients who already have pre-
clinical cataracts, not yet diagnosed. However prior dose might be playing a role in the 
development of de-novo cataracts. Cumulative doses greater than 1000mg PEQ were 
associated with a 30% increased risk of developing cataracts, whereas cumulative 
exposure greater than 4000mg PEQ had the greatest impact, with a threefold increase 
in risk. A dose of 4000mg PEQ equates to a daily dose of 5mg for just over 2 years, a 
dose often reported to be safe for long-term use (26). Cumulative dose has previously 
been shown to be important in the development of cataracts in other cohorts with 
giant cell arteritis (GCA)(27) and systemic lupus erythematosus (SLE)(28). Broder et al 
(27) found that the effects of cumulative dose on the development of cataracts 
increased with age (up to age 80), with a HR of 2.88 (95%CI 2.34, 3.54) for PEQ 
cumulative dose in those aged 70-79. However, by categorising cumulative dose, we 
have added to this knowledge by demonstrating levels at which cumulative dose 
becomes a concern. Compared to patients with RA, patients with GCA are expected to 
be older and to be exposed to greater cumulative doses, with no patients expected to 
be unexposed to GCs post diagnosis. 
 
When compared to cataracts, there was less prior knowledge regarding oral GC use 
and the development of glaucoma, with a recent systematic literature review of RA 
studies concluding that there is a lack of robust evidence in this area (11).  A case-
control study using data from the Quebec universal health insurance program for the 
elderly, looked at the risk of developing ocular hypertension or OAG associated with 
oral GC use in patients aged 65 years or older (29). It found that GC current use (in the 
past 14 days) was associated with an increased risk of developing glaucoma (OR 1.41, 
95%CI 1.22-1.63), but former use in the past 15-45 days (OR 1·18, 95% CI 0·87–1·62) or 
46-365 days (OR 0·92, 95%CI 0·78–1·08) was not. It also showed that the risk increased 
with average daily dose (PEQ daily dose 0.4- <10mg OR 1.26, 10- <20mg OR 1.40, 
≥20mg 1.88) and duration of continuous GC therapy of 3 months or more (3-5 months 
OR 1.63, 6-11 months OR 1.87, ≥12 months OR 1.52). Another recently published 
study using CPRD data looked at GC use and the development of glaucoma and other 
GC AEs in patients with and without RA (30). This study did not find an association 
between GC use  in the past 180 days and glaucoma (OR 1.27, 95%CI 0.87–1.84)  but 
did show an increased risk of glaucoma associated with cumulative prednisolone 
equivalent doses of 700- <3500mg (OR 1.53, 1.10-2.13) and ≥7000mg (OR 1.71, 95%CI 
1.07- 2.72).While there were some similarities with our study, the nested case-control 
design was very different, comparing GC associated AEs in both RA and non-RA 
patients. While a nested case control design should give comparable results to a Cox 
regression analysis, our study found that this was not the most appropriate model. 
 
This is the first study to quantify the risk of developing glaucoma associated with time-
varying models of GC exposure, and all three models extend current knowledge 
substantially. Previous studies looking at oral rather than topical or intraocular GC use 
date back to the 1970s, and demonstrated an increase in intra-ocular pressure (IOP) in 
patients treated with long-term GCs of varying doses and durations (31, 32). In 
contrast to our study, in these studies dose and duration of therapy were not found to 
be associated with the rise in IOP, but rather the important factor was whether or not 
the treated patient was a steroid responder. The concept of a steroid responder 
relates to whether IOP rises in response to topical dexamethasone in a given 
individual, and is well described in the literature relating to topical GC use(33, 34). 
 
Uveitis is a recognised risk factor for the development of cataract and glaucoma(35, 
36), and was significantly associated with both outcomes in all three models. Although 
not investigated specifically, it is assumed that the risk associated with uveitis captures 
both the inherent risk of the inflammatory eye disease, as well as the increased risk 
associated with topical GC use, which is commonly used as first line therapy for uveitis. 
Contrary to the literature (37, 38), there was no clear association seen with female 
gender and the development of cataracts. In the third GC exposure model, male 
gender was shown to be associated with the development of glaucoma, which is in 
keeping with the literature (39, 40). Smoking is often cited as a risk factor for both 
cataract and glaucoma(7, 41-44), however this was not found to be the case in our RA 
cohort. 
 
The time varying exposure models selected for this study provide clinically useful 
results, which will enable better informed risk-benefit discussions between doctors 
and patients. These models capture the effects of current exposure (yes/no), current 
dose, lagged dose and cumulative dose. More complex, weighted cumulative dosing 
(WCD) models of GC exposure have been used in recent studies to capture differences 
in the importance of recent versus distant dosing (24, 45, 46). These WCD models 
could be considered as the current gold-standard of exposure models, however they 
are also based on the proportional hazards assumption, which was not met for our 
cataracts dataset. Furthermore, the WCD models require the outcome to be 
accurately recorded on the date of onset. For cataracts and glaucoma, the onset of 
disease may pre-date the first code by months. Therefore, we instead opted for 
models that could provide certain similar information to that obtained using a WCD 
approach. A systematic approach was taken when selecting the appropriate 
parametric time to event survival models and models were shown to fit the data well.   
 
The incidence of cataracts in our cohort was 12.3 per 1000 patient years (equivalent to 
12.3% per 10 years), which is substantially lower than the 38-54% incidence over 10 
years reported in general population cohorts in the Blue Mountains Eye study (BMES) 
and the Beaver Dam Eye Study (BDES) (37, 38). Similar to these studies, the incidence 
of cataract increased with age in our cohort, however the magnitude was lower, with 
an incidence rate of 31/34 (Males/Females) per 1000 patient years for those aged over 
75 years, compared to a 10-year cumulative incidence of 87% in those aged over 75 
years in the BBMES and BDES. This is likely due to the fact that the general population 
studies diagnosis was based on eye examinations rather than primary care records, 
which is likely to capture a greater number of cases. Regular eye examinations are 
recommended for patients with SLE receiving GCs (47-49) and may also be beneficial 
in older RA patients. The incidence of glaucoma of 3.1 per 1000 patient years was in 
keeping with previous reports of 3.5 per 1000 person years (39) and a cumulative 
incidence of 1.1%  (probable or definite OAG) over 5 years (50) and 2.2% over 4 years 
(51). 
 
The main limitation of this study is that it uses prescription data, with no information 
available on dispensing or adherence.  A recent small study comparing patient 
reported GC use as ‘true exposure’ to prescription data in CPRD, found that although 
the misclassification of current GC use was low, with 86% correctly classified as 
currently on/off GCs, this was sufficient to impact the observed OR  (52).  However, 
this limitation is countered by the fact that CPRD is a large dataset that captures 
meaningful information from real-life practice. As this is a primary care dataset, there 
is no collection of formal measures of RA disease activity. Unlike other outcomes 
related to GC use, such as infection risk, there is no evidence that disease activity is 
linked to the development of cataracts and glaucoma, outside of the uveitis pathway. 
Therefore, no surrogate for disease activity was included in the models. Traditional 
models of drug exposure often include duration of therapy. We chose not to directly 
look at duration of GC use because individuals in our cohort were followed up for 
differing lengths of time, which would bias the duration of time available for GC 
exposure. Instead, duration of treatment was indirectly captured, using cumulative 
dose. We did not account for GC use that occurred prior to cohort entry. An incident 
RA cohort was selected in order to minimise the chance of prior exposure. However, 




This study has demonstrated that current GC exposure is associated with a two-fold 
increased risk of developing cataracts and a 60% increased risk of developing 
glaucoma in patients with RA, and that the risk associated with GC use increases with 
age. Our models have also shown that doses given at the time of diagnosis and 6-12 
months prior to the diagnosis of cataracts are important, with this bimodal effect 
perhaps reflecting that GCs can accelerate cataracts that have already developed but 
not yet been diagnosed, as well as precipitate de-novo cataract development.  Doses 
given 3-12 months prior to the diagnosis of glaucoma are important but current dose 
is not, perhaps reflecting a lower background incidence of glaucoma compared to 
cataract. For cataracts, cumulative doses greater than 1000mg PEQ are associated 
with increased risk, more so at doses above 4000mg PEQ, whereas for glaucoma, the 
risk is seen only with higher cumulative doses greater than 4000mg. It is hoped that 
the quantification of these risks will lead to better informed risk-benefit discussions in 
the clinic setting. In the future, health economic modelling could be used to assess 
whether screening for cataracts and glaucoma in patients with RA prior to GC use is 
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Table 1: Patient Demographics/Descriptors 
 
Incident RA Cohort Characteristics  n (%)1 
N 22,607 
Age- years median (IQR) 66 (37-84) 
Female gender 15,421 (68.2%) 
Duration of follow up- years median (IQR) 8.7 (1.8-19.8) 
Baseline GC use 2,488 (11.0%) 
Ever GC use 8,746 (38.7%) 
GC dose-mg median IQR2 5 (2-15) 
Baseline Cataracts 241 (1.1%) 
Ever Cataracts3 1671/22,365 (7.5%) 
Baseline Glaucoma 164 ( 0.7%) 
Ever Glaucoma3 436/22,442 (1.9%) 
Uveitis 122 (0.5%) 
Baseline smoking status  
Never 9105 (40.2%) 
Former 6729 (29.8%) 
Current 5339 (23.6%) 
Missing 1434 (6.3%) 
1unless otherwise stated 
2prednisolone equivalent daily dose in GC users throughout follow up 
3baseline RA cases excluded 
Table 2: Log-logistic parametric survival models for cataracts, with age as the time scale. Three models for 
glucocorticoid (GC) use were estimated, with covariates (1): GC use (2) GC dose (with a square root 
transformation derived from fractional polynomial power analysis and (3) Cumulative GC dose. Results are 
expressed as Accelerated Failure Time (AFT) loge coefficients and odds ratios. 
 
Variable AFT Coefficient (95% CI)1 Odds Ratio (95% CI)2 p-val 
Model 1    
Female -0.016 (-0.033, 0.001) 1.14 (0.99, 1.31) 0.067 
Uveitis -0.261 (-0.352, -0.171) 8.73 (4.11, 18.52) < 0.001 
Smoking (base: Never)    
former -0.008 (-0.027, 0.011) 1.07 (0.91, 1.25) 0.40 
current 0.003 (-0.018, 0.024) 0.97 (0.82, 1.16) 0.76 
missing 0.011 (-0.018, 0.039) 0.92 (0.72, 1.16) 0.46 
GC use -0.098 (-0.12, -0.076) 2.25 (1.89, 2.68) < 0.001 
constant 4.518 (4.499, 4.536)   
gamma 0.121 (0.115, 0.126)   
Model 2    
Female -0.017 (-0.034, 0.000) 1.15 (1.00, 1.32) 0.055 
Uveitis -0.259 (-0.35, -0.168) 8.55(4.01, 18.24) < 0.001 
Smoking (base: Never)    
former -0.008 (-0.027, 0.011) 1.07 (0.91, 1.25) 0.43 
current 0.006 (-0.015, 0.027) 0.95 (0.8, 1.13) 0.57 
missing 0.012 (-0.017, 0.040) 0.91 (0.72, 1.15) 0.42 
10mg GC: lag 0d -0.056 (-0.102, -0.009) 1.59 (1.08, 2.33) 0.019 
10mg GC: lag 1m 0.019 (-0.033, 0.070) 0.86 (0.56, 1.31) 0.47 
10mg GC: lag 3m -0.001 (-0.048, 0.046) 1.01 (0.68, 1.49) 0.97 
10mg GC: lag 6m -0.048 (-0.094, -0.002) 1.49 (1.02, 2.17) 0.039 
10mg GC: lag 1y -0.089 (-0.133, -0.044) 2.08 (1.45, 3.00) < 0.001 
10mg GC: lag 2y -0.040 (-0.082, 0.001) 1.39 (0.99, 1.96) 0.059 
constant 4.522 (4.504, 4.541)   
gamma 0.121 (0.115, 0.127)   
Model 3    
Female -0.016 (-0.033, 0.001) 1.14 (0.99, 1.31) 0.066 
Uveitis -0.259 (-0.350, -0.167) 8.51 (3.98, 18.19) < 0.001 
Smoking (base: Never)    
former -0.008 (-0.027, 0.011) 1.06 (0.91, 1.25) 0.44 
current 0.008 (-0.013, 0.029) 0.94 (0.79, 1.12) 0.47 
missing 0.015 (-0.014, 0.043) 0.88 (0.70, 1.12) 0.31 
Cumulative Dose (base:0)    
1-125mg -0.003 (-0.061, 0.055) 1.02 (0.63, 1.65) 0.925 
126-250mg -0.027 (-0.068, 0.013) 1.26 (0.89, 1.76) 0.188 
251-500mg -0.031 (-0.067, 0.006) 1.29 (0.96, 1.74) 0.097 
501-1000mg -0.011 (-0.046, 0.024) 1.10 (0.82, 1.46) 0.535 
1001-2000mg -0.059 (-0.090, -0.028) 1.63 (1.26, 2.10) < 0.001 
2001-40000mg -0.062 (-0.094, -0.030) 1.67 (1.29, 2.17) < 0.002 
>40000mg -0.139 (-0.165, -0.112) 3.15 (2.56, 3.88) < 0.003 
constant 10.428 (10.409, 10.448)   
gamma 0.121 (0.115, 0.127)   
 
1Accelerated Failure Time (AFT) loge coefficients. The coefficients represent the approximate proportional 
change in age associated with each predictor variable level and exponentiation gives the age ratio. 
2The odds ratio is derived from the cumulative failure probability associated with each predictor variable 
level 
  
Table 3: Weibull parametric survival models for glaucoma, with age as the time scale. Three models for 
glucocorticoid (GC) use were estimated, with covariates (1): GC use (2) GC dose and (3) Cumulative GC dose. 
Results are expressed as Accelerated Failure Time (AFT) loge coefficients and hazards ratios. 
Variable AFT Coefficient (95% CI) Hazards Ratio (95% CI) p-val
Model 1 
Females 0.042 (-0.011, 0.096) 0.85 (0.69, 1.04) 0.12 
Uveitis -0.403 (-0.582, -0.225) 4.69 (2.42, 9.09) < 0.001 
Smoking (base: Never) 
former 0.006 (-0.054, 0.067) 0.98 (0.77, 1.23) 0.84 
current -0.001 (-0.067, 0.065) 1.00 (0.78, 1.29) 0.98 
missing 0.086 (-0.014, 0.186) 0.72 (0.49, 1.05) 0.093 
GC use -0.122 (-0.188, -0.055) 1.60 (1.26, 2.02) < 0.001 
constant 4.947 (4.865, 5.029)
p 3.83 (3.336, 4.397)
Model 21 
Females 0.089 (-0.033, 0.212) 0.85 (0.70, 1.05) 0.15 
Uveitis -0.711 (-1.215, -0.207) 3.51 (1.81, 6.79) 0.006 
Smoking (base: Never) 
former 0.004 (-0.128, 0.135) 0.99 (0.79, 1.25) 0.96 
current 0.122 (-0.030, 0.274) 0.81 (0.63, 1.03) 0.12 
missing 0.139 (-0.100, 0.378) 0.78 (0.53, 1.15) 0.25 
10mgGC dose: lag 0d  -0.112 (-0.325, 0.102) 1.22 (0.84, 1.76) 0.30 
10mgGC dose: lag 1m -0.079 (-0.299, 0.141) 1.15 (0.78, 1.69) 0.48 
10mgGC dose: lag 3m -0.244 (-0.453, -0.034) 1.54 (1.13, 2.10) 0.022 
10mgGC dose: lag 6m -0.143 (-0.348, 0.062) 1.29 (0.91, 1.81) 0.17 
10mgGC dose: lag 1y  -0.268 (-0.473, -0.062) 1.60 (1.20, 2.14) 0.011 
10mgGC dose: lag 2y 0.117 (-0.166, 0.399) 0.81 (0.50, 1.33) 0.42 
constant 11.149 (10.760, 11.538)
p 1.765 (1.106, 2.817)
Model 3 
Females 0.065 (0.006, 0.124) 0.77 (0.61, 0.97) 0.030 
Uveitis -0.261 (-0.484, -0.037) 2.83 (1.17, 6.88) 0.022 
Smoking (base: Never) 
former 0.009 (-0.061, 0.079) 0.96 (0.73, 1.28) 0.80 
current -0.056 (-0.127, 0.015) 1.25 (0.94, 1.67) 0.12 
missing -0.008 (-0.110, 0.093) 1.03 (0.69, 1.55) 0.87 
Cumulative Dose (base:0) 
1-125mg -0.072 (-0.225, 0.081) 1.33 (0.73, 2.45) 0.36 
126-250mg 0.033 (-0.101, 0.168) 0.87 (0.51, 1.5) 0.63 
251-500mg -0.065 (-0.173, 0.042) 1.30 (0.85, 1.99) 0.23 
-0.014 (-0.123, 0.094) 1.06 (0.69, 1.63) 0.79 
-0.072 (-0.17, 0.026) 1.33 (0.91, 1.96) 0.15 
501-1000mg 
1001-2000mg 
2001-4000mg -0.063 (-0.162, 0.036) 1.29 (0.87, 1.90) 0.21 
>4000mg -0.096 (-0.18, -0.013) 1.47 (1.07, 2.02) 0.024 
constant 10.848 (10.739, 10.956)
p 3.998 (3.381, 4.729)
1FP analysis indicated that no transformation of GC dose was necessary for glaucoma data 
Figures 
 





Figure 2. Cumulative incidence (Kaplan-Meier failure function) for A. Cataracts B. 
Glaucoma and smoothed hazard function for C. Cataracts and D. Glaucoma. Shaded 





Figure 3. Predicted mean difference in age of onset of cataracts and glaucoma 






Table S1. Read codes used to define cataracts and glaucoma.  
 
Medical code Read term  
   
296  Cataract  
703  Bilateral cataracts  
1622  O/E - cataract present 
4242  Posterior subcapsular polar cataract  
4260  Intracapsular extraction of cataract  
4358  Other cataract  
4439  O/E - lens opacity  
4459  [V]State following cataract extraction  
5325  Posterior subcapsular polar senile cataract  
5361  Other extraction of cataract  
5518  H/O: cataract  
6317  Cataract NOS  
6330  Extracapsular extraction of cataract  
6547  O/E - Right cataract present  
6876  Nuclear senile cataract  
7257  Cortical cataract  
7793  Nuclear cataract  
9931  O/E - Left cataract present  
10010  Senile cataract 
10659  Diabetic cataract  
11255  Subcapsular cataract  
11767  Referral for cataract extraction  
11941  Referral to cataract clinic  
11970  H/O: Bilateral cataract extraction  
15589  Other cataract NOS  
16751  O/E lens - early opacity  
17545  Type I diabetes mellitus with diabetic cataract  
18089  Capsular cataract  
22022  Cortical senile cataract  
23631  Immature cataract NOS  
23883  Needling of lens for cataract  
24467  Unspecified secondary cataract  
26097  Punctate cataract  
26850  After-cataract with vision obscured  
28513  H/O: R cataract extraction  
28515  H/O: L cataract extraction  
29770  Senile cataract NOS  
33482  After cataract  
33793  Total, mature senile cataract  
38641  Discission of cataract  
41668  Infantile, juvenile and presenile cataracts  
42452  Vitreous syndrome following cataract surgery  
44260  Insulin dependent diabetes mellitus with diabetic cataract  
44294  Immature cortical cataract  
44487  After cataract NOS  
44779  Type 2 diabetes mellitus with diabetic cataract  
44982  Type 2 diabetes mellitus with diabetic cataract  
47566  Unspecified senile cataract  
48148  Incipient cataract NOS  
48192  Type II diabetes mellitus with diabetic cataract  
49085  Other senile cataract  
49554  Type 1 diabetes mellitus with diabetic cataract  
51162  Hypermature cataract 
57805  Unspecified presenile cataract  
58078  Nonsenile cataract NOS  
58120  Drug induced cataract 
58625  Cataract associated with other syndromes  
59125  Anterior subcapsular polar cataract  
59914  Capsular and subcapsular cataract  
61325  Cataract with neovascularization  
62188  Unspecified cataracta complicata  
63640  Morgagni cataract  
64196  Cataract observation  
69278  Non-insulin depend diabetes mellitus with diabetic cataract
  
70201  [X]Other specified cataract  
70257  Combined senile cataract  
70403  Other nonsenile cataract  
88738  Capsular or subcapsular cataract NOS  
89585  Other after cataract with vision normal  
92358  Anterior subcapsular polar senile cataract  
93727  Type II diabetes mellitus with diabetic cataract  
94348  Cataract operation planned  
94430  Cataract due to other disorder NOS  
94474  Combined nonsenile cataract  
96385  Cortical and zonular cataract  
98962  Cortical or zonular cataract NOS  
100770  Insulin dependent diabetes mellitus with diabetic cataract  
101939  [X]Other senile cataract  
103508  Cataract extraction and insertion of intraocular lens 
104553  Keratopathy following cataract surgery  
105971  Bullous aphakic keratopathy following cataract surgery  
110400  Type 1 diabetes mellitus with diabetic cataract 
 
1611  Ocular hypertension 
1798  Open-angle glaucoma 
2074  Glaucoma 
2399  Glaucoma monitoring 
4581  Primary open-angle glaucoma 
8001  Glaucoma NOS 
8132  Low tension glaucoma 
8955  H/O: glaucoma 
8971  Borderline glaucoma 
9260  Borderline glaucoma NOS 
9469  Low tension glaucoma 
10070  Open angle glaucoma with borderline intraocular pressure 
11059  Pan retinal photocoagulation for glaucoma 
24860  Unspecified preglaucoma 
28189  Open-angle glaucoma NOS 
30649  Simple chronic glaucoma 
35528  Steroid-induced glaucoma 
36737  Borderline glaucoma steroid responder 
42447  Unspecified open-angle glaucoma 
44295  Other specified glaucoma NOS 
44338  Glaucoma - absolute 
46069  Operations following glaucoma surgery 
48132  Steroid-induced glaucoma NOS 
53879  Normal pressure glaucoma 
65079  Needling of bleb following glaucoma surgery 
68094  Steroid-induced glaucoma residual stage 
70195  [X]Other glaucoma 
72394  Open-angle glaucoma residual stage 
88142  Other specified operations following glaucoma surgery 
88595  Revision of bleb NEC following glaucoma surgery 
89934  Injection of bleb following glaucoma surgery 
91442  Removal of releasable suture following glaucoma surgery 
93967  Laser suture lysis following glaucoma surgery 
94229  Suspected glaucoma 












person-time failures rate (95% CI)1 person-time failures rate (95% CI)1 
Males         
<55 yrs 10394.19 11 1.06 (0.59, 1.91) 10366.56 8 0.77 (0.39, 1.54) 
55-65 yrs 10482.68 48 4.58 (3.45, 6.08) 10544.07 26 2.47 (1.68, 3.62) 
65-75 yrs 11507.85 155 13.47 (11.51, 15.77) 11797.17 49 4.15 (3.14, 5.50) 
>75 yrs 8656.82 271 31.3 (27.79, 35.26) 9499.3 63 6.63 (5.18, 8.49) 
Females         
<55 yrs 27758.39 34 1.22 (0.88, 1.71) 27768.75 28 1.01 (0.70, 1.46) 
55-65 yrs 23561.51 107 4.54 (3.76, 5.49) 23532.48 59 2.51 (1.94, 3.24) 
65-75 yrs 22606.31 338 14.95 (13.44, 16.63) 23400.23 78 3.33 (2.67, 4.16) 
> 75 yrs   20540.64 707 34.42 (31.97, 37.05) 23794.96 125 5.25 (4.41, 6.26) 
Total 135508.38 1671 12.33 (11.75, 12.94) 140703.52 436 3.10 (2.82, 3.40) 
 
Table S3. AIC and BIC, for both cataract and glaucoma data, showing the fit of 




AIC BIC AIC BIC 
Exponential 6 3337.5 3410.6 2166.4 2240.1 
Weibull 7 1866.0 1949.6 2034.2 2118.3 
Gompertz 7 1915.0 1998.5 2037.9 2122.1 
Log normal 7 1870.3 1953.9 2082.7 2116.9 
Log-logistic 7 1804.1 1887.7 2032.3 2116.4 
Generalised Gamma 8 1835.2 1929.2 2034.1 2128.8 
 
  
Figure S1. Comparison of the predicted survival functions estimated by parametric 
regression with the observed Kaplan-Meier survival function for A. Cataracts 
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GCs remain important therapeutic options in the treatment of many chronic 
inflammatory diseases. Although they have been available for more than 60 years, there 
are still many unanswered questions surrounding optimal use and harm minimisation. 
In the literature, and in clinical practice, opinions around GCs are strikingly divided and 
discussion often provokes emotive responses (82).  This thesis has furthered current 
knowledge with regard to glucocorticoid use and adverse effects in clinical practice, 
particularly in the field of rheumatology. The three main sections of this thesis 
addressed different aspects of GC use: Firstly, it investigated how GCs are used among 
patients with RA, secondly it looked at GC AEs from the patient perspective and thirdly 
it evaluated the risk of GC exposure associated with the development of cataracts and 
glaucoma. In addition, the thesis describes the research databases and methodologies 
used to explore these sections of work. 
 
Dataset strengths and limitations 
For the epidemiological components of this work, two different datasets were used. 
CPRD is a large UK-based dataset derived from primary care EMRs and ARAD is an 
Australian-based rheumatology biologics registry, which collects patient-reported data. 
There were pros and cons to using each of these datasets. CPRD is a very large dataset, 
which has been validated and shown to be representative of the UK population (203, 
204). It also has its own internal validation processes to ensure logical consistency of 
patient registration data and longitudinal records that are complete, continuous and 
plausible. It contains real-life data that reflects real-life practises, with long-term follow 
up over many years, and is therefore an ideal setting for exploring safety outcomes. 
Data is provided as a number of different files with common variables, which allow them 
to be merged together using statistical software. However, the data available is 
dependent on what is entered into the EMR, and as a consequence significant data 
cleaning and preparation is required to deal with missing, duplicate and implausible 
data in order to achieve an analysis-ready dataset. Using CPRD to explore medication 
use relies on prescription data, with no dispensing or adherence information available.  
 
Although not on the same scale as CPRD, ARAD is also a large database that provides 
information about patients followed prospectively over many years in Australia. As a 
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registry, there is consistent and streamlined data collection with standardised fields, 
which makes the data cleaning process significantly easier compared to CPRD. It uses 
patient reported medication exposure, which potentially reflects actual use more 
closely than prescription data although, like CPRD, it does not collect information on 
adherence. A recent study comparing patient reported GC use as ‘true exposure’ to 
prescription data in CPRD, found the misclassification of current GC use to be low with 
86% correctly classified as currently on/off GCs (226). As with CPRD, ARAD provides data 
from a real-life population with real-life medication exposures in which to study long-
term safety outcomes, as opposed to the more artificial setting of clinical trials. There 
are, however, potential biases related to the ARAD data collection processes. These 
include a potential recall bias with patient reported data collected at 6 to 12 month 
intervals. There is also a potential selection bias due to voluntary ‘opt-in’ participation, 
and it is not known if those who join and continue to contribute to ARAD are 
fundamentally different from those who do not. ARAD is also limited by what fields are 
collected, for example it does not collect standard measures of disease activity or 
medication dosages. Data linkage with Australian pharmaceutical (Pharmaceutical 
Benefits Scheme, PBS) and medical (Medicare Benefits Schedule, MBS) billing databases 
has recently become available and will help to address some of these limitations in the 
future. 
 
Glucocorticoid use in Rheumatoid arthritis 
RA is a chronic inflammatory disorder often treated with GCs, for which there are many 
alternative therapeutic options, making it an ideal setting in which to explore GC use. 
The first section of work in this thesis has extended current knowledge about how GCs 
are used in RA and the factors than can influence this. A greater understanding of how 
GCs are used in a condition for which other therapeutic options are available, allows us 
to identify areas which might be targeted to improve the balance between the benefits 
and harms of treatment.  
 
In a primary care based cohort of RA patients in the UK, it was shown that nearly 50% 
of RA patients were ever prescribed GCs, with nearly 40% receiving doses greater than 
20mg per day and nearly 20% receiving doses greater than 30mg per day (227). 
International guidelines recommend low dose GCs (<=10mg ACR, <=7.5mg EULAR) for 6 
months or less (42, 43), indicating that doses far greater than recommended are used 
in clinical practice. Further analyses suggested that this may in part reflect GC use for 
other comorbidities such as asthma (OR 1.63, 95%CI 1.33–1.99), COPD (OR 1.58, 95%CI 
1.42–1.76) or lower respiratory tract infections (OR 1.22, 95%CI 1.11–1.34) (227). 
However, it may also reflect use of high dose GC protocols such as COBRA (Dutch 
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acronym for COmbinatietherapie Bij Reumatoide Artritis) (228) and COBRA-Light (229), 
which include prednisolone doses starting at 60mg and 30mg per day respectively. GC 
prescribing was also more likely in patients who were older (OR 1.17, 95%CI 1.14–1.20), 
current smokers (OR 1.22, 95%CI 1.13–1.32) and/or had cardiovascular disease (OR 
1.25, 95%CI 1.03–1.51) at baseline. While these patient factors may be associated with 
more severe disease necessitating GC therapy, they are also characteristics that may 
predispose to GC AEs. These findings can therefore be translated to the clinical setting 
as they identify patient characteristics that may alert clinicians to the need for a more 
careful risk-benefit assessment.  
 
This study also explored whether the factors that influence GC prescribing differ 
according to prescriber. Prescribers were classified as either high or low GC prescribers 
according to their GC prescribing habits across all patients. This analysis revealed that 
high prescribers were more likely to prescribe to higher risk patients including those 
who were older (OR 1.26, 95%CI 1.23–1.29, P<0.001) and those with hypertension (OR 
1.29, 1.17–1.41, P=0.039). GC use prior to follow up was the most important predictor 
of GC ever use during follow up in high prescribers compared to low prescribers (OR 
11.76, 95%CI 10.24–13.51, P<0.001). These findings again provide an opportunity for 
clinical translation, as they suggest that those who are more frequent GC prescribers 
are using GCs in patients who may be at increased risk of AEs. In the future, this 
information could be used to formulate guidelines for risk benefit assessments.  
 
To expand this knowledge further, factors affecting GC use were also explored in an 
Australian RA cohort using ARAD. In this group, patient-reported GC ever use was higher 
than the CPRD cohort at 60%. GC use over time was only examined within the ARAD 
cohort and was shown to be decreasing over time. This finding was in keeping with our 
hypothesis that GC use was likely to be higher in those who joined ARAD in the initial 
years following its inception and reduce over time as bDMARDS became more readily 
available and accepted as standard care. In contrast to the UK based population, 
increasing age was associated with reduced GC use (OR 0.24, 95%CI 0.07–0.81) in the 
ARAD cohort. It is possible that this reflects different practices in the UK compared to 
Australia, or perhaps even differences in GC use between a primary care based cohort 
and a cohort referred from rheumatologists. However, the analyses were also carried 
out differently with the impact of baseline characteristics on GC ever use explored in 
CPRD, compared to the impact of current characteristics on GC current use evaluated in 
the ARAD cohort, making direct comparisons difficult. 
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Panel regression was used in the ARAD analysis to compare current characteristics with 
current GC use. While the results of this analysis can only be interpreted as an 
association, rather than causation, the most likely direction of an association needs to 
be carefully considered within the clinical context, when interpreting the results. For 
example, GC use in ARAD patients was associated with lower pain scores (less pain) (OR 
0.94, 95%CI 0.90–0.98), and is in keeping with current knowledge that GCs rapidly 
reduce inflammatory joint pain. However, GC use was associated with higher HAQ 
scores (poorer quality of life) (OR 1.52, 95%CI 1.30–1.79), suggesting that poorer quality 
of life may predispose to increased GC use, but any improvement in quality of life is 
delayed compared to the improvement in pain. 
 
Factors that influence whether a patient commences or comes off GC therapy were 
explored, with poorer quality of life (higher HAQ scores) (HR 1.94) and higher levels of 
pain (HR1.1) associated with an increased HR for commencing GCs. Factors associated 
with a reduced HR for commencing GCs included older age (HR 0.87) and use of other 
medications including bDMARDs (HR 0.54), csDMARDs (HR 0.27), NSAIDs (HR 0.57) and 
opioids (HR 0.64). Female gender was associated with an increased HR for ceasing GCs 
(HR 1.30), while increasing age (HR 0.92) and poorer quality of life (HR 0.77) were 
associated with a reduced HR for ceasing GCs.  
 
The use of transition state analysis to explore GC use in terms of commencement and 
cessation was a novel approach to understanding GC use in more detail. Of particular 
interest were factors that had an impact on both commencement and cessation of GCs.  
The effect of increasing age was an example of this, with older patients less likely to 
commence GCs but also less likely to come off GC treatment, once started. It was 
hypothesised that bDMARD use would have a steroid-sparing effect and although those 
using bDMARDs were less likely to commence GCs, their use did not affect GC cessation. 
Similarly, there was no association seen between GC cessation and other concomitant 
medications including csDMARDS, NSAIDs and opioids. Female gender was in fact the 
only factor found to be associated with GC cessation in all of the transition state 
analyses.  This reflects the phenomenon often described by rheumatologists in clinical 
practice, that once GCs are commenced, they are often difficult to cease. This suggests 
that there may be some discordance between how patients perceive the benefits and 
harms of GC treatment, versus the benefits and harms deemed important by clinicians. 
 
The impact of glucocorticoid use from the patient perspective 
Having shown that GC use is common in the first section of this thesis, the second 
section examined at how patients perceive both the wanted and unwanted effects of 
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GCs. The patient perspective is well recognised as an important quality measure and it 
has previously been shown that doctor’s and patient’s opinions differ in regards to the 
importance of GC AEs (94). This thesis has shown that many GC AEs that are important 
to patients, occur commonly and are not easily measurable in the clinic setting. In 
addition, most patients feel that GCs help their disease ‘a lot’ and that the benefits of 
treatment outweigh the harms. Many GC AEs were more frequent in RA patients who 
had used GCs compared to those who had not, confirming that these symptoms are 
appropriately attributed to GC use. This work contributes to a broader body of work 
being undertaken by the OMERACT GC SIG, which aims to develop a GC PRO for use 
across all systemic inflammatory diseases.  
 
Since this work began, other GC outcome measures have been published, including the 
GTI (93) which consists mainly of physician measured outcomes, a disease specific PRO 
for SLE (230), a PRO for inhaled corticosteroids (219) and a PRO for IV 
methylprednisolone (231). However, a recent systematic review found that a PRO for 
measuring the effects of systemic GCs across all inflammatory diseases has not yet been 
developed (83). In a soon to be published systematic review of qualitative and 
quantitative studies, patient-reported GC outcomes were found to fall into four main 
categories including physical and psychological symptoms, participation and contextual 
factors (83). The participation and contextual factors categories were identified in the 
qualitative studies, with participation including the impact on work, family and friends 
and contextual factors including negative attitudes of family, friends and the wider 
community as well as the concept of management and mastery of disease. 
 
The work in this thesis is a step towards the development of a GC PRO, for use in future 
clinical trials and observational studies which include GC use. A PRO will lead to better 
quality data collection and help fill the remaining gaps in the literature more efficiently 
and effectively. This knowledge needs to be translatable into clinical practice and 
capturing the patient perspective is a means of ensuring research outcomes are relevant 
to patients’ needs. 
 
Glucocorticoid use and the risk of developing cataracts and glaucoma  
In addition to understanding the benefits and harms of GC use from the patient 
perspective, it is also important to be able to communicate the potential risks of 
treatment, which requires us to know both the probability that an AE will occur as well 
as how important this may be to the patient(47). Knowing that GC use is high and that 
GC AEs are common, the third section of this work focused on the need to better 
quantify the risks of specific GC AEs and in particular ophthalmic AEs, including cataract 
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and glaucoma. These were selected as AEs of interest, as they have been shown to be 
important to patients when they occur(225, 232) and the frequency at which they occur 
in the setting of oral GC use is not well understood. RA was again selected as an ideal 
setting to explore these risks. There were two components to this section of work, 
including a systematic literature review (SLR) with meta-analysis and an observational 
study, which used data from CPRD. The SLR included observational studies looking at 
GC use and the development of cataracts and glaucoma in RA and all RCTs looking at GC 
use in RA. It found that the majority of RCTs (25/28) did not report cataracts and 
glaucoma, an indication that these outcomes are under-reported in the literature. This 
observation was explored further, by comparing the 2% two-year cumulative incidence 
of cataracts reported in the three RCT cohorts to the much higher 12% general 
population cumulative incidence seen in the BMES over two years. This under-reporting 
may in part reflect that many of the RCTs dated back to the 1990s, and lacked the 
rigorous reporting of outcomes that would be expected of more contemporary studies. 
This factor drove the development of the CONSORT extension for better reporting of 
harms in RCT which was published in 2004 (233). 
 
In the three RCTs that did report cataracts, no association was seen between GC use 
and their development, which differed from the meta-analysis of observational cohort 
studies where the odds of developing cataracts doubled with GC use. No association 
was seen between GC use and the development of glaucoma in the meta-analysis of 
RCTs or cohort studies. However, data were very limited and the review concluded that 
the GC-associated risk of developing cataracts and glaucoma in patients with RA could 
not be accurately quantified, based on the existing literature. More so, no conclusions 
about the effect of dose and duration of GC treatment could be drawn from these 
studies.  
 
In order to address the gaps in the literature identified in the SLR, an observational study 
using CPRD data was carried out. Different models of GC exposure were used to explore 
the effect of current GC use (yes/no), GC dose (current prednisolone equivalent daily 
dose (PEQ) and lagged dose) and cumulative dose. In keeping with the findings of the 
SLR, current GC exposure was shown to be associated with a two-fold increased risk of 
developing cataracts. However, unlike the SLR in which no association could be found 
between GC use and glaucoma, this study found there to be a 60% increased risk of 
developing glaucoma in patients with RA currently using GCs. This study was able to 
extend existing knowledge, finding that doses given 12 months prior to the diagnosis of 
cataracts and 3-12 months prior to the diagnosis of glaucoma were of greatest 
importance. However, the lag between the onset of disease and diagnosis/date of first 
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CPRD code is not defined. For cataracts, cumulative doses greater than 1000mg PEQ 
and 4000mg PEQ were associated with a 60% and 3-fold increased risk respectively, 
whereas for glaucoma the risk was increased by approximately 50% with cumulative 
doses greater than 4000mg.  
 
These findings directly address the need to better quantify the risk of GC AEs so that 
patients can be informed of the risks and benefits of GCs prior to treatment as per 
international guidelines (91). The study also found that the cumulative incidence of 
cataracts and glaucoma rises steeply from around age 60-65, which is in keeping with 
previous studies (99, 100). The smoothed hazard also increased steeply between the 
ages of approximately 60 and 85 for cataract and around 50 and 85 for glaucoma. This 
information could be used to inform future guidelines regarding the need to screen for 
cataracts and glaucoma in patients exposed to GCs, particularly older patients who are 
likely to be exposed to higher cumulative doses. It is well recognised that screening for 
AEs is only worthwhile if there is the opportunity to modify the outcome with early 
detection. The current literature suggests that GC cessation or dose reduction should 
be part of the management of GC induced cataracts and glaucoma, and may necessitate 
the addition of a steroid-sparing agent. A future study comparing screening to routine 
care could help to determine if there is a role for screening for these GC AEs. 
 
Challenges to overcome and skills developed 
There were a number of challenges to overcome to create the body of work included in 
this thesis, particularly when working with CPRD data. Clinical knowledge and 
experience were essential when making decisions in the data cleaning process. 
However, significant skill acquisition in the field of epidemiology and statistics was 
required together with statistical coding skills to create complex data cleaning scripts. 
Stata statistical software was used for data preparation and analyses throughout the 
thesis. The statistical code created for both data preparation and analysis needed to be 
saved in a format that allowed for large sections to be re-run efficiently if changes had 
to be made. This was achieved in Stata by creating do-files with text descriptors 
between code, so it was clear what each section was coding for. These descriptors were 
most useful when kept concise but frequent throughout the do-files. The logical naming 
of do-files according to their purpose was also important. Simple macros were used to 
refer to the different data files used throughout the do-files, making it simpler to update 
the code with newer versions of the dataset, when required. It is accepted that there 
should be transparency in research, and there is increasing recognition that data and 
code should be made available for results to be replicated and validated. Creating 
clearly labelled do-files is also good practice for sharing code.   




The size of the CPRD dataset meant that errors could be difficult to detect and care had 
to be taken to check how the data were affected by each section of the data cleaning 
script. Following the outcomes of different decisions in a small selection of patients was 
a useful solution for checking for errors. The size of the dataset also meant that 
adequate secure data storage space was required and complex analyses could take a 
long time to run.  CPRD data had to be accessed and analysed remotely from Australia 
using a secure server in the UK. This required IT skills development to troubleshoot 
problems as they arose. My candidature has required the acquisition and integration of 
clinical, epidemiological, coding and statistical skills necessary for a clinician-researcher 
to work with large datasets derived from real-life clinical practice. As EMRs are 
increasingly being used in hospitals and well as primary care, future research 
opportunities using these skills as a clinician researcher are likely to be vast. 
 
Unanswered questions and future directions 
The overarching theme of this PhD was to extend current knowledge about the use and 
impact of GCs in order to promote the safer, better use of these agents, which are 
important therapeutic options for chronic inflammatory disorders and remain essential 
in the management of many life or organ threatening complications. An assessment of 
the benefits and harms underlies any treatment decision in clinical practice (47). There 
are a number of foreseeable ways in which the work in this thesis can be translated into 
clinical practice to help both patients and clinicians make a clearer assessment of the 
benefits and harms of GC treatment. The first section of work provided insights into the 
factors associated with GC use and identified situations where increased caution might 
be needed when prescribing GCs, particularly in older patients and those with 
comorbidities that could potentially put them at increased risk of harm from GC AEs. 
Future work is needed to expand on these results by developing predictive algorithms 
to inform guidelines or prescribing alerts within EMRs.  
 
The second section of work is based on current knowledge that the patient perspective 
of medication benefits and harms is different but complementary to the clinician 
perspective (95, 234-236). In identifying GC AEs that are important to patients, and 
demonstrating that patients are correctly attributing these effects to GC use, this work 
has contributed to the early phases of developing of a GC PRO. With subsequent work 
for the OMERACT GC SIG, we have already added to these initial findings and are a stage 
closer to the development of such a PRO (83, 218).  The next step will be to decide on a 
Core Domain Set, which will include items that are important to measure in all studies. 
From there, the OMERACT GC working group will look in more detail at existing 
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instruments that measure GC use and then the process of developing a new instrument 
will begin. This will include decisions about which items should be binary measures of 
whether an outcome has occurred or not, and for which items it will also be important 
to measure effect size or severity. The aim is to develop a PRO that will have utility in 
both clinical and research settings, and consideration will need to be given to how it is 
administered and the results disseminated.  Ideally, it would be available digitally with 
the option for remote reporting so that it can be completed by patients outside of the 
time constraints of clinic or research visits.  Further work will see the development of 
this PRO completed and then validated in different cohorts. If risk-benefit discussions 
about GC use are to be properly informed in the future, it is essential that a PRO is 
developed so that patient-relevant aspects of GC use can be accurately and consistently 
measured in clinical trials and observational studies.  
 
In the final section of work for this thesis, the risks of developing cataracts and glaucoma 
associated with exposure to GCs was quantified. These findings can be directly 
translated into the clinic setting, allowing patients and clinicians to better understand 
the risk of developing these ophthalmic AEs with different exposure to GCs. Further 
exploration of how these risks are best communicated to patients is warranted. It is 
recognised that many patients, as well as clinicians, will find it difficult to conceptualise 
common statistical risks such as relative and absolute risks, odds ratios, hazard ratios 
and number needed to treat or harm (47, 237). It has instead been suggested that 
natural frequencies (1 person out of 10 treated with GCs will develop ‘x’) are a better 
understood descriptor (238, 239). The use of visual aids such as the 1000 person Paling 
pallete (240) can greatly improve the communication of risk (48, 241). Future work is 
still needed to make this information readily available to patients and clinicians. 
Consideration will need to be given to how this information is provided in the context 
of also needing to communicate many other GC AEs. This can be a time-consuming 
process, taking over two hours per subject in a research study (85). In order to meet the 
needs of a broad range of patients, this information could be made available in different 
formats including printable handouts, online recourses and as part of eHealth apps. 
Novel modalities for helping patients to understand the experience of the benefits and 
harms of GCs could be considered, such as short videos of patients describing their own 
different experiences. Communicating risk is also complicated by the fact that risk varies 
according to age, gender, comorbidities and differing GC exposure patterns (48). This 
has led to the development of personalised risk calculators to guide clinical decision 
making, including the risk of developing cardiovascular disease (242) and  fracture risk 
in osteoporosis(243, 244), and future work could see the development of similar risk 
calculators for GC AEs.  
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While this work has quantified the risk of developing incident cataracts and glaucoma 
associated with GC use in RA, future work is still needed to determine the impact of GC 
use on RA patients with pre-existing cataracts and glaucoma. Another planned 
expansion of this work is to explore the GC-associated risks of developing cataracts and 
glaucoma in other disease groups, and ISAC approval has already been obtained to do 
this in CPRD. This should also be explored in an Australian population, which may be at 
increased risk of GC related eye disease due to greater exposure to UV radiation. This 
would be possible using ARAD data linked to dispensing data from the PBS and MBS 
codes for cataract surgery. 
 
International collaboration was a key component to this thesis, beginning with a year 
spent at the University of Manchester in the Arthritis Research UK Centre for 
Epidemiology.  This collaboration provided initial training in epidemiology, statistics and 
statistical coding required for the body of work undertaken in the thesis. It also provided 
the opportunity to work with CPRD data, a unique dataset with no real Australian 
equivalent. Ongoing collaboration, mentorship and supervision continued for the 
duration of the thesis and the working relationships formed will pave the way for 
ongoing collaboration in the future. International collaboration was also an important 
aspect of the patient-perspective section of work. Along with patient participation, 
international collaborative research underpins the principles of OMERACT and it is a 
requirement that each SIG has representation from at least three continents. Working 
together with colleagues from the UK, US and Australia has highlighted some of the 
challenges of international collaboration, including long-distance communication, time-
zone differences and the need to make the most of often limited opportunities for face-
to-face contact with collaborators. However, these challenges are far outweighed by 
the benefits of collaborative research, including access to a wider range of facilities and 
resources, the opportunity to work with field-leaders and contribute to some of the 
highest impact research activity (245). Other benefits include the range of skills and 
different international experiences, meaning that research outcomes are more likely to 
be relevant to a broader range of patients. 
 
Benefits and harms- the broader perspective 
In an online essay, Herxheimer (47) identifies four dimensions of any benefit or harm: 
“1. Its nature, described by its quality, its intensity, and its time course (onset, duration, 
and reversibility). 2. The probability that it will occur. 3. Its importance to the person 
experiencing it. 4. How the benefit can be maximised, or the harm prevented or 
minimized.”. This thesis has tried to address each of these issues to differing extents: 1. 
In the introduction, a description of the literature summarises relevant aspects of what 
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is known about the nature of the benefits and harms of GC use, 2. The probability of 
developing ophthalmic harms of GC use is addressed in the cataract and glaucoma 
section of work, 3. The importance of GC benefits and harms to the person experiencing 
them is explored in the patient perspective section and 4. The work on GC use in RA 
identifies factors associated with GC use that might be targeted to minimise of prevent 
harm related to GC use in the future.  
 
Shared decision making is well recognised as an important aspect of best-practice 
clinical care (246). It relies on the clinician and patient having sufficient information 
about a disease and treatment options to be able to make an informed assessment of 
the benefits and harms. This will often include quantifiable measures, such as the risk 
of the disease worsening without treatment and the likelihood of the treatment being 
effective. These need to be weighed against quantifiable harms such as the 
development of AEs.  
 
In addition to quantifiable risks, contextual factors also play an important role in 
clinician and patient decision making (47). Contextual factors may include clinician, 
patient and family attitudes to GCs and prior experience with GCs (247). Patients are 
also likely to weight positive and negative treatment outcomes differently, depending 
on their individual circumstances. For example, the risk of visual impairment from 
cataracts or glaucoma may be weighted more highly by someone who already has visual 
loss in one eye or has experienced recurrent falls. Conversely, an older patient may be 
less worried about developing an AE if they know that this takes years to develop and is 
unlikely to occur within their life expectancy. Whether a patient has experienced a 
particular GC AE also influences how important that AE is to them, with serious GC AEs 
such as diabetes, cardiovascular disease or eye disease being very important to patients 
who have experienced them but less important to those who have not (232). How best 
to include these contextual factors in shared decision making discussions is an ongoing 




In conclusion, this thesis has extended current knowledge about the benefits and harms 
of GC use in three key ways. It has identified patient and prescriber characteristics 
associated with GC use and in doing so uncovered situations for potential harm 
minimisation, such as increasing age. It has captured further knowledge about which GC 
AEs are most important to patients and identified that many of these are not easily 
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measured, while also confirming that the majority of patients consider GCs are effective 
treatments, with benefits outweighing harms. Finally, it has quantified the risk of 
developing cataracts and glaucoma associated with different patterns of GC exposure 
in RA for the first time, having identified this as a gap in the literature by means of a SLR 
and meta-analysis.   
 
Following on from this work, there are a number of planned next steps to both expand 
this research and mobilise the new knowledge obtained. Further development of a GC 
PRO is already under way within the OMERACT GC working group. The next steps will 
include the completion of a Delphi exercise to confirm a core domain set and then the 
process of selecting and developing appropriate measurement instruments will begin. 
To expand the cataract and glaucoma work, ISAC approval has already been obtained 
for similar analyses to be conducted in other disease populations within CPRD. In 
addition, there are plans to explore this in an Australian population, who may be at 
increased risk of GC related eye disease due to increased exposure to UV radiation. This 
can be done within ARAD, using PBS and MBS data linkage. Further work is also needed 
to determine whether screening for cataract and glaucoma prior to or during periods of 
GC exposure would alter outcomes. This will require a collaborative approach involving 
ophthalmologists, and will need to take into consideration other factors that affect risk 
such as increasing age.  
 
Future work will also include making this knowledge accessible to patients and clinicians 
in different formats. This translational process will require a collaborative approach 
involving patient and clinician focus groups to develop materials that are accessible and 
useful to a wide range of patients. It will be important to engage with patient-focussed 
organisations such as Arthritis Australia, who are frequently the providers of risk-benefit 
information and are therefore able to offer experience, advice and resources. This work 
would also be strengthened by collaboration with colleagues who have expertise in 
digital health, in order to develop this information in different electronic formats. It 
would also be informative to incorporate electronic patient feedback into these 
resources, to allow for ongoing development.  
 
The underlying aim of this body of work was to improve clinical practice by adding to 
current knowledge, allowing for better-informed discussions about the benefits and 
harms of GC treatment. The work was designed with ‘clinical-translatability’ in mind, 
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ABSTRACT. Objective. The need for a standardized instrument to measure the effect of glucocorticoid (GC) therapy
has been well documented in the literature. The aim of the first GC Special Interest Group was to
define a research agenda around the development of a patient-reported outcome measure (PROM) in
this area.
Methods. The results of a background literature search and the preliminary results of a pilot survey
and 2 qualitative studies were presented to facilitate the development of a research agenda.
Results. It was agreed that there was a need for a data-driven PROM that identified both positive and
negative effects of GC therapy to be used across all inflammatory indications for systemic GC use in
adults. A research agenda was developed, consisting of further qualitative work to assess the effect of
GC across different groups including various indications for GC use, different age groups, different
dosages, and duration of treatment.
Conclusion. There was agreement on the need for a PROM in this area and a research agenda was
set. (First Release April 1 2017; J Rheumatol 2017;44:1754–8; doi:10.3899/jrheum.161083)
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Glucocorticoids (GC) have had a prominent role in the
treatment of inflammatory diseases for over 60 years, with
0.5%–1% of adults considered  current longterm users1,2,3.
They are effective antiinflammatory agents; however, they
have many known associated adverse effects (AE). While GC
AE have been well documented4,5,6,7,8, the absolute risk of
many GC AE has not been quantified5,9. This may be because
AE are poorly identified in randomized controlled trials
(RCT), or may reflect differences in AE when GC are
prescribed for different indications and doses10,11,12,13,14. A
European League Against Rheumatism (EULAR) taskforce
on GC therapy has published 2 systematic reviews
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concluding that there is a need to systematically identify GC
AE in a standardized manner10,12. In addition, EULAR
recommendations for GC monitoring suggest that new tools
are required13, supporting the need for the development of
outcome measures to assess the effect of GC therapy across
a wide range of indications.
The recently developed GC toxicity index (GTI) measures
the physiological AE of systemic GC use, and includes items
such as body mass index, glucose tolerance, blood pressure,
lipids, and bone density, among others15. However, it is not
a patient-reported outcome measure (PROM). Discordance
between rheumatologists and patients regarding GC AE16
suggests that patients may perceive GC AE very differently
from doctors. Therefore, development of a PROM that
specifically addresses the positive and negative effects of GC
on patients’ quality of life and experience would complement
the GTI. The aim of the GC Special Interest Group (SIG) was
to review current knowledge and define a research agenda
for measuring the life effect of GC to identify relevant
domains. Items achieved on the Outcome Measures in
Rheumatology (OMERACT) Master Checklist are available
on the OMERACT Website.
Main Findings
A literature search revealed a PROM that measures the effects
of inhaled GC, but no PROM for the effects of systemic GC
was found. The preliminary results of a pilot survey and 
2 qualitative studies demonstrated that patients report
outcomes including sleep disturbance, weight gain, and skin
fragility that are not typically measured by clinicians. These
data facilitated discussion regarding the need for a PROM for
the effect of GC.
Systematic Literature Review of PROM for GC AE
A librarian-assisted search was carried out in OVID
MEDLINE (1946 to February, Week 3, 2016) and OVID
EMBASE (1974 to February 26, 2016; Supplementary 
Table 1, available with the online version of this article).
Titles and abstracts of 146 articles were screened, and 7
papers were chosen for full-text review. No PROM for identi-
fying the effects of systemic GC use was identified; however,
2 articles described the Inhaled Corticosteroid Questionnaire
(ICQ)17,18, a PROM for inhaled GC use (Supplementary
Figure 1, available with the online version of this article). The
ICQ contains 57 items across 15 categories; 38 items
identified inhalation-related AE affecting the oropharynx,
taste, and voice, and 19 items were related to systemic AE of
inhaled GC including mood, skin/hair/nails, perspiration, and
tiredness, among others (Figure 1).
GC AE Reported in RCT of Inflammatory Disorders
An analytical exercise to determine which GC AE have been
reported in RCT was carried out using the studies reported in
the systematic literature review of polymyalgia rheumatica
(PMR; 9 RCT), Crohn disease (14 RCT), and ulcerative
colitis (UC; 6 RCT)19,20,21. In addition, 28 rheumatoid
arthritis (RA) RCT comparing systemic GC use in 1 arm to
nonuse (placebo or no treatment) in at least 1 comparator arm
were identified in a systematic literature search. GC AE data
was extracted by review of the manuscripts identified. There
were 63 different AE reported in the RCT distributed among
11 categories (Figure 1) that differed between diagnostic
groups. AE in all categories were reported in the RA, PMR,
and Crohn disease trials, but no UC trials report cardiovas-
cular or ocular AE.
GC AE: The Patient Perspective (Pilot Survey)
A cross-sectional pilot survey was performed to determine
GC AE from the patient perspective. Participants attended an
Australian tertiary rheumatology clinic (n = 55) and were
currently taking oral prednisone or had taken it within the
past 12 months. The survey included a checklist of known
AE and participants were asked “Which were the worst side
effects you had?” Participants were also asked to indicate
whether GC therapy helped “not at all,” “a little,” “a lot,” or
“not sure,” and whether the AE they experienced were worse
than the benefits of treatment (Yes/No/Not sure).
There were 55/88 questionnaires returned. Responders
were 71% women, with a median age of 68 years (range 
33–89 yrs). The disease range was broad [14 connective
tissue disease, 14 RA, 14 PMR, 5 giant cell arteritis (GCA),
3 other vasculitis, 2 other arthritis, 1 retroperitoneal fibrosis].
All patients reported at least 1 GC AE (median 8, range
2–19). The most common AE were thin skin/easy bruising
(45/55), weight gain (36/55), stomach upset/gastric reflux
(30/55), and sleep disturbance (30/55).
The “worst” AE were weight gain, skin fragility, and sleep
disturbance. Most patients (43/55) felt that GC helped their
disease “a lot,” 6/55 felt they helped “a little,” 5/55 were “not
sure,” and 1/55 felt that GC did not help at all. Most (30/55)
felt the benefits of treatment were greater than the AE, 9/55
thought that the AE were greater than the benefits, and 13/55
were undecided. (Data on this question were missing for 3
patients.)
A Qualitative Assessment of GC Use in ANCA-associated
Vasculitis (AAV)
The OMERACT vasculitis working group members are key
collaborators in the international development of a PROM
for patients with AAV. AAV is a multisystem disease that can
be organ- and life-threatening unless treated with high-dose
GC and other immunosuppressants, all of which can signifi-
cantly affect patients’ health-related quality of life. During
the qualitative phase of this project, 50 individual patient
interviews were performed with participants from the United
Kingdom, United States, and Canada22. Participants were
purposely sampled to include a range of disease features (for
example, renal disease vs limited respiratory, ENT
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involvement; time since onset of the disease; and severity of
disease) and demographic features. The interviews were
broad-ranging to identify the full breadth and depth of themes
of importance to patients in relation to both the disease itself
and its treatment, including symptoms, effect on function,
psychological and emotional health, and social interactions.
The interviews were semistructured and used a topic guide
including questions specifically related to GC and other treat-
ments. Themes related to the positive and negative aspects
of treatment with GC rapidly emerged as being of high
importance to patients, with in-depth questioning revealing
a range of differing patient perspectives. A detailed analysis
across the 50 interviews looking more in depth at cross-
cutting themes within the dataset was therefore performed.
Inductive analysis was used. Preliminary results were
presented for discussion during the GC SIG; the full report
will be submitted for separate publication. Interviewed
patients reported many positive aspects of GC treatment,
including rapid onset and effectiveness in controlling organ-
and life-threatening features of vasculitis. They also reported
a range of physical and psychological AE in keeping with
previous findings in other diseases. GC SIG patient partici-
pants (underlying diagnoses included RA and PMR)
confirmed GC’s positive effects and emphasized difficulties
they experienced with dose reduction, including symptom
recurrence. Some reported a perceived value judgement from
family and friends attached to difficulty reducing their dose,
and a feeling of failure if they were unable to “get off
steroids.” Fear surrounding longterm use of GC was
suggested as a driver of patients’ and doctors’ seemingly
emotional response to GC use, but further work is needed to
analyze this.
A Qualitative Assessment of GC Use in PMR and GCA
Patients attending rheumatology clinics at an Australian
tertiary hospital with a diagnosis of PMR or GCA were
invited to participate in a qualitative study (supported by
Arthritis Australia). Fourteen participants attended 1 of 4
discussion groups (2 were interviewed by phone because they
were unable to attend a group discussion), where analytical
data were gathered using facilitated discussions by nonclin-
ician researchers. Questions focused on onset of symptoms,
process of diagnosis, treatment, AE of treatment, and ongoing
management of their condition(s). All discussion groups were
transcribed verbatim and a “framework analysis” was used
to analyze and interpret the data (Nvivo 10 software).
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Figure 1. Categories of glucocorticoid adverse effects reported in randomized controlled trials. CNS: central
nervous system; Abx: antibiotics; UTI: urinary tract infection; GI: gastrointestinal; CVS: cardiovascular system;
BP: blood pressure; HTN: hypertension; MI: myocardial infarction; CCF: congestive cardiac failure; GC: gluco-
corticoid; MSK: musculoskeletal; osteoporotic #: osteoporotic fractures; BMD: bone mineral density; BSL: blood
sugar level; psych: psychiatric; BMI: body mass index.
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Preliminary findings highlight a wide range of experiences
related to GC use. AE tended to occur after an initial positive
treatment effect and dosage was identified as an influencing
factor. Weight gain, changes in shape of face and neck, and
insomnia with fatigue were commonly reported. The
cumulative characteristic of AE was also acknowledged,
along with difficulties in distinguishing AE from symptoms
of the condition (e.g., fatigue). Some participants also
reported having to manage distrust expressed by clinicians,
family, and friends related to GC AE, while concurrently
benefiting from the treatment effect. 
Summary of the OMERACT 2016 GC SIG
Participants in the inaugural GC SIG agreed on the need for
a data-driven PROM that identifies both positive and
negative effects of GC therapy to be used across all inflam-
matory indications for systemic GC use in adults. The partici-
pants recognized the difficulty of determining how this might
fit within the OMERACT framework because the Filter 2.023
has not been designed to address AE as an outcome; however,
it was felt that the framework would nonetheless be helpful.
A research agenda was drawn up for development of a GC
effect PROM:
1. To conduct further qualitative work in populations
with different GC indications to identify relevant domains.
2. To address differences in age groups (adults), GC
dose, and duration of use. 
3. To define and quantify the value patients place on
GC benefits and harms, and to determine differences from
physicians.
4. To analyze the sense of conflict patients describe
when physicians recommend tapering, while patients feel
they need ongoing GC therapy.
In addition, it was agreed that this group would benefit
from engagement and collaboration with the OMERACT
Drug Safety Group.
When assessing novel therapies for inflammatory condi-
tions treated with GC, it is important to identify the relevant
GC-related risks and benefits. Based on the background
evidence presented, attendees agreed that a PROM
instrument should be developed. A research agenda has been
established to broaden our understanding of the positive and
negative effect of GC across different indications, ages, and
doses. The group will be well placed to develop a preliminary
core outcome set at OMERACT 2018.
ONLINE SUPPLEMENT
Supplementary material accompanies the online version of this article.
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ABSTRACT. Objective. To understand the effects of glucocorticoids (GC), which are of importance to patients.
Methods. The results of 2 literature reviews, a patient survey, and a qualitative study were presented.
Results. No validated instrument exists to evaluate GC effect on patients. Survey data revealed skin
thinning/bruising, sleep disturbance, and weight gain as the most frequent adverse effects. The quali-
tative research yielded rich data covering rapid benefits and physical and emotional consequences of
GC.
Conclusion. It was agreed that a patient-reported outcome to measure GC effect was required and a
research agenda was developed for this goal. (J Rheumatol First Release January 15 2019;
doi:10.3899/jrheum.181082)
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Glucocorticoids (GC) have a substantial role in the treatment
of inflammatory diseases1,2. However, while adverse effects
(AE) are well documented, the absolute risk of many GC AE
remains unquantified3 and the effects of greatest importance
to patients are not known. With the aim to define a research
agenda for measuring the effect of GC to identify relevant
domains, the Outcome Measures in Rheumatology
(OMERACT) GC Impact Working Group (WG) held its
inaugural meeting at the 2016 OMERACT meeting4. The
presented work included a literature search that confirmed
that there was not an already developed patient-reported
outcome (PRO) for the effects of systemic GC use.
Additionally, the preliminary results of a pilot survey and 2
qualitative studies identified that patients are concerned and
affected by outcomes that are not commonly assessed by their
treating clinician, such as skin fragility, sleep disturbance,
and weight gain. At that meeting, there was agreement on the
need for a data-driven PRO identifying both positive and
negative effects of GC therapy to be used across inflam-
matory conditions. However, it was agreed that further work
was required to gain additional understanding of the effects
of GC prior to the development of a PRO. Following the steps
of the current OMERACT filter5,6, we sought to generate
candidate domains from which to propose a core domain set.
To this end, 2 literature reviews, a cross-sectional survey, and
a qualitative study were undertaken and presented at
OMERACT 2018 to better understand the effect of GC across
various patient groups.
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MATERIALS AND METHODS/RESULTS
Systematic literature review (SLR) of PRO for the effect of systemic GC. At
OMERACT 2016, a systematic review revealed that no PRO had been
developed to assess the effect of systemic GC use. We updated the original
search, using OVID MEDLINE (2013 to Week 1 of October 2017) and
OVID EMBASE (1974 to October 16, 2017). There were 208 unique articles
identified and screened. Although no PRO measuring the effects of systemic
GC across all inflammatory diseases were identified, 2 disease-specific PRO
were found: 1 for multiple sclerosis (MS) and 1 for systemic lupus erythe-
matosus (SLE)7,8. The Methylprednisolone Adverse Effects Questionnaire
assessed the presence and severity of 15 items including facial flushing, sleep
disturbance, and feeling angry or bad tempered in those with MS with a
confirmed relapse. However, patients did not clearly participate in the devel-
opment of the questionnaire and the psychometric properties of the question-
naire were not evaluated. The SLE Steroid Questionnaire measured 50 items
across 7 domains. Although patients were involved throughout the devel-
opment process, this PRO has not been tested across a large population of
patients, and psychometric testing and adequate measurement properties
have not been demonstrated.
Cross-sectional survey of GC AE from the patient perspective on 2 conti-
nents. To complement the survey performed and previously presented within
an Australian tertiary rheumatology clinic, the same survey was subsequently
administered to both GC users and nonusers from the rheumatoid arthritis
(RA) database at the Hospital for Special Surgery (HSS; New York)9. The
questionnaire included a checklist of 19 known AE and asked participants
to rate the 3 “worst” AE. Similar results were found in the HSS GC users
when compared with the initial Australian cohort, suggesting that the
patient’s perception of GC AE appear similar despite cultural and geographic
differences. The most frequent AE across the 2 groups of GC users were
sleep disturbance, thin skin/easy bruising, and weight gain. Weight gain was
described most frequently as the worst AE in both cohorts. Compared to the
HSS GC nonusers, many GC AE were significantly more frequent among
GC users, suggesting that these AE were due to the use of GC, rather than
to other medications or the underlying disease itself.
Qualitative assessment of GC use in RA. Patients with RA at the HSS with
experience of GC use were invited to participate in a qualitative study to
supplement the qualitative work that had already been conducted and
reported on in antineutrophil cytoplasmic antibody-associated vasculitis
(AAV), giant cell arteritis, and polymyalgia rheumatica, conditions in which
both the dose as well as duration of GC may be significantly different from
those in RA4,10. Eleven participants with RA (9 female) attended 1-to-1
semistructured interviews to describe the experience (benefits and harm) of
taking GC. Ages ranged from 26–83 years. Eight participants were currently
taking GC (range 2-20 mg daily of prednisone equivalent). Four themes
emerged (Table 1). Overall, GC had been beneficial in the control of RA
symptoms such as swelling and pain. However, this had “come at a price,”
the participants said, referring to the unintended physical and emotional
effects of GC, such as weight gain and feelings of anger. Additionally, there
was an acknowledgment of the necessity of GC use in certain contexts
because of the need to be able to function for family and work purposes.
Finally, there was uncertainty over attribution of potential symptoms solely
to GC or to other disease-modifying antirheumatic drugs or to RA itself.
Compared to the themes that emerged from the interviews conducted in AAV,
similarities included the beneficial effects (which were quick), the adverse
effects both physical and emotional, as well as the need to balance both in
relation to the participants’ current life situation. However, those with AAV
voiced uncertainty regarding the dose-reduction process, whereas those with
RA were at times uncertain whether particular effects were due to GC use.
SLR of the effect of GC from the patient perspective. To establish whether
GC therapy carried similar effects in nonrheumatological inflammatory
conditions, a further SLR was undertaken to identify the effects of systemic
GC in adults across any condition in which systemic GC were used11. An
academic librarian searched OVID EMBASE, OVID MEDLINE,
PsycINFO, and CINAHL for articles published from inception to October
2017, related to 3 concepts: GC, the patient perspective, and AE. Inclusion
criteria included systemic GC use for any indication in an adult population
and both qualitative and quantitative research methodology. The initial
search retrieved 1356 articles, of which 24 (18 quantitative, 6 qualitative)
were deemed suitable for quality assessment and data extraction. Studies
included the assessment of GC use across a variety of diseases both rheuma-
tological (e.g., RA, vasculitis) and nonrheumatological (including asthma,
inflammatory bowel disease, and MS). Four major themes emerged among
the 71 discrete outcomes (Table 2): physical symptoms (44), psychological
symptoms (18), effect on participation (6), and contextual factors (3). The
metasynthesis of the qualitative work was richest for outcomes that had not
been as well represented previously, including the effect on work/relation-
ships, the cognitive load of debating the benefits and harm of GC use but
also the sense of self-management and mastery of one’s own disease, and
the appropriate use of GC. Using a qualitative metasummary, frequency and
intensity effect sizes will be calculated to identify those outcomes most
prominently featured across all reviewed articles.
DISCUSSION
The session was well attended and insightful discussion took
2 The Journal of Rheumatology 2019; 46:doi:10.3899/jrheum.181082
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Table 1. Description of themes from thematic analysis of interview transcripts.
Theme                         Key Points with Quotes
Benefits                       Pain and swelling
                                          •    “…it does reduce the swelling. And when the swelling is reduced, the joints feel much better.”
                                   Return to functional activities
                                          •    “If I can’t move my hands, I can’t take a shower, I can’t wash my hair, I can’t brush my teeth. So how do I get to work? For me 
                                                that was debilitating…the prednisone allowed me to do that because I would feel the effects within 2–3 days...”
Challenges                  Physical (e.g., weight gain and recurrent infections)
                                          •    “I looked like a white whale with a harpoon in my hip… I looked like Moby Dick.”  “I had a respiratory infection a lot; I seem 
                                                subject to those. I would get skin infections, I had to be so careful not to break my skin and things.”
                                   Emotional (e.g., anger and low mood)
                                          •    “…inside I felt like a terrorist. I really did. I could have killed somebody. I’m not kidding, I had a terrible temper…”  “My parents
                                                …for them to see me unhappy and just not feeling like myself, in that way, is really hard on them and it’s hard on me…”
Necessity                    Frustration with need
                                          •    “I was angry that I had to take them. I did not want to take them, but I had no choice, because they do reduce the inflammation.”
Attribution                  Unsure whether GC solely responsible
                                          •    “…when I’m taking all this…it’s hard to precisely point to what’s working and what’s not working, what’s good, what’s bad…”
GC: glucocorticoid.
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place among attendees and WG members, who identified
issues to consider for future work, including:
         1. The ongoing challenge of being able to clearly
attribute an outcome to GC, rather than to the underlying
disease or other medication(s).
         2. How to create a PRO to be used across a broad
range of rheumatic diseases in which GC use may be very
different regarding dose, duration, and frequency.
         3. How to integrate with the work of the Drug Safety
WG and whether a generic core set for drug safety in addition
to a GC-specific core set would be appropriate.
         4. The importance of life context in determining the
relative importance of a GC effect and how this can change
over time.
         5. That 3 main areas should be considered when
assessing the effect of GC: the intended effects, the
unintended effects, and the life context in which those effects
take place.
         A summary of both the presentation and subsequent
discussion was also identified in cartoon form (Figure 1).
Despite these issues, there was overall agreement that a PRO
primarily concentrating on measuring the life effect of GC
use is needed, and the following research agenda was
developed:
         1. Complete a Delphi exercise to prioritize outcomes.
         2. Assess whether a different approach to the Delphi
is needed to prioritize true GC effects (as opposed to the
effects of the underlying disease or other medications).
         3. Investigate novel ways of incorporating GC
outcomes into the OMERACT onion5,6, because having the
effect of a medication as the outcome may require some
adaptation.
3Cheah, et al: OMERACT GC SIG proceedings
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2019. All rights reserved.
Table 2. Outcomes with the most frequently reported outcome per theme.
Theme                                      Outcome
Physical symptoms                   Weight gain
                                                 Sleep problems
                                                 Skin changes
                                                 Upper GI problems
                                                 Cardiopulmonary
Psychological symptoms          Irritability and mood swings
                                                 Depression
                                                 Anxiety
                                                 Hyperactivity and euphoria
                                                 Process of debating GC use
Participation                             Effect on sexual relationships
                                                 Effect on work
                                                 Effect on family
Contextual factors                    Lack of support from community or media
                                                 Self-management and mastery
                                                 Lack of support from family and friends
GI: gastrointestinal; GC: glucocorticoid.
Figure 1. Summary of the Glucocorticoid Impact Special Interest Group session. OMERACT: Outcome Measures in Rheumatology; GC: glucocorticoid; AE:
adverse effects; MS: multiple sclerosis. OMERACT logo from OMERACT; used with permission. 
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         4. Develop a preliminary core domain set to be voted
on at OMERACT 2020.
         The ability to measure the effect of GC, both positive
and negative, is crucial at a time when there are an increasing
number of steroid-sparing agents requiring rigorous evalu-
ation in clinical trials. Therefore, there is an unmet need to
measure the outcomes of GC use from the patient
perspective. Developing a core domain set to create such a
PRO remains the goal of the WG.
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